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Abstract 
Atopic Eczema (AE) is a common, complex, genetic skin disease. It usually 
begins in infancy and can affect any part of the body but often occurs in the 
flexures of the elbows and knees. The cohort used in this study is of Bangladeshi 
origin and all subjects reside in East London. 
Using a combination of techniques, such as the Illumina goldengate assay, PCR 
and sequencing, both novel and previously associated genes have been studied in 
this thesis. Previously associated genes were used to validate this population and 
also to investigate the variation of genes associated in different ethnic populations. 
Six of eleven previously associated genes were replicated in this population. In 
order to identify novel genes of interest in AE, sixteen novel genes were chosen 
for investigation. Of these sixteen, eight showed association with AE. 
A recently identified gene involved in the pathogenesis of AE, Filaggrin (FLG), 
was also investigated. This was done using a combination of PCR, sequencing 
and Taqman SNP assays. Only six families out of 80 in this population were 
found to harbour the two known common FLG mutations. These families were 
clinically reassessed for Ichthyosis Vulgaris (IV) which is also associated to the 
same FLG mutations. After this reassessment the FLG mutations were shown to 
be associated with IV in this population with variable penetrance. No association 
with AE was found. 
ABCA12 was also investigated as a candidate gene for AE, again using the 
Illumina goldengate assay and microsatellite linkage markers. Association was 
observed with this gene and AE. Harlequin Ichthyosis (HI) mutations were also 
screened in this gene for twelve additional HI patients. 
This thesis has provided a greater insight into the variation of gene associations 
between populations with AE, highlighting novel genes, including KY-NU and 
JAK3/INSL3, which need to be investigated in other populations. 
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Chapter 1 
Introduction 
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1.1 The skin 
1.1.1 Overview of the skin 
The skin is a vital organ responsible for temperature regulation, the sensations of 
pain and touch and also as a barrier and regulator of immune defence. The skin is 
also the largest organ in the body and covers the whole external surface of the 
body and the surface area exceeds 2 m` (Montagna and Parakkal, 1974). Within 
the skin there are three major structural areas, the epidermis, the dermis and the 
hypodermis or subcutaneous tissue (Figure 1.1). 
Layers & Structures of the Skin 
Moir shaft 
Pore of 
swoao gland 
Stolurn 
coeneum 
Dermal 
Papillae 
DIRMI S 
Owlet, rool 
sh"Ib 
Magi bulb 
Ecaine 
swGoº gland 
susaTAN FOUS 
ISSUE Vein 
Figure 1.1 - An overview of the skin. The epidermis is only a very small part of 
the skin as a whole and is mainly responsible for protection. It contains no blood 
vessels and nourishment comes from the dermis. The dermis contains blood 
vessels, hair follicles and sweat glands. The hypodermis or subcutaneous tissue is 
the main insulator of the body. [Taken from (Segre, 2003)]. 
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The skin is a highly organised and specialised organ with many different cell 
types such as fibroblasts, keratinocytes, melanocytes and basal cells, that each 
contribute to its many different functions (Chuong et al., 2002). Skin and 
underlying tissues start to proliferate as early as the fourth week of embryonic 
development. This leads on towards maturation and differentiation into more 
specialised structures such as hair, teeth and nails. 
1.1.2 Structure of the skin 
1.1.2.1 The epidermis 
The epidermis is very thin (approx. 0.1 mm) everywhere on the body with the 
exception of the palms and soles of the hands and feet where it can be up to 1.4 
mm thick. It consists of highly organised stratified layers as can be seen in Figure 
1.2 and described as follows. 
The basal layer - This is the lowest layer of the epidermis and mainly consists of 
tall epithelial cells which undergo rapid mitosis and provide a constant supply of 
cells moving through all the layers. This layer is normally only one cell thick. 
Melanocytes are also spread throughout the basal layer and produce melanin 
which is the pigmentation of skin and hair. The basal keratinocytes are attached 
to the underlying basement membrane by hemidesmosomes (Borradori and 
Sonnenberg, 1999). 
The spinous layer - The cells within the spinous layer look to be anchored by 
thin strands and they actively synthesise intermediate filaments called cytokeratins 
and these filaments are bound to desmosomes which give the cells a spiky look 
and provide structural support (Royce and Steinmann, 2002). 
The granular layer - This is where the cells, which originated in the basal layer, 
have begun to flatten and die and lose their nuclei before they become the stratum 
corneum. This is also where many cells accumulate lamellar granules which 
contain stacks of lipid lamellae which in turn are comprised of cholesterol, 
phospholipids and glucosylceramides (Freinkel and Traczyk, 1985; Kalinin et al., 
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2001). These lipids are the precursors of the stratum corneum lipid bilayers and 
are released just as the cells transition into the stratum corneum. Filaggrin 
granules are also present in the granular layer. Filaggrin is required for 
aggregation of intermediate filaments and the flattening of keratinocytes into the 
stratum corneum (Kuechle et al., 1999). Tight junctions hold cells together and 
also prevent the movement of ions and molecules between the cells (Bazzoni and 
Dejana, 2002). Loricrin is the major component of the cornified envelopes in the 
stratum corneum (Yoneda et al., 1992). 
The stratum corneum - This is the surface of the skin and the keratinocytes are 
flattened, dead and contain no nuclei. The main role of the stratum corneum is as 
a barrier against infiltration of chemicals or microbes but it is also involved in the 
regulation of transepidermal water loss (Proksch et al., 2008). It consists of a 
continuous sheet of corneocytes which are keratinocytes which have been 
collapsed due, in part, to cross linking of filaggrin. The cornified envelope is a 
protein and lipid structure around the outside of a corneocyte. The lipid bilayer is 
required for the waterproof sealing of the skin. Adjacent corneocytes are linked 
together by modified desmosomes known as corneodesmosomes (Williams and 
Elias, 2003). 
1.1.2.2 The dermis 
The dermis lies directly below the epidermis and consists of two specific areas: a 
papillary layer and a lower reticular layer. The border between the epidermis and 
the papillary layer is not flat but has large projections into the epidermis called 
dermal papillae (Figure 1.1). These projections contain small blood vessels and 
also nerves. It provides oxygen and sustenance to the basal layer so it can 
continue cell division. The papillary layer itself contains thin fibres of collagen 
which provides strength and flexibility. The reticular layer is much denser and 
consists of thick collagen fibres and also elastin fibres. Also embedded in the 
dermis are hair follicles and many glands and nerve endings. 
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Figure 1.2 - Stratification of the epidermis. Two of the three main areas of the 
skin are shown, with the epidermis consisting of the stratum corneum, granular 
layer, spinous layer and the basal layer and the dermis directly below this. (Segre, 
2003). 
1.1.2.3 The hypodermis 
The hypodermis or subcutaneous tissue is the deepest layer and is often indistinct 
from the lower layers of the dermis. It consists of loose fibrous tissue which is 
rich in blood vessels, lymphatic vessels and nerves and is mainly used for fat 
storage. Cells within the hypodermic are fibroblasts, adipose cells and 
macrophages. 
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1.1.3 The function of skin 
One of the skins most important functions is the protective barrier it provides 
against the environment via the stratum corneum. Although many bacteria come 
into contact with the skin they are normally unable to infect the area. Bacteria can 
penetrate the skin either through injuries to the skin or through diseased skin 
(Mohammedamin et al., 2006). When infections do occur they can range in size 
from a small spot to covering a large area of the body. Infections in the skin can 
also spread into the blood stream having a much wider effect. Staphylococcal and 
streptococcal infections are common in patients with skin diseases and also people 
with wounds (Hanifin and Rogge, 1977). 
The skin also has a very important role in protecting the body from ultraviolet 
(UV) radiation. This is done through melanin and this is produced by 
melanocytes in the skin. UV light is important in many chemical reactions such 
as the breakdown of vitamin D3 which is vital for normal teeth and bone 
development and also for calcium absorption from food, however it is known that 
over-exposure to UV radiation can lead to skin cancer (Reichrath, 2006). 
Temperature regulation is also a function of the skin. Large amounts of liquid are 
lost from the skin during perspiration and this then evaporates to cool the skin. 
Blood vessels in the skin dilate when the body's temperature is too high and 
constrict to conserve heat and loss of liquid. Sweat also contains waste material 
such as nitrogen and urea. 
The lymphatic system of the skin is more prominent in the hypodermis than the 
dermis and is important in the immune system's defence when bacteria or foreign 
bodies penetrate the skin. Keratinocytes play a major role in maintaining the 
structural integrity of the skin but also synthesise and release many 
immunologically important factors such as cytokines to exert an immunological 
reaction within the skin. Epidermal Langerhans cells are manufactured in the 
bone marrow but migrate to the skin through blood vessels (Katz et al., 1979). 
They can then migrate through the dermis and epidermis and capture foreign 
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antigens which they can then use to activate T cells and start an immune response 
(Shamoto, 1983). 
1.1.4 Skin barrier 
The skin barrier is essential for life for humans and mammals. The main function 
is providing a barrier for keeping the inside of the human or mammal in and 
keeping the outside out. Apart from the physical structure of the skin itself, the 
main component of the skin barrier is the lipid component which is present in the 
extracellular space of stratum corneum between corneocytes. This lipid 
component could be described as the mortar between the corneocytes and keratin 
filament bricks where the lipids seal the whole structure together (Nemes and 
Steinert, 1999). The lipid mortar is excreted from lamellar granules (or bodies) 
which can be seen clearly in figure 1.2. Tight junctions are also extremely 
important in the formation of the skin barrier. Mice with claudin-1 deficiency, a 
tight junction adhesion molecule, die within one day of birth due to dehydration 
through transepidermal water loss (Furuse et al., 2002). Claudins 2,5 and 8 have 
been found to disrupt the barrier function within the colon of patients with Crohns 
disease (Zeissig et al., 2007). Claudin 14 has also been associated with profound, 
congenital, recessive deafness in two Pakistani families (Wilcox et al., 2001). 
Keratin is the major structural element within keratinocytes and they are essential 
for keratinocyte cell strength and therefore an essential part of the skin barrier 
(Proksch et al., 2008). 
1.1.5 Differentiation 
The creation of the stratum corneum involves a large number of processes. 
Keratinocytes produced from stem cells in the basal layer undergo differentiation 
as they progress from the basal layer towards the stratum corneum. It is known 
that at least twenty genes are involved in this progression, with proliferation, 
differentiation and cell death all requiring their own set of genes (Volz et al., 
1993). The main genes involved in the formation of the stratum corneum are 
expressed in the epidermal differentiation complex located at chromosome l q21 
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(Volz et al., 1993). These include filaggrin (FLG), loricrin, transglutaminase 1 
and small proline rich proteins (SPRs). 
1.2 The immune system 
1.2.1 Overview of the immune system 
The immune system is essential for healthy regulation of the body. It is a 
collection of biological cells and processes which identify and kill pathogens such 
as viruses, bacteria or even parasitic worms. The immune system can distinguish 
between the host's own cells and tissues and foreign bodies and target these 
specifically. The immune system consists of two different arms, the innate and 
adaptive immune systems. 
Innate immunity - The innate immune response is a non-specific response to 
infection (Clark and Kupper, 2005). This does not confer protective immunity as 
in the adaptive immune system. The innate immune response is the first defence 
against infection. The first obvious sign of the innate immune system is 
inflammation at the site of infection. Inflammation provides a barrier against 
spread of infection. Obvious signs of inflammation are redness, heat, swelling 
and pain. In general, immune system cells such as mast cells, macrophages, 
neutrophils and dendritic cells are recruited to sites of infection and inflammation 
by cytokines (Clark and Kupper, 2005). 
Adaptive immunity - The adaptive immune response is antigen and pathogen 
specific (Clark and Kupper, 2005). This is a much stronger immune response 
however it often takes some time from infection to response which is why the 
innate immune response is so important. Activation of the adaptive immune 
response requires antigen presentation which is when antigens are captured by 
immune system cells and presented to T-cells for recognition as non-self. T-cells 
and B-cells are the main response cells of the adaptive immune response. 
Immune memory is also created through the adaptive immune response so that 
responses can be mounted quicker. 
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1.2.2 The immune system in skin 
The skin provides one very obvious role in the immune system, it provides a 
physical barrier to pathogens. However when this barrier is disrupted the skins 
immune defences come into action. If a bacterium was to infect the skin the first 
line of defence would be the stratum corneum, followed by a cytokine, chemokine 
and microbicidal cascade initiated by keratinocytes (Meyer et al., 2007). The 
chemokines are particular important as they signal to cells within the innate 
immune system such as dendritic cells and phagocytes but they also signal to the 
adaptive immune system cells such as T cells (Meyer et al., 2007). Dendritic cells 
can capture the pathogenic antigens and then present these to T cells and activate 
the adaptive immune response (Clark and Kupper, 2005). Lymphocytes which are 
involved in the adaptive immune response were first categorised in 1949 and were 
found to make up 1-4% of the basal layer, this was conducted by staining of skin 
biopsies and characterisation of 100 cells from each biopsy (Andrew and Andrew, 
1949). In 1987 lymphocyte subpopulations were characterised and it was found 
that no B cells resided in the epidermis, however T cells were found (Bos et al., 
1987). This indicates that there is a component of the adaptive immune system 
ready and waiting within the skin. The skin clearly has one of the most important 
roles in the immune system. 
1.3 Atopic eczema 
1.3.1 Atopic eczema overview 
Atopic eczema (AE) is a common, chronic and relapsing inflammatory skin 
disorder (Bowcock and Cookson, 2004) and affects approximately 15% of 
children and 2% of adults in the UK (Banfield et al., 2001) and is a considerable 
health economic burden. It is typified by itchy, inflamed skin often occurring in 
the flexures of the elbows and knees but can also be found anywhere on the body 
and usually begins in infancy (Cookson, 2004; Hoffjan and Epplen, 2005; 
Thestrup-Pedersen, 2000). AE is often the first disease present in the atopic 
march followed by asthma which is present in -60% of children with severe AE. 
Atopy means "strange disease" and is recognised by positive skin prick tests to 
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common allergens, by the presence of allergen specific IgE in their serum or by 
elevated total IgE in their serum (Bowcock and Cookson, 2004). Total serum IgE 
has shown around 50% heritability (Mathias et al., 2001). Patients with AE are at 
a high risk of bacterial skin infections due to their skin being inflamed and 
damaged. It is thought that the barrier function is as important as the immune 
response in AE (Bonness and Bieber, 2007). There also seems to be an altered 
lipid composition in the stratum corneum in AE patients and this can lead to 
higher permeability to allergens and irritants (Novak et al., 2003). 
1.3.2 Prevalence of atopic eczema 
Countries with a high prevalence (over 15%) of AE include the Baltic region, 
Australia, New Zealand and Northern and Western Europe and urban Africa. 
Countries that have a low prevalence (less than 5%) include China, Eastern 
Europe and central Asia. The Bangladeshi population in East London shows a 
similar prevalence to the general UK population of around 15-20%. In 
Bangladesh itself there is a low prevalence of only 6-7% (Williams et al., 1999). 
This makes it clear that environmental factors are extremely important in the 
pathogenesis of AE. 
1.3.3 Clinical manifestations of atopic eczema 
AE occurs as a relapsing disease where sufferers may have periods of remission. 
The most obvious effect of AE on patients is the itching and dry skin. This can 
lead to a severe disruption in the skin barrier through scratching and can in turn 
lead to further complications such as bacterial infections. 
There are three stages of AE and these are determined by age of onset and can be 
separated by periods of remission. In infants (under the age of 2 years) surfaces 
of the body that can be affected are the face, neck, extensor surfaces and groin. 
This stage can be difficult to distinguish from seborrhoeic dermatitis on clinical 
grounds (Rudikoff and Lebwohl, 1998). In children (2 years to 12 years of age), 
stage two, surfaces most affected tend to be flexural, specifically antecubital 
(elbow) and popliteal fossae (knee creases). Ankles, necks and wrists are also 
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often affected. In adults (from puberty onwards), stage three, facial involvement, 
especially the forehead and around the eyes is common. Lichenification can also 
occur in the flexural regions. Wrists, hands, fingers and toes can also be affected. 
(Rudikoff and Lebwohl, 1998). Acute or early AE skin lesions are characterised 
by spongiosis of the epidermis (Banfield et al., 2001). 
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Figure 1.3 - Clinical presentation of Atopic Eczema. (A) A young child can be 
seen with the classic presentation of dry flaky skin on the cheeks of the face. (B) 
The posterior aspect of a knee showing eczematous scaling. (C) Is the hand of an 
adult showing eczematous lesions on the wrist and down the side of the hand. 
(Clinical pictures courtesy of Prof. E. O'Toole). 
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1.3.4 Diagnosis of atopic eczema 
Diagnosis of AE is difficult to define and several groups have tried to set 
diagnostic criteria. Often diagnosis entails a list of symptoms and patients must 
have three or more of these. These lists can include: pruritus (itching), typical 
morphology and distribution (flexural lichenification or linearity in adults, facial 
and extensor involvement in infants and children), chronic or chronically- 
relapsing dermatitis and personal or family history of atopy (asthma, allergic 
rhinitis, atopic dermatitis) (Rudikoff and Lebwohl, 1998). 
The diagnostic criteria set down by Hanifin, Lobitz and Rajka in 1980 listed the 
main clinical features of AE. However they were found to often be unrepeatable 
and very complex. Therefore they were used as a basis for the UK working 
party's group of sixteen physicians to more closely define AE associated features. 
The UK working party's criteria is now: An itchy skin condition in the last twelve 
months plus three or more of the following: onset below two years of age, history 
of flexural involvement, history of generally dry skin, personal history of other 
atopic disease and visible flexural dermatitis as per photographic protocol 
(Williams et al., 1994a; Williams et al., 1994b; Williams et al., 1994c; Williams, 
2000). These guidelines have now been rigorously validated by many different 
groups and in many different ethnic groups and have become the standard method 
of evaluating AE. 
In the diagnosis of the severity of AE there are three main systems. The SCORing 
Atopic Dermatitis (SCORAD) (Oranje et al., 2007; Sprikkelman et al., 1997; 
Stalder and Taieb, 1993), the Eczema Area and Severity Index (EASI) (Barbier et 
al., 2004; Hanifin et al., 2001) and the Six Area, Six Sign Atopic Dermatitis 
(SASSAD) (Berth-Jones, 1996; Charman et al., 2002) systems are all in use. The 
SCORAD system is the most widely used. SCORAD was developed by the 
European Task Force on Atopic Dermatitis in 1993. This comprises the scoring 
of AE on six clinical signs of the disease with a score ranging from 0-3. Added to 
this is a score for itch and sleep loss. It is often then categorised as mild if the 
score is less than 15, moderate if the score is 15 to 40 and severe disease if over 
40. 
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The EASI system was described in 1998 and involves an assessment of the 
average intensity of four clinical signs - erythema, induration/papulation, 
excoriations and lichenification, scored 0-3, on four defined body sites. Disease 
extent is also assessed in each of the four regions on a scale of 0-6. The total 
score for each body region is obtained by multiplying the sum of the severity 
scores of the four key signs by the score of the specific body area. This is then 
multiplied by the constant weighted value. The constant weighted value is the 
contribution of each of the defined body areas to the total body surface area. 
The SASSAD was described in 1996 and comprises an assessment of six clinical 
signs (erythema, exudation, excoriation, dryness, cracking and lichenification) 
over six defined body areas (head and neck, arms, hands, legs, feet and trunk). 
These are assessed on a scale of 0-3 and added together. All three scoring 
systems have their advantages and disadvantages but in general patients diagnosed 
by one type of assessment would also have the same diagnosis with an alternative 
assessment. 
1.3.5 Genetics of atopic eczema 
It has been known for some time that AE has a genetic component and its 
pathogenesis is related to the interaction of genetic components with 
environmental factors. Prior to this study, some twelve regions of the human 
genome have been linked to atopy and eczema (Table 1.1). 
1.3.6 Twin studies 
Comparisons of monozygotic twin pairs to dizygotic twin pairs allows the genetic 
and environmental involvement in the pathogenesis of specific disease to be 
estimated (Bataille, 1999). Monozygotic twin pairs are 100% identical meaning 
that their DNA will have exactly the same mutations within it, however there may 
be epigenetic factors. Dizygotic twin pairs only share, on average, 50% identical 
genetic makeup. Twin studies of eczema show concordance rates of 0.72-0.86 in 
monozygotic twins and 0.21-0.23 in dizygotic twin pairs (Bowcock and Cookson, 
2004; Larsen et al., 1986; Schultz Larsen, 1993). Heritability has been seen in 
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many atopic diseases. A Swedish study showed 33-76% heritability to atopy 
(including AE) in a set of twins aged 7-9. This study also showed the importance 
of sex variation as AE was found to be more prevalent in females than males 
(Lichtenstein and Svartengren, 1997). Studies on the genetic variation of IgE 
production has also revealed that susceptibility to atopy has a major genetic 
component (Wuthrich, 1998; Wuthrich et al., 1981). Total serum IgE levels have 
shown a heritability of -50% (Gerrard et al., 1978; Palmer et al., 2000). 
1.3.7 Whole genome linkage screens in atopic eczema 
A genome wide linkage screen typically comprises 400 microsatellite markers 
evenly spaced throughout the genome typed in families. In this case the Applied 
Biosystems PRISM LMS v2.5 10 cM panel was used and has previously been 
used with success (Kelsell et al., 2005). This works on the theory that markers 
close to the disease gene will be co-inherited. Gene identification is then carried 
out by positional cloning (Boehm, 1998). This allows researchers to find the gene 
influencing disease susceptibility without prior knowledge of its function. In 
complex traits most linkage studies have little power due to small sample sizes. 
Genome wide linkage screens have been completed in four populations for AE. 
There are few overlapping regions of linkage in all four of these studies (Table 
1.1) and this could be due to sample size, the marker panels used, statistical 
methods used or it could even be related to the classification of AE in their study 
populations (Hoffjan and Epplen, 2005). 
39 
Reference Study 
population 
Sample Phenotypes Regions of 
highest 
linkage 
P-value 
(Lee et al., European 199 families AE 3 21 8.42x10 
2000) with ?: 
2 
affected 
siblings 
Allergic 
sensitization 
3g21 6.7x10 
(Cookson et British 148 nuclear AE l q21 0.0005 
al., 2001) families 17q25 0.0004 
recruited via 
children with 
AE plus 
Asthma 
20p 0.0005 
active AE Serum IgE 16 -tel 0.0007 
5 31 0.004 
(Bradley et al., Swedish 109 families AE 3q24-22 0.001 
2002) (197 affected 5p13 0.005 
full sib-pairs, 9 6 16 0.01 
affected half- 10 13-12 0.01 
sib pairs) AE plus 18 21 0.001 
specific IgE 4q24-26 0.005 
6 0.01 
l p32 0.01 
Extreme AE 18p 0.005 
21 21 0.005 
7p]4 0.005 
Severity score 13 l4 7.4x10 
of AE 15 14-15 7.4x10 
17 21 7.4x10 
3 14 7.4x10 
(Haagerup et Danish 23 affected AE plus 3p26-24 0.001 
al., 2004) sib-pair specific IgE 4 l4-15 0.0126 
families 18 11-12 0.004 
18 11-12 0.004 
Table 1.1 - Whole genome microsatellite linkage studies performed in AE. 
Four different Northern European populations were analysed for linkage to AE 
however even with the geographical proximity of the populations there is little 
replication of linkage to specific chromosomal regions. Adapted from Hoffjan and 
Epplen, 2005. 
1.3.8 Whole genome microsatellite scan in Bangladeshi population 
In collaboration with Oxagen, a microsatellite whole genome scan was performed 
using 60 AE families with at least one family member with severe AE. This was 
conducted prior to any work contained in this thesis. Linkage was identified in a 
number of chromosomal regions. Chromosome 2,3 and X all showed regions of 
linkage. This is shown in figure 1.4 A, B and C. Chromosome 2 had a linkage 
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peak in relation to IgE levels as did the X chromosome. Chromosome 3 had a 
linkage peak with affected status. 
Initially linkage analysis was done using both parametric and non-parametric 
analysis. However it is thought that non-parametric analysis is most appropriate 
for complex disease analysis as a mode of inheritance does not have to be 
assumed and therefore is more robust with less error. 
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Figure 1.4 (A) - Chromosome 2 linkage. Maximum likelihood score (MLS) for 
chromosome 2 with MLS scores > 1. LOD scores are computed for all markers 
using non-parametric analysis. A linkage peak of around 1.8 can be seen at 
approximately 190 cM. 
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Figure 1.4 (B) - Chromosome 3 linkage. Maximum likelihood score (MLS) for 
chromosome 3 with MLS scores > 1. LOD scores are computed for all markers 
using non-parametric analysis. A linkage peak of around 1.75 can be seen at 
approximately 70 cM. 
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Figure 1.4 (C) -X chromosome linkage. Maximum likelihood score (MLS) for 
the X chromosome with MLS scores > 1. LOD scores are computed for all 
markers using non-parametric analysis. A wide linkage peak of -1.8 can be seen 
between 50 and 90 cM. 
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Comparison of the previous four linkage screens for AE which were carried out in 
Northern European populations and this linkage screen in the Bangladeshi 
population indicates little overlap in these results. No chromosome two or X 
chromosome regions have been highlighted in the previous studies. The 
chromosome three region has previously been identified by the Haagerup et al 
(2001) study. 
Reproducibility of whole genome linkage data is extremely sporadic, as can be 
seen in table I. I. The power of linkage results is intrinsically linked to sample 
size, pedigrees versus sibling pair studies and the polygenic nature of inheritance. 
Multiple testing can also have a great effect on statistical robustness. There has 
been limited reproducibility of whole genome linkage results in several other 
diseases such as osteoporosis (Deng et al., 2002), hypertension (Patel et al., 2003) 
and prostate cancer (Xu et al., 2005). 
1.3.9 Candidate gene association studies in atopic eczema 
Candidate gene association studies can be studied using unrelated cases and 
controls and also with families. They have the power to detect genes with more 
modest effects in populations. There are many sources of error in this type of 
approach such as false-positive results, population stratification and correction for 
multiple testing. Some twenty genes have all been previously associated with AE 
(Table 1.2) with varying results. Some genes have been robustly replicated such 
as FLG and others have contradictory results such as IL-4. From these twenty 
identified candidate genes only ten have come from areas identified in the 
previous linkage scans. Six of these genes come from one chromosomal region, 
5g31. 
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Candidate gene association studies 
Gene Gene name Location Variant Phenotype Population Association? Reference 
FLG Filaggrin 1g21 R501X AE Irish Yes (Palmer et al., 
2006) 
AE British Yes (Barker et at., 
2006) 
AE German Yes (Weidinger et 
al., 2006) 
Extrinsic German Yes (Weidinger et 
AE at., 2007) 
Early onset German Yes (Weidinger et 
AE al., 2007) 
AE Japanese No (Nomura et 
al., 2007) 
AE European Yes (Marenholz et 
al., 2006) 
AE British Yes (Morar et al., 
2007) 
AE German Yes (Ruether et 
al., 2006) 
AE German Yes (Stemmler et 
al., 2006) 
2282de14 AE Irish Yes (Palmer et at., 
2006) 
AE British Yes (Barker et at., 
2006) 
AE German Yes (Weidinger et 
al., 2006) 
Extrinsic German Yes (Weidinger et 
AE at,, 2007) 
Early onset German Yes (Weidinger et 
AE al., 2007 
AE Japanese No (Nomura et 
al., 2007) 
AE British Yes (Mohr and 
Takashima, 
2007) 
AE European Yes (Marenholz et 
al., 2006) 
AE German Yes (Ruether et 
al., 2006) 
AE German Yes (Stemmler et 
al., 2006) 
3321 delA AE Japanese Yes (Nomura et 
at., 2007) 
AE Irish No (Nomura et 
al., 2007) 
3702de1G AE Japanese No (Nomura et 
al., 2007) 
S2254X AE Japanese Yes (Nomura et 
al., 2007) 
AE Irish No (Nomura et 
at., 2007) TLR2 Toll like 4q32 Arg753G1n Severe AE German Yes (Ahmad- 
receptor 2 Nejad et at., 
2004) 
IRF2 Interferon 4q35 -467 G/A AE Japanese Yes (Nishio et at, 
regulatory 2001) 
factor 2 
CSF2 Colony 5g31 -677 A/C AE British Yes (Rafatpanah 
stimulating et al., 2003 factor 2 3606 T/C, AE at 12 Canadian Yes (He et at, 
3928 C/T months and 2003a) 
24 months 
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Candidate gene association studies 
Gene Gene name Location Variant Phenotype Population Association? Reference 
IL4 Interleukin 4 5q31 -590 C/T AE Japanese Yes (Kawashima 
et al., 1998b) 
Extrinsic German Yes (Novak et al., 
AE 2002) 
AE Australian No (Elliott et at., 
2001) 
Intrinsic Japanese No (Tanaka et at., 
AE 2001) 
1L13 Interleukin 13 5g31 Arg13OGln AE Canadian Yes (He et at., 
2003b) 
AE Japanese Yes (Tsunemi et 
at., 2002c) 
AE German Yes (Liu et at., 
2000)) 
-1111 C/T AE Dutch Yes (Hummelshoj 
et al., 2003) 
AE Japanese No (Tsunemi et 
at., 2002c) 
1L5 Interleukin 5 5q31 -703 C/T Blood Japanese Yes (Yamamoto et 
eosinophili at., 2003) 
a in AE 
CD14 Monocyte 5q31 -159 C/T AE American Yes (Gern et al., 
differentiation (interaction 2004) 
antigen CD14 with dog 
ownership) 
AE German No (Sengler et 
at., 2003) 
ILI2B Interleukin 5g31-33 1188 A/C AE, Japanese Yes (Tsunemi et 
12B Psoriasis at., 2002a) 
SPINK5 Serine 5q32 Glu420Lys AE British Yes (Walley et al., 
Protease 2001) 
Inhibitor, AE Japanese Yes (Kato et at., 
Kazal type 5 2003) 
AE Japanese Yes (Nishio et al., 
2003) 
Asthma German Yes (Kabesch et 
with AE al., 2004) 
Disease Japanese Yes (Kusunoki et 
severity at., 2005) 
and food 
allergy in 
AE 
FCERIB High affinity 11g13 Rsalinl, AE British Yes (Cox et at., 
IgE receptor, Rsalex7 1998) 
Beta chain 
GSTPI Glutathione- 11g13 I1e105Vat AE Russian Yes (Safronovaet 
S-transferase haplotypes al., 2003) 
AE Russian Yes (Vavilin et at., 
2003) 
PHF11 Plant 13g14 T/C intron Childhood Australian Yes (Jang et al., 
homeodomain 3, G/A AE 2005) 
zinc finger 11 3'UTR 
protein 
CMAI Mast cell 14g11 BstXI AE Japanese Yes (Mao et al., 
chymase 1996) 
AE Japanese Yes (Mao et al., 
1998) 
AE Japanese No (Kawashima 
et al., 1998a) 
AE Italian No (Pascale et at., 
2001 
-1903 G/A IgE levels British Yes (Iwanaga et 
in AE at., 2004 
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Candidate gene association studies 
Gene Gene name Location Variant Phenotype Population Association? Reference 
IL4RA Interleukin 4 16p12 Gln551Arg Severe AE American Yes (Hershey et 
receptor alpha al., 1997) 
chain Adult AE Japanese Yes (Oiso et al., 
2000) 
AE British Yes (Callard et al., 
(interaction 2002) 
with 
infection) 
Intrinsic Japanese No (Tanaka et al., 
AE 2001) 
-3223 C/T Extrinsic German Yes (Novak et at., 
AE 2002) 
AE Japanese Yes (Hosomi et 
at., 2004) 
CARDIS Caspase 16g12 2722 G/C AE German Yes (Kabesch et 
recruitment al., 2003) 
domain 
containing 
protein 15 
RANTES Regulated 17g11- -403 A/G AE German Yes (Nickel et at., 
upon 12 2000) 
activation, AE Hungarian No (Kozma et al., 
normally T 2002) 
cell expressed 
and secreted 
EOTAXIN Eotaxin 17g21 -426 C/T, - IgE levels Japanese Yes (Tsunemi et 
384 A/G in AE at., 2002b) 
TGFB1 Transforming 19g13 Arg25Pro AE British Yes (Arkwright et 
growth factor al., 2001) 
beta 1 
SCCE Stratum 19g13 AACCins AE British Yes (Vasilopoulos 
Corneum et al., 2003) 
chymotyptic 
enzyme 
Table 1.2 - Candidate gene association studies in AE. Studies have been 
conducted in several different ethnic populations. Twenty genes have been 
identified as being involved in the pathogenesis to date, although many of which 
have had limited replication. Adapted from Hoffjan and Epplen, 2005. 
Many genes have been identified, both previously associated and novel, as 
candiates of interest within the Bangladeshi population. These genes are 
discussed further in the following sections (1.3.10 -1.3.26). 
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1.3.10 Filaggrin 
Filaggrin (filament aggregating protein - FLG) is an essential protein which is 
found in the epidermis of the skin. Profilaggrin is cleaved into singular repeats of 
the FLG peptide and it then aggregates the keratin cytoskeleton which causes the 
collapse of the granular cells into the flattened anuclear squams of the stratum 
corneum (Proksch et al., 2008). 
In 2006, loss-of-function mutations were reported in FLG as a pre-disposing 
factor for AE in families with Ichthyosis Vulgaris (IV) and also in case-control 
studies (Palmer et al., 2006). These same mutations were also found to be 
associated with IV (Smith et al., 2006). As early as 1987 it was known that FLG 
was absent from biopsies of patients with IV skin, so this finding confirmed 
previous immunoblotting studies (Fleckman et al., 1987; Penabad et al., 1998). 
FLG is located within the epidermal differentiation cluster at 1g21. It consists of 
three exons, however the start site is located in exon two with most of the coding 
region within exon three. Exon three consists of between ten and twelve tandem 
repeats and three common versions of the FLG repeats have been identified. 
Generally individuals have repeat eight repeated, repeat ten repeated or they have 
both repeats eight and ten repeated (Sandilands et al., 2007a). This means that 
individuals can either have ten, eleven or twelve repeats in total. 
1.3.11 SPINK5 
The SPINK5 gene encodes the protein lymphoepithelial Kazal type related 
inhibitor (LEKTI) which in turn is a 15-domain serine protease inhibitor. LEKTI 
is expressed specifically in tissue which contains stratified epithelia such as skin, 
thymus and oesophagus (Bitoun et al., 2003). In the skin, expression is mainly in 
the epidermis within the granular layer which is where terminal differentiation 
leading to stratum corneum formation occurs (Deraison et al., 2007). LEKTI 
expression has been localised to intracellular lamellar granules until it is secreted 
into extracellular space between granular cells and cornified cells (Ishida- 
Yamamoto et al., 2005). A variety of single multi-domain LEKTI fragments are 
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produced as the LEKTI precursor is cleaved by furin. These fragments are then 
secreted in cultured keratinocytes and in the epidermis (Deraison et al., 2007). It 
has also shown inhibition of the human kallikreins 5,7 and 14 (Deraison et al., 
2007) as well as trypsin, cathepsin G, plasmin, subtilisin A and neutrophil elastase 
have all been shown to be inhibited by the full-length LEKTI protein (Mitsudo et 
al., 2003). 
Recessive SPINK5 mutations underlie Netherton syndrome (Chavanas et al., 
2000). Nethertons syndrome is a rare autosomal recessive skin disorder where the 
patients have ichthyosiform erythroderma and also a specific hair phenotype - 
bamboo hair (trichorrhexis invaginata) (Judge et al., 1994). However patients also 
display elevated IgE, hayfever, asthma and food allergies, showing an immune 
system sensitisation and overlap with the symptoms of atopy. Several studies 
have shown SPINK5 to be implicated in AE in different ethnic populations 
(Kabesch et al., 2004; Kato et al., 2003; Nishio et al., 2003; Walley et al., 2001). 
SPINK5 mutations/LEKTI deficiency causes abnormal desmosome cleavage at 
the granular layer-stratum corneum junction (Descargues et al., 2005; Hewett et 
al., 2005; Ishida-Yamamoto et al., 2005; Tartaglia-Polcini et al., 2005; Yang et al., 
2004). The result of this is the loss of skin barrier which is caused by defective 
stratum corneum adhesion (Descargues et al., 2005; Hewett et al., 2005; Tartaglia- 
Polcini et al., 2005; Yang et al., 2004). 
1.3.12 NOD! 
NOD] is located at Chr 7p15. It was the first member to be identified of the Nod- 
like receptors (NLRs) family and to date more than 20 NLR genes have been 
identified through bioinformatic analysis in the human genome. They are thought 
to be located in the cytosol so that they can continuously screen this compartment 
for the presence of microbes. Studies have found Nodl (murine) to be located in 
the cytosol and be responsible for the activation of NFKB following S. Flexneri 
infection (Girardin et al., 2001). Many functions of NODI are as yet unknown 
but it has been found to have a crucial role in the inflammatory response and 
instruction of adaptive immunity. Many studies have indicated that activation of 
NOD1 results in the transcription of a large number of genes 
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Two studies have previously associated NOD] haplotypes with AE (Laitinen et 
al., 2001; Weidinger et al., 2005). The study by Laitinen et al (2001) was a 
linkage study for asthma and atopy and revealed that an area of linkage to atopy 
and elevated IgE levels was in the 7p15 region where NOD] lies. The study by 
Weidinger et al (2005) was the first to show NODI polymorphisms and 
haplotypes that were associated with atopy susceptibility. 
NOD] is a single copy gene consisting of fourteen exons which produce the 
NOD1 protein. NLR family genes are made up of three domains. The N-terminal 
domain is a variable-effector binding domain, which could be a pyrin domain, a 
Toll/IL-1 receptor domain or a baculoviral inhibitor of apoptosis domain. NODI 
has an N-terminal Caspase Activation and Recruitment Domain (CARD). The N- 
terminal region is the main region of variation within the NLR family. The final 
two regions are a Nucleotide-binding Oligomerization Domain (NOD) and a C- 
terminal Leucine-Rich Repeat domain (LRR) (Coussens et al., 2007). The LRR is 
required for ligand recognition. Once a ligand has been recognised NOD I 
initiates the activation of NFiB through CARD-CARD interactions with receptor 
interacting serine/threonine kinase (RICK). Mutations in the CARD domain of 
NOD] disrupt the activation of NFKB and it is through this that NOD 1 is thought 
to be essential for activation of inflammatory and apoptotic pathways (Inohara et 
al., 1999). 
1.3.13 IL4RA 
IL4RA is a receptor for both IL-4 and IL-13 and is coupled to the JAK/STAT 
pathway (Nelms et al., 1999). The gene IL4RA encodes the 140 kDa alpha 
subunit of the IL4 receptor. This subunit of the receptor is responsible for binding 
IL-4 and transduces its growth promoting and transcription activating functions. 
The main function is the regulation of IgE production. The production of IgE is 
initiated by antigen presenting B cells interacting with antigen specific type 2T 
helper cells (Bonnefoy et al., 1996). Binding of IL-4 to its receptor (IL4RA) on 
the B cell delivers the first signal for isotype switching and induces the production 
of the IgE antibodies (Bacharier and Geha, 2000). 
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Associations with atopy and atopic phenotypes have been reported in two case- 
control studies (Hershey et al., 1997; Mitsuyasu et al., 1998) and in one family 
based study (Ober et al., 2000). Specifically the ile50 allele has been associated to 
atopic asthma and the arg551 allele has been associated with hyper IgE syndrome 
and atopy. Hershey et al showed that the mutation arg551 segregated in patients 
with hyper IgE syndrome and therefore hypothesized that it may contribute to the 
pathogenesis of a number of allergic diseases. They also demonstrated that the 
mutant allele seemed to be inherited in a dominant manner but with variable 
penetrance due to a number of carriers showing no signs of atopy. However this 
study had a very low sample number and therefore it is difficult to anticipate if 
this is a correct finding. Mitsuyasu et al studied the ile50 variant in relation to 
atopic asthma. Their data suggests that the ile50 variant significantly upregulates 
the receptor response to IL-4, and therefore STAT6, and this results in increased 
cell proliferation and IgE production. Ober et al investigated IL4RA in a Hutteries 
population. They found that variation not within the coding region was 
responsible for the linkage and associations found by previous studies and also 
their own. However the evidence does suggest that the association is coming 
from within the IL4RA gene region because the linkage disequilibrium does not 
extend beyond the intracellular domain of IL4RA in outbred families. These 
studies have all indicated that IL4RA may be of some significance in the search 
for genes which contribute to AE susceptibility and it was for these reasons that 
the gene was selected for investigation. Additionally, the V50 allele of the ile50 
variant (Mitsuyasu et al., 1998) has been associated with slow progression to 
AIDS after HIV infection. 
IL4RA belongs to a larger superfamily of haematopoietin receptors (Idzerda et al., 
1990). This family was additionally identified by the presence of highly 
conserved cysteine residues and also a WSXWS motif within another region of 
less well conserved amino acids. Both of these regions lie within the extracellular 
portions of the proteins. IL4RA can also be alternatively spliced so that along 
with the membrane bound receptor it can also be secreted (Kruse et al., 1999). 
The secreted version of IL4RA contains no transmembrane region or the 
cytoplasmic membrane charged residues which anchor the protein to the 
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membrane (Cosman, 1993). The gene itself consists of eleven exons and is 
located at chromosome 16p12. 
1.3.14 ST2 
ST2 is an orphan receptor which has relevance to AE due to its expression in type 
2T helper cells and not type 1 (Yanagisawa et al., 1997). ST2 production has also 
been reported in mast cells (Moritz et al., 1998), which are effector cells in the 
acute stages of AE. It has been shown that the absence of ST2, in ST2 deficient 
mice, macrophages produce increased amounts of proinflammatory cytokines in 
response to IL-1, bacterial lipoprotein, and lipopolysaccharide (LPS) (Brint et al., 
2004; Trajkovic et al., 2004). IL-1 is key in preliminary inflammatory responses 
and therefore an absence ST2 and therefore an increase in IL-1 could lead to 
atopy, AE or any number of inflammatory diseases. 
A SNP in a distal promoter to ST2, rs6543116 (-26999G/A) (Shimizu et al., 2005) 
was found to be associated with AE. This study was done in a Japanese 
population. This SNP was found to regulate transcriptional activity of ST2 and 
with that the -26999A allele seemed to contribute to higher levels of serum ST2 
and also IgE. ST2 is located at chromosome 2q12 and consists of eleven exons 
spanning 40 kB. Other genes within the 2q12-14 region, where ST2 maps, which 
is predominantly an ILI R gene cluster, have also been associated with asthma 
(Karjalainen et al., 2002; Mao et al., 2000; Wjst et al., 1999) and therefore genes 
in this region seem to be involved in the immune response to allergic disease and 
could therefore be involved in AE. The SNP in the distal promoter could in fact 
be having a regulatory effect on other genes within this genomic region. 
ST2 is a member of the Toll-interleukin 1 receptor (TIR) superfamily (O'Neil, 
2000). There are three subgroups of TIR genes. The first group have 
extracellular immunoglobulin domains (includes ST2). The 2nd have extracellular 
leucine-rich repeats and the third consists of cytosolic proteins that act as 
adaptors. They are all defined as having an intracellular TIR domain and initiate 
immunity through the activation of the transcription factor NFicB which then lead 
on to the production of proinflammatory cytokines. ST2 however does not 
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activate NFKB but has been suggested as an important effector molecule of Th2 
responses. 
1.3.15 STAT6 
STAT6 is a member of the STAT protein family, of which there are seven 
members. STAT6 carries out a dual function, it is responsible for signal 
transduction of various stimuli and it is involved in IL-4 (Takeda et al., 1996) and 
IL-13 (Palmer-Crocker et al., 1996) activation. Both IL-4 and IL-13 are important 
mediators in the allergic immune response (Weidinger et al., 2004). STAT6 is 
phosphorylated in response to cytokines and growth factors and then translocates 
to the cell nucleus and acts as a transcription activator. STAT6 also has a primary 
role in the regulation of T cell and eosinophil migration into sites of allergic 
inflammation (Hebenstreit et al., 2006). 
SNPs in a Japanese population have been associated with allergic disease, 
including asthma and AE (Negoro et al., 2006; Tamura et al., 2001). The STAT6 
mutation (G2964A) was found be to linked to eosinophilia in local inflammatory 
sites, especially in the population of patients with high levels of eosinophils in the 
blood (Negoro et al., 2006). Tamura et al (2001) discovered a dinucleotide repeat 
in exon 1 of the STAT6 gene which when further analysed allowed them to class 
individuals into 4 groups depending on the number of repeats in the GT repeat (13 
repeats to 16 repeats). The 1" group with 13 GT repeats was found to have a 
higher frequency in the number of children with allergic disease compared with 
controls although this did not reach statistical significance. Another association to 
allergic disease was found in a group who were group 1 (13 GT repeats) and 
group 3 (15 GT repeats) heterozygous. This was not linked to IgE levels. This 
group had previously found no association to the G2964A variant and this gives a 
mixed message as to the importance of STATE in AE and atopy. 
STAT6 is located at chromosome 12g13.3. There are 23 exons within STATE and 
is 19 kb in length. There are many proteins which are known to interact with 
STAT6 and these include IL4RA and NFKB. There are also approximately 35 
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known proteins which are regulated by STAT6, these include IL4, CD40 and the 
polymeric Ig receptor (Hebenstreit et al., 2006). 
1.3.16 TIM3 
TIM3 is located at 5q33.3 and encodes a T-cell immunoglobulin and Mucin 
domain 3. TIM3 is expressed on type 1T helper cells (Thl) but not type 2T 
helper cells (Th2) and a mouse model has shown that abrogation of interaction 
between TIM3 and its ligand leads to heightened Thl responses (Sabatos et al., 
2003). The addition of an antibody against TIM3 in mice, enhanced the 
detrimental effects of an experimental autoimmune disease (Monney et al., 2002). 
It is now thought that interaction of TIM3 and its recently identified ligand, 
Galectin-9 (Zhu et al., 2005), may have an effect on the Thl dependent immune 
response (Monney et al., 2002; Sabatos et al., 2003). Three SNPs in TIM3 have 
been found to be associated to atopy and AE (Graves et al., 2005). None of these 
associations were translated over to any asthmatic phenotypes. Two of the three 
SNPs remained significant after correcting for multiple testing in relation to 
association with AE. The three significant SNPs were also found to be in high 
LD. 
The T-cell immunoglobulin domain and mucin domain protein family located at 
chromosome 5q33 have been implicated in several linkage studies in relation to 
allergic diseases (CSGA, 1997; Holberg et al., 2001; Ober et al., 1998; Xu et al., 
2001; Yokouchi et al., 2000). TIM3 spans 23.3 kb and consists of seven exons. 
1.3.17 SLC9A3R1 
SLC9A3R1 (SoLute Carrier family 9, isoform 3 Regulatory factor 1) is an apical 
membrane phosphoprotein and it links membrane proteins to the actin 
cytoskeleton (Helms et al., 2003). It is also thought to have a role in the function 
and localisation of G-protein-coupled receptors and platelet-derived growth 
factors by bringing together membrane and non-membrane proteins to regulate 
cell metabolism and growth (Voltz et al., 2001). Immunohistochemistry has 
shown that this protein is expressed in the granular layer where terminal 
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differentiation occurs and is also in T cells (Helms et al., 2003). It has also been 
suggested that SLC9A3R1 is a negative regulator of T-cell activation (Itoh et al., 
2002) and this was shown when T cells were activated and SLC9A3R1 mRNA 
levels were examined (Helms et al., 2003). It has been previously associated with 
psoriasis and is located in a region of linkage with psoriasis (Helms et al., 2003). 
SLC9A3R1 could have a negative regulatory role in the epidermis also by 
modulating keratinocyte response to an immune signal. Terminal differentiation 
could also be affected in AE and SLC9A3R1 may also have a role in this by 
switching from wound-repair to homeostatic growth. SLC9A3R1 is located at 
17q25.1 and consists of six exons. It binds members of the Ezrin-Radixin-Moesin 
(ERM) family during the reorganisation of the actin cytoskeleton. 
1.3.18 CD86 
CD86 is a type I membrane protein of the immunoglobulin superfamily. It has 
been found that CD86 interacts with CD28 to provide co-stimulatory signals for T 
cell activation and has been implicated in the activation of the The subset of CD4+ 
T helper lymphocytes that are thought to have a pivotal role in mediating allergic 
inflammation (Lanier et al., 1995). Linkage to the 3g21 region with AE, where 
CD86 resides in the genome, has also been previously described (Lee et al., 2000). 
CD86 is located at chromosome 3g21, consists of seven exons and spans 65.76 
kb. 
1.3.19 Tenascin-C 
Tenascin-C (TNC) is an extracellular matrix protein which is expressed during 
embryogenesis and wound healing. Normal skin expression of TNC is low but its 
expression can be elevated in skin tumours and in wound healing (Latijnhouwers 
et al., 1996). Regulation of TNC is by cytokines and therefore could be involved 
in the immune regulation of the skin (Latijnhouwers et al., 1998). In cultured 
keratinocytes it was found that TNC is upregulated by IL-4 and IL-13 and 
moderately by interferon y. It has been found to be upregulated in lesional skin of 
AE patients and was not found to be upregulated in normal skin or psoriatic skin 
(Ogawa et al., 2005). Upregulation of TNC in AE patients lesional skin suggests 
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its role may be specific to AE and therefore it may be involved in the immune 
regulation of AE. TNC is located at 9q33, consists of twenty eight exons and 
spans 97.68 kb. 
1.3.20 Kynureninase 
Kynureninase (KYNU) is an enzyme involved in the tryptophan degradation 
pathway (Ito et al., 2004). The upregulation of this pathway confers antibacterial 
and antiparasitic effector functions on monocytes, macrophages, fibroblasts and 
epithelial cells (Ito et al., 2004). T cell proliferation is also inhibited by changes 
in this pathway (Munn et al., 1999). It has been found that KYNU mRNA is 
upregulated in skin lesions in all AE patients in comparison with involved skin in 
AE patients and normal controls (Nomura et al., 2003). KYNU was also induced 
in mice with the formation of AE like skin lesions (Ito et al., 2004). This 
indicates that the tryptophan degradation pathway could be involved in the 
pathogenesis of AE. KYNU is located at 2q22.3, consists of fourteen exons and 
spans 164.77 kb. 
1.3.21 ACVR1 
Activin-A (ACVR1) seems to be structurally and functionally similar to 
Transforming Growth Factor beta (TGF-ß) and like TGF-ß it has been found to be 
involved in the pathogenesis of asthma (Karagiannidis et al., 2006). It has been 
described to induce apoptosis and regulate growth and development in the early 
phases of embryogenesis and haematopoiesis (Karagiannidis et al., 2006). It also 
seems to promote proliferation in fibroblasts (Karagiannidis et al., 2006). Human 
mast cells are an abundant source of ACVR1 and these cells are well known for 
their role in allergy and inflammation. Control of proliferation and apoptosis and 
ACVR1's role in mast cells are ways in which ACVR1 could be involved in AE. 
ACVR1 is located at 2q23-24, consists of eleven exons and spans 138.66 kb. 
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1.3.22 CCR4 
CCR4 is a member of the G-protein-coupled receptor family. It is a receptor for 
the CC chemokine RANTES. Chemokines are a group of small polypeptides, 
structurally related molecules that regulate cell trafficking of various types of 
leukocytes. The chemokines also play fundamental roles in the development, 
homeostasis, and function of the immune system, and they have effects on cells of 
the central nervous system as well as on endothelial cells involved in angiogenesis 
or angiostasis. CCR4 expressing cells have been found at sites of allergic 
inflammation (Banwell et al., 2003). Therefore CCR4 could be involved in the 
immune aspect of AE. CCR4 is located at 3p24, consists of two exons and spans 
3.34 kb. 
1.3.23 JAKS 
JAK3 is a tyrosine kinase of the non-receptor type, involved in the interleukin-2 
and interleukin-4 signalling pathway. It phosphorylates STAT6, IRS1, IRS2 and 
P13K and seems to play a role in IgE receptor/mast cell response. The NC/Nga 
mouse established in 1957 seems to show similar AE like symptoms and is often 
used as a model for AE (Matsuda et al., 1997; Vestergaard et al., 2000; 
Vestergaard et al., 1999). These mice show AE-like skin lesions and markedly 
upregulated IgE levels. In these mice it has been found that enhanced tyrosine 
phosphorylation of JAKS mediated by IL-4 results in hyper-IgE production 
(Matsumoto et al., 1999). It has therefore been proposed as a mechanism for the 
pathogenesis of AE. JAKS is located at 19p13.11, consists of twenty four exons 
and spans 21.84 kb. 
1.3.24 ILIORA 
ILIORA is a receptor for IL-10 and binds IL-10 with a high affinity. It is involved 
in JAK-STAT pathway. Allergic responses of young children have been 
characterised and production of IL-10 was found to be impaired when stimulated 
with food, vaccines and staphylococcus aureus, a pathogen to cause many 
infections in AE lesions (Dunstan et al., 2005). Impairment of the IL10 receptor 
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could be involved in AE due to the observation that IL10 is impaired in atopic 
patients. ILIORA is located at 11 g23.3, consists of seven exons and spans 15.09 
kb. 
1.3.25 PTGDS 
Prostaglandins are recognised as mediators that increase pain and inflammation 
(Arai et al., 2004). Prostaglandin D2 (PTGDS), a constitutive prostaglandin 
endoperoxidase synthase, is involved in a variety of biological processes such as 
platelet aggregation and relaxation of vascular and nerve cell function (Hirai et al., 
2001). PTGDS has been shown to attract basophils, The cells and eosinophils 
(Kanaoka and Urade, 2003) which indicates its potential role in allergic and 
inflammatory diseases. PTGDS has been shown to play a role in the inhibition of 
itching in mice with atopic like dermatitis. Scratching as a reaction to itching 
causes injury to the skin, which, in-turn further increases the itching, the so called 
itch-scratch cycle (Sugimoto et al., 2007). It is thought to play a role in 
inflammation, arthritic disease and cancer and has been shown to be regulated by 
some of the interleukins, although this mechanism is yet to be fully explored. 
PTGDS is located at 9q34, consists of seven exons and spans 4.24 kb. 
1.3.26 ABCA12 
ABCA12 is thought to transport lipids (Akiyama et al., 2005) to the cornified 
envelope and therefore is very important in the skin barrier formation. Recessive 
mutations in ABCA12 cause the skin disease Harlequin Ichthyosis (HI) (Kelsell et 
al., 2005; Thomas et al., 2006; Thomas et al., 2007). HI is a severe disease where 
the barrier function of the skin is severely disrupted. ABCA12 is also implicated 
in two other barrier function disease lamellar ichthyosis type 2 (L12) (Lefevre et 
al., 2003) and Non-Bullous Congenital Ichthyosiform Erythoroderma (NBCIE) 
(Natsuga et al., 2007). The barrier formation and function is thought to be as 
important in AE as the immune response and the defects in FLG and SPINK5 
demonstrate genes involved in the epidermal barrier to be associated with AE. 
The variation in severity of each of these diseases indicates that ABCA12 
mutations can have wide ranging effects and so minor amino acid changes in 
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ABCA12 could have a less dramatic effect on the skin barrier and be involved in 
AE. Other genes involved in both monogenic skin barrier disease and with AE, 
such as FLG (Palmer et al., 2006; Smith et al., 2006) and SPINK5 (Chavanas et 
al., 2000; Kato et al., 2003; Moffatt, 2004), have been described. 
1.3.27 Overview of objectives of thesis 
The aim of this thesis was to investigate the genetics of AE in the Bangladeshi 
population of East London. This involved investigating previously associated 
genes and also novel genes. The previously associated gene investigation will 
allow validation of this population for use in genetic studies and it will also allow 
investigation into the overlap of gene associations between populations. As AE is 
a common complex disease there may be many more genes involved than those 
already identified and therefore several novel candidates were selected either due 
to their biological function or position within the genome. FLG in particular was 
investigated as this is a gene which has recently come to light as having a 
meaningful contribution to AE and IV. 
This will give a great insight into AE within a unique population and allow 
understanding of the variation between different ethnicities and gene associations 
found in AE, whilst also investigating new gene associations which should be 
investigated in other ethnic populations. This is very important in the 
understanding of common complex diseases. 
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Chapter 2 
Materials and Methods 
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2.1 Recruitment of subjects 
2.1.1 Families 
Eighty families in total were recruited for this study. All originate from Sylhet in 
Bangladesh but now reside in the borough of Tower Hamlets, London. At least 
two children are affected with Atopic Eczema (AE) in each family and all 
available first degree relatives were recruited. Each family was identified through 
the Paediatric Dermatology outpatient department at the Royal London hospital. 
All patients were carefully selected using the UK working party's diagnostic 
criteria (Williams et al., 1994a; Williams et al., 1994b; Williams et al., 1994c). 
Informed consent was given by all families for a genetic and epidemiological 
study. This has also involved a questionnaire (Appendix A), atopic phenotyping 
by IgE levels and blood sampling. Home interviews were performed for the blood 
sampling and completion of the questionnaire by a Sylheti speaking research 
assistant (Ms. Ruma Choudry) trained in phlebotomy and AE diagnosis. Details 
of each family, their affection status (eczema, asthma and hayfever) and their IgE 
levels can be found in appendix B. 
2.1.2 DNA extraction 
Bloods were collected in 0.25mM EDTA tubes to prevent clotting before DNA 
extraction and were then processed immediately or frozen at -80°C. Genomic 
DNA was extracted from whole blood samples using a commercially available kit 
(Qiagen). This was then performed using a robotic workstation based in the 
Genome Centre or at Oxagen. 70 of the families were processed at Oxagen. 
DNA was extracted from blood samples using the QIAGEN FlexiGene DNA kit. 
Table 2.1 shows a list of reagents used for l Oml of blood. These were then scaled 
up or down depending on the total volume of blood in each sample. 
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Reagent 10m1 Blood sample 
Buffer FG1 ml 25.0 
Buffer FG2/IAGEN Protease (ml) 5.0 
100% iso ro anol (ml) 5.0 
70% ethanol (ml) 5.0 
Buffer G3 (ml) 1.0 
Table 2.1 - DNA extraction. Reagents required for processing 10m1 Blood 
samples. 
The protocol was carried out as stated in the FlexiGene DNA handbook. 
2.1.3 Atopic phenotyping 
Total serum IgE levels in all affected patients were quantified using the 
Pharmacia's CAP system (Pharmacia & UpJohn Diagnostic AB, Uppsala, 
Sweden). This was performed by Oxagen. 
2.2 Candidate genes studies 
2.2.1 DNA quantification 
DNA samples were quantified using the PICO green system or using the 
NanoDrop ND- 1000 spectrophotometer (Thermo Fisher Scientific, USA). 
PICO Green is an automated measurement of double stranded DNA in a particular 
sample. Briefly this procedure is set-up using the Biomek FX liquid handling 
robot (Beckman Coulter, USA). A standard curve is set-up using a serial dilution 
of Calf Thymus DNA (Sigma) where 3 µl of the calf thymus DNA is added to 
tube one along with 1250 µl of Tris-EDTA (TE) and mixed thoroughly, tubes 2-7 
all contain 650 µl of TE. 650 pl of tube one is then transferred to tube 2 and 
mixed again. This procedure is repeated from tube 2 to 3 and so on until a serial 
dilution of 7 tubes is achieved. Tube 8 contains H2O as a control. The PICO 
green solution (Molecular Probes) is then defrosted and 34.6 µ1 of it added to 
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9146 pl of TE and mixed thoroughly. All mixtures and DNAs are set up on the 
robot with a series of empty 384 well dilution plates. The estimated concentration 
of the DNA dictates how many plates are required for the dilution. The dilution 
plates are then sealed and centrifuged at a high RPM. The plate is then read on a 
Victor plate reader (Wallac). For a sample to be reliable the coefficient of 
variation (CV) must be less than 20 and samples with a CV more than 20 should 
be re-tested. 
To measure the quantity of DNA in a sample by NanoDrop, 1 µl of DNA is 
pipetted onto the NanoDrop lower measurement pedestal. The optical density 
(OD) was measured as absorbance at 260 and 280 run and the ratio of absorbance 
at 260/280 run was used to assess the purity of the DNA. A ratio of absorbance 
between 1.8 and 2.0 is acceptable. The concentration of the sample was calculated 
from the absorbance measured at 260 nm using a constant of 50 µg/ml =1 OD at 
260 nm for double stranded DNA. 
2.2.2 Primer design 
Primers were designed using the primer 3 website (primer3 www. cgi v 0.2) 
unless otherwise specified. Briefly primers were designed to cover the full coding 
region of the specific exon and included intron/exon boundaries. ABCA12 exon 
primers were as published (Lefevre et al., 2003). 
Name ` Forward Primer ''Cý, Reverse Primer,, -- TA'ý bp 
D2S325 CTT-CAG-AAA-TGC-CGT-TGA-AT AGC-CAA-ATA-GAA-TTG-GAA-CC 60 111 
D2S2382 ACA-TGC-AAC-CGT-GTG-G AGC-ACT-CTT-CAG-TCC-GAA-C 60 221 
D2S126 TGC-CTA-GCA-CAG-AGC-CTA-CT TCC-ATG-GCA-TAG-AAC-AAA-AGT 60 141 
D2S128 AAA-CTG-AGA-TTT-GTC-TAA-GGG- 
G 
AGC-CAG-GAA-TTT-TTG-CTA-TT 58 146 
D2S1345 GCA-CTA-AAA-CCC-GTG-TGA-TC AAA-AGC-TAC-AGG-CCA-GTG-TG 58 169 
Table 2.2 -ABCA12 microsatellite primers. Product size is shown in base pairs 
(bp) and the annealing temperature (TA) in °C. 
Name Forward Primer Reverse Primer -- TA'- = bp 
TCF15-1 CCC-CTC-CCT-CGC-CTA-TAA GAG-GGA-CGC-AGC-ACA-CTC 55 659 
SCRT-2a ACT-TCT-CGC-CCC-CTC-CAG CGT-AGG-TCT-TGC-CGC-AT 55 378 
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Table 2.3 - Anonychia primers. Product size is shown in base pairs (bp) and the 
annealing temperature (TA) in T. 
Name Forward Primer Reverse Primer T b 
R501X ACC-TGA-GTG-TCC-AGA-CCT-ATT CAC-GGA-AAG-GCT-GGG-CTG-A 56 312 
2282de14 AAT-AGG-TCT-GGA-CAC-TCA-GGT GGG-AGG-ACT-CAG-ACT-GTT-T 55 811 
FILr1 CAG-GCC-ATG-GAC-AGG-CTG- 
GTC-A 
GAA-GTC-TCT-GCG-TGA-GGA-GTT 62 751 
Table 2.4 - FLG primers. Primers for 2 common filaggrin mutations (R501X 
and 2282de14) and also for screening of the 2 new mutations (FILr1). Product size 
is shown in base pairs (bp) and the annealing temperature (TA) in °C. 
Name '- Forward primer ""_ Reverse Primer T bJ 
Exon I CCA-CCC-TTG-ACC-TTT-TTC-CT GTG-TGC-ATC-TGC-GCC-TAC 67 389 
Exon 2a CAT-GGG-GTA-GCA-TGT-CCT-CT ACC-CAT-CCC-AGG-AGG-TAA-TC 67 389 
Exon 2b GTC-TGG-TCT-GGT-GAG-CTC-CT CAC-ACA-GGG-ACT-GAC-TGA-GG 70 350 
Table 2.5 - INSL3 primers. Product size is shown in base pairs (bp) and the 
annealing temperature (TA) in °C. 
Name Forward Primer' Reverse Primer ri- - T b Exon I CCT-GGT-TCC-TGT-CTC-TTA-ACT-G GAA-AAA-TAC-CCC-AAA-GCC-ACT 62 190 
Exon 2 ATT-CAT-TCT-CCT-GGG-TGG-TG GAA-CAA-CTG-GAA-GCA-AAC-TGC 62 390 
Exon 3 TCT-TTT-CAT-TTG-ATC-ATT-TCA- 
GGA 
AGC-AGG-GTG-AAA-GAA-GAT-GG 67 298 
Exon 4 TTT-CAC-AAT-GCT-AAG-TGA-CTC- 
TTT-T 
TCT-ATT-TCC-TTC-CAA-ATT-TCT- 
TCT-T 
63 250 
Exon 5 TGA-AGA-AU-ACT-GAG-AAG-GAA- 
ATG-G 
GCT"GTT-CCC-ACT-TCG-ACT-TC 56 263 
Exon 6 TTCA-GAA-GAA-CTT-GAA-AAA- 
CAT-TGC 
ACA-GGG-GTC-ATA-TGG-AAG-GA 56 250 
Exon 7 AAA-ATG-CCA-GTC-GCA-GAA-GT AGG-GGA-AGA-GGA-TGG-TTC-TC 67 233 
Exon 8 GCA-CCT-GCA-AAG-TAG-GCA-TT TCA-GGT-GAT-CAA-AGT-CTC-AGA- 
AA 
63 223 
Exon 9 AGC-CAA-CAT-CCA-TGT-ATC-AGT-T GGG-AGA-AAA-ACT-TGG-TAT-TTG-C 67 387 
Exon 10 AAG-TTG-TAC-TTC-TTG-TTT-TCA- 
TTT-TCA 
GCA-TGA-ATT-TCT-GTC-CCT-AAT-G 67 235 
Exon 11 TGT-TTA-AAG-CAT-TAG-ACT-GAT- 
AAG-AAA 
CAG-AAG-CAG-GGA-AAT-GGA-AG 63 595 
Table 2.6 - ST2 primers. Product size is shown in base pairs (bp) and the 
annealing temperature (TA) in °C. 
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Name Forward Primer Reverse Primer TA bp 
Exon 10 CAT-GAA-GAT-CGG-AAG-CAT-CTC CCC-CCA-CAC-ACA-CAC-AAG-T 58 183 
Exon 29 GAT-GGA-TGA-ACG-GGA-GAA-AA CAT-GGC-TTT-GTC-CCT-TTT-TG 60 243 
Exon 33 CAA-GTG-TCC-TGC-ATG-TTG-GT ACA-AAA-CCA-GAA-CCC-AGT-GC 60 242 
Table 2.7 - SPINKS primers. Primers for exons 10,29 and 33 were redesigned 
due to sequence differences found on examination of the sequence. All other 
primers came from (Bitoun et al., 2003). Product size is shown in base pairs (bp) 
and the annealing temperature (TA) in °C. 
Name Forward Primer Reverse Primer T b 
Exon I CTG-GAA-AGA-AGC-CCT-CAC-TG TTT-TTA-TCA-GCG-CCT-CAA-GC 62 290 
Exon 2 AAA-GGG-CTC-ATT-TTC-TAC-AGG-A AAA-TTT-AAA-AAC-CTT-CCC-AGC-A 56 280 
Exon 3 GCT-TAA-CAA-TAC-CAT-ACT-GAA- 
AAA-GC 
TGT-GAT-TTT-GTA-AAT-TTT-TGT- 
ATG-AGA 
56 247 
Exon 4 TCA-CAC-ACA-TGC-ACA-TAA-AAG- 
C 
CAA-TTC-ATT-TGG-AAA-AAC-TTC-AG 59 174 
Exon 5 TGA-TTG-AGT-GAA-GTC-TTC-CTA- 
CTT-TG 
ACC-CCC-AGA-AGC-TCA-TGA-AT 59 236 
Exon 6 TGT-ATT-AAT-GCT-TTC-TCA-ATA- 
AAT-CCA 
TGC-TTG-GAA-AAG-CCT-AGT-GA 59 211 
Exon 7 TGT-GCT-CTC-AGC-TTG-ATT-TGA TCA-TGC-TTT-CTT-GAA-AGT-TCC-AT 59 240 
Exon 8 TCG-ATA-TGA-CCT-AAC-TTG-TGC- 
CTA 
TGT-TTG-GAG-TAA-GGT-GGG-AAG 67 222 
Exon 9 TTC-TAA-TCA-TGA-AGC-AAA-CTT- 
AAA-GC 
TTA-AAA-TTG-GCC-CAC-AGA-CC 59 233 
Exon 10 TGA-TCA-AAT-GTT-GTG-GTT-TCA-A CAT-CAC-CAA-AGA-ATT-AGC-TGA- 
AGA 
62 212 
Exon 11 CCT-AGG-CAG-CAG-AGC-AAG-AC CTC-TCC-CTG-GGG-CAT-ATA-CA 62 221 
Exon 12 AAG-TCT-TGC-TCT-TTT-ACT-CTC- 
CAG 
TGT-GGG-AAG-GTT-GAA-ACA-CA 62 209 
Exon 13 TCT-GAT-TGT-TTC-TCA-TTC-CAC-A CGG-CCC-ATA-GAC-AAA-ATC-TG 67 297 
Exon 14 TGG-AAT-GTA-GAT-TTT-CAA-CGT-G CCC-TGT-GGA-CTC-CTT-AGT-GC 67 376 
Table 2.8 - KYNU primers. Product size is shown in base pairs (bp) and the 
annealing temperature (TA) in T. 
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Name Forward Primer Reverse Primer T b 
Exon 1 GGA-AGC-ACA-GGT-CAG-CAC-TA CAC-GCC-ATT-AAT-AGC-CAA-CA 55 179 
Exon 2 CTC-AGG-CTG-CTC-CTG-TGT-CT CAC-AAC-CTC-CCC-AAA-CCT-C 64 204 
Exon 3 GCC-TAC-AGG-TGA-CCA-GCC-TA AGG-CAG-CTG-TGG-GAA-CAC 64 246 
Exon 4 ATG-GGG-GAG-TCA-CTG-CAT-AG CCC-CAG-AGG-TCA-CAG-AAA-AA 55 243 
Exon 5 GGC-TGG-TGC-CCT-AAC-ATC-T CCA-TTG-CTT-AGG-CCT-CTT-GA 55 219 
Exon 6 GCT-GTA-CCA-TGG-CTG-ACC-TC CCT-GCA-CTC-CAG-AGG-GAC-T 60 195 
Exon 7 AGG-AGC-GTT-CAC-CTG-TCA-AT ATG-TCC-TCA-TCC-ACG-CCT-AC 60 162 
Exon 8 CTG-CAA-GGC-CAC-TCT-GCT CCA-ATT-CTA-TCA-CCT-TCC-CAA-T 60 151 
Exon 9a CTG-AAC-CCT-GAC-CAA-CCT-TT CTCAGGCGATGCACAGAAG 66 298 
Exon 9b AGAGCAGCAGGGATGACTTC GGGCGTCTCTGTGCAAGT 59 299 
Exon 9c ACCTGACTTGCACAGAGACG GCCTTGTAACCAGCCTCTCC 59 373 
Exon 9d CAGTGCTGTGTCCCCAGA TGGCAGGTAAGGGCTGAGTA 60 321 
Exon 9e GTGTCATGGCCAGGAGGAT CTTCCAGGAGGTGGCATTT 60 379 
Table 2.9 - IL4RA primers. Product size is shown in base pairs (bp) and the 
annealing temperature (TA) in T. 
Name Forward Primer Reverse primer -, 
I TA bp 
rs4571054 GGG-TGC-TGC-TGA-AAC-ATC-CTA GTC-CCG-AAT-TCA-GTG-GAC-AG 60 292 
Table 2.10 - rs4571054 primers. Product size is shown in base pairs (bp) and the 
annealing temperature (TA) in °C. 
Name Forward primer, Reverse primer TA' I bp 
rs1054131 TGT-ATC-CCT-TTG-ACC-CCA-AG CCC-AGA-AGA-GAC-TGG-CAA-TG 53 512 
Table 2.11 - rs1054131 primers. Product size is shown in base pairs (bp) and the 
annealing temperature (TA) in °C. 
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2.2.3 Polymerase chain reaction (PCR) 
Standard PCR reactions were carried out using Taq polymerase (Roche, USA) in a 
PCR reaction with a total volume of 15µl. These reagents as well as 
concentrations used are shown in table 2.12. 
Standard PCR reaction 
5 15n ng/p 
1.5 1 lOX NH2 Buffer 
1.8 1 (25 mM M C12 
0.5 1 (10 mM) dNTPs 
0.1 1 Ta of erase 
1 1 (10 pmol/pl) Forward primer 
1 1 (10 moll 1 Reverse primer 
4.1 1 dH2O 
Total = 15 1 
Table 2.12 - Table of PCR reagents 
All PCRs were carried out using a DNA engine tetrad PCR system (Bio-rad, UK). 
Cycling conditions were standard unless otherwise stated with initial denaturing at 
94°C for 2 min followed by 35 cycles of 94°C for 30 s followed by the specific 
annealing temperature for 30 s and then 72°C for 1 min, with an extended 
elongation step at 72°C for 5 min in the final cycle. 
2.2.4 High fidelity PCR 
The ABgene Hi-Fidelity PCR mastermix (ABgene, USA) was used in amplifying 
a particularly difficult template for FILr1. The extensor high fidelity PCR master 
mix is a ready to use enzyme mix for long and accurate PCR. Here buffer 2 was 
used as this is specific for longer or particularly problematic PCRs. 
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Reagents Volume (ILI) 
Master mix 12.5 1 
DNA50n 1 21 
Forward primer (10 pmol/ 1 11 
Reverse primer (10 mol/ 1 11 
H2O 8.5 1 
Total 50 pI 
Table 2.13 - ABgene high fidelity PCR reagents 
These were then placed on a PCR tetrad for the following conditions: 94°C for 2 
min followed by 32 cycles of 94°C for 10 s, 62°C for 30 s and 68°C for 1 min 
followed by 68°C for a further 7 min. 
2.2.5 Microsatellite genotyping 
Five microsatellites were examined in the population using the primers found in 
table 2.2. The position and sequence of these markers were found using Ensembl 
(http: //ensembl. org). 
These were then amplified using the standard PCR reaction described in 2.2.3. 
The reverse primer was labelled with a fluorescent dye on the 5' end of the primer 
to enable detection on the ABI 3700 sequencer (Applied Biosystems, UK). Then 
2µl of the 5 PCR products were pooled together in a 96 well format using the post 
PCR robot and then 2µl of this mixture was removed and placed in an ABI 
sequencing plate. Iml of HiDi formamide and 20µl of Genescan Rox400 
(Applied Biosystems, UK)) were mixed together with 8 t1 of this dispensed into 
each well of the plate. This was then denatured at 95°C for 5 minutes. Samples 
were then loaded onto the ABI 3700 sequencer. 
Analysis of the samples was done using the ABI Genotyper software (Applied 
Biosystems). 
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2.2.6 Sequencing 
PCR products were purified using ExoSAP-IT (Amersham Pharmacia Biotech, 
Sweden). This contains two hydrolytic enzymes, Exonuclease I and Shrimp 
Alkaline Phosphatase for the removal of unwanted primers and deoxynucleotides 
respectively. 1.5 µl of ExoSAP-IT was added to 3.5 pl of sample and transferred 
to the PCR block for the following conditions: 37°C for 15 min, 80°C for 15 min 
followed by 4°C for 2 min. 
ABI BigDye Terminator reagents (Applied Biosystems, UK) were used as shown 
in table 2.14. In all cases the forward primer was used first and the reverse primer 
was used only for unclear sequences. All reactions were then placed on a PCR 
tetrad for the following conditions: 25 cycles of 96°C for 30 s, 50°C for 15 s and 
then 60°C for 2 min followed by 4°C for 2 min. 
Reagent Volume 1 
Bi De Terminator Master Mix v3.1 11 
Better buffer 3l 
Primer 10 mol/ 1 IPI 
Template 4l 
dH2O 11 
Total volume 10 1 per reaction 
Table 2.14 - Sequencing reaction reagents 
Post sequencing clean up was then required to remove the unincorporated 
BigDye. 60 µl of 100% ethanol: 7.5 M ammonium acetate (33: 1) was added to 
each sample well. The plate was then sealed and inverted several times to mix. 
The plate was then spun in a centrifuge with a 09100 rotor at 3100 xg at 4°C for 
30 min. The supernatant was immediately removed and the plate spun upside 
down on tissue paper at 250 xg for 1 min. 100µl of 70% chilled ethanol was 
added to each well and the plate was spun at 3100 xg at 4°C for 2 min and this 
step was repeated once more. The supernatant was tipped off and the plate spun 
upside down at 250 xg for 1 min. The plate was allowed to air dry for 10 min 
before re-suspending in 10 gl dH2O. 8 µl of HiDi formamide was added to each 
well of an ABI plate (Applied Biosystems, UK) and the dH2O was transferred to 
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this plate before being placed onto an ABI 3700 sequencer (Applied Biosystems, 
UK). 
2.2.7 DNA sequence analysis 
Sequence analysis was carried out using PhredPhrap and Consed and variants 
were detected using reference sequences found in Ensembl Genome Browser 
(http: //www. ensembl. org/index. html) (Ewing et al., 1998) (Ewing and Green, 
1998) (Gordon et al., 1998). 
2.2.8 Restriction Fragment Length Polymorphisms (RFLP) 
Two restriction enzymes were used for analysis of the two common filaggrin 
mutations R501 X and 2282de14. R501 X was analysed using Nalll (New 
England Biolabs, USA) and 2282de14 was analysed using Dralll (New England 
Biolabs, USA). 
Reagents Amount 
NEBuffer 4 21 
Bovine Serum Albumin (BSA) 0.2 1 
Enzyme 0.1 1 
H2O 6.7 1 
PCR product 11 PI 
Total 20 1 
Table 2.15 - R501 X restriction enzyme protocol. Incubate overnight at 37°C 
on a PCR tetrad. 
ACC'r(GAG ITG 1'('('z1GnCC'I'A'l I'TACCGATTGCTCGTGGTGGGATCCCTGC 
CTTCCTCCTCTGCTTGACCCCGGGTGTCCACGAATGGTGTCCTGACCCT 
CTTGGGACGCTGAATGCCTGGAGCTGTCTCGTGCCTGCTCG'I'GGTGCG 
ATCCTTGTCTTCCTCCAGTGCTGGTCCCGGTCCGTCCA"I'(GGCAGAGTC 
AGGCTGTTCA'I'GAGTGCTCACCTGGTAGAGGGAAGACCCTGAACGTCC 
AGACCGTTCCCCTGACCGGCCACGTGTGGACTCTTGGTGGCTCTGCTGT 
C"f(': ý(. ('('C. AG('(. ý.. ýI CCGI G 
Figure 2.1 - R501X fragment sequence. Primers are highlighted in red. Normal 
restrictions sites highlighted in Blue and restriction site if mutated in green with 
the base change in pink. 
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The R501 X mutation generates an N1aIII restriction site and so therefore in a 
wildtype individual the NaIII restriction fragment sizes are 186bp, 105bp and 
21 bp. A heterozygous individual would have fragments 186bp, 131 bp, 105bp, 
55bp and 2lbp. An individual that is homozygous for the mutation would have 
fragments 131 bp, 105bp, 55bp and 21 bp. 
Reagents Amount 
NEBuffer 3 21 
BSA 0.2 l 
Enzyme 0.05 1 
H2O 6.75 µl 
PCR product 11 PI 
Total 20 µl 
Table 2.16 - 2282de14 restriction enzyme protocol. Incubated overnight at 
37°C on a PCR tetrad. 
(G( nGGAC"I'C' \(; A(' I'G"1'1'TATGAGTGCTCACCTGGTAGAGGAAAGACC 
CTGAACGTCGAGACCTTTCCCCTGACCGGTCACGTGCGGACTCTTGGT 
GGCTCTGCTGATGGTGACCAGCCTGTCCATGGCCTGA('A('"I'(i \(' I'()'1 G 
I( iTCTGAGTCTTCTGAATGTCCCTCACTGTCAGTGGCCTGACTACCACT 
GGACCCTCGGTGTCCACTGTCTCTGACTGCAGATGAAGCTTGTCCGTG 
CCCAGTGCCTGAGTGTCTGGAGCTGTCTGCTGACTGGAGCTGGTGGCG 
GGATCCATGTCTTTCTCCTGCACTTGATCTTGCCTGTTCATGGGATGAC 
GCAGCCTGTCCACTAGAGGAATTCTGTGTGTGACGAGTGCCTGATTTT 
CTGGAGCTGTCTGCAGAGTGCCCATGACCAGCTCTGTCTTCGTGATGG 
GACCTGGGGTGTCTGGAGCCATCTCTTGACTGCTCCTGAGCAGATCCA 
TGATGGTTTCTGGAAGCAGACCCAGACCACCTCTCAGAGTCI'TCTGAG 
TGTCCCTGACTGTCACTGTCCTGGCTAACACTGGATCCCTGGTTCCTAC 
TTGTCCTGGGCCCCGATGATTGTCCCTGGCCCACCTGTGAGTGTCTAGA 
GCTGTCAGCCTGAGAGGAAGCTTCATGATGACGTGACCCTGAGTGCCT 
GGTGCCGTCTCCTGATTGTTCCTCATTTCGTGTTTGTCTGCTTGCACTTC 
TGGATCCTGACTGCCCATGGGAGGCATCAGACCTTCCCTGGGATGTGG 
TGTGGCTGTGATGGGAA('(' I"GAGTG"I'CCA(GAC'C'I'A 1°I' 
Figure 2.2 - 2282de14 fragment sequence. Primers highlighted in red and 
restriction site in pink. The 4 bp deletion highlighted in green allows this 
restriction enzyme to cut when mutated. 
The 2282de14 mutation generates a DraIII restriction site and so therefore in a 
wildtype individual the Drauf restriction fragments are the same as a normal PCR 
product, 811 bp. In a heterozygous individual the fragment sizes are 811 bp, 668bp 
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and 143bp. An individual that is homozygous for the mutation has restriction 
fragments of 668bp and 143bp. 
2.2.9 Agarose gel electrophoresis 
DNA fragments were analysed on agarose gels, which were made between 2% 
and 3% agarose dissolved in lx TBE. The solution was then heated in a standard 
microwave until boiling and cooled before the addition of ethidium bromide to a 
final concentration of 20pg/ml. After pouring the gel and allowing to set, DNA 
products were loaded onto the gel using 6X loading dye within submarine tank 
(Bio-rad, USA) and the gel was then run at 140 volts. The size standard used was 
the 100bp ladder (Invitrogen, USA). Products were visualized using an ultra violet 
transilluminator and photographed for reference. Table 2.17 shows all the 
solutions required for agarose gel electrophoresis. 
- 6X Loading Dye 100bp ladder, , (Invitrogen, USA) 
'IX TBE 
0.25% bromophenol blue 10% 100b ladder 45mM Tris-Borate 
15% Ficoll in H2O 16% 6X loading dye 2mM EDTA 
0.25% xylene cyanol FF 74% H2O 
Table 2.17 - Agarose gel solutions 
2.2.10 Genomiphi 
Some DNA samples were found to have not enough DNA available for PCR and 
sequencing so a commercially available kit was used for whole genome 
amplification, Genomiphi (Amersham Pharmacia Biotech, Sweden). The kit was 
used according to the protocol in the kit. 
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2.2.11 Taqman 
SNPs analysed by Taqman are listed in table 2.18. 
SNP id (Assay by design)',, SNP id (Assay on demand), 
rs12730241 rs1805012 rs2303066 rs3814299 
rs2065955 rs1805013 rs2303067 rs3814300 
rs2065958 rs1805014 rs2303068 rs6587665 
rs2184953 rs1805015 rs1800875 rs1805010 
rs2011331 rs2303061 rs2583476 rs6543116 
rs11582620 rs2303062 rs2847655 rs2975632 
rs1805011 rs2303063 rs2598483 
rs1805012 rs2303065 rs3001428 
rs3024974 rs2736726 rs2907748 
rs1059513 rs2075817 rs5743368 
rs4559 rs2075822 rs3020207 
Table 2.18 - Taqman assays ordered from Applied Biosystems, UK. 
Reaction volume 1 41 
Number of reactions 384 
Primer and probe concentration 40X 
% coverage 200% 
Taman universal master mix 2X 384 l 
Primers and Probes 40X 19.2 l 
H2O 364.8 l 
Total 768 l 
Table 2.19 - 40X Taqman primers and probes reaction master mix. Used for 
the Assay on Demand Taqman SNPs. 
Reaction volume 11 
Number of reactions 384 
Primer and probe concentration 20X 
%. coverag e 200% 
Taman universal master mix 2X 3 84 l 
Primers and Probes 20X 38.4 l 
H2O 345.6 1 
Total 768 1 
Table 2.20 - 20X Taqman primers and probes reaction master mix. Used for 
the Assay by Design Taqman SNPs. 
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Three days prior to this experiment 2 t1 of DNA at 5ng/gl was dispensed into 384 
well plates using the pre-PCR robot. These were then kept at room temperature 
and left to dry out. On the day, master mixes were made up and dispensed in 1 µl 
volumes using the Equator GX (Deerac Fluidics, Ireland). Plates were then 
loaded onto the ABI 7900 (Applied Biosystems, UK). 
2.3 Illumina candidate gene association study 
2.3.1 Candidate genes 
Candidate genes were picked either because they had a possible biological 
function in AE or were in a location of a LOD score hit from the microsatellite 
whole genome scan. Some genes were also picked to replicate other studies that 
had previously found association with AE. 
2.3.2 HapMap project tagSNPs 
Once the final candidate gene list was gathered together a tagSNP picking strategy 
was formulated. This consisted of a custom MySQL database being constructed 
by 2 bioinformaticians located at the Genome centre (Richard Dobson and 
Timothy Nugent, QMUL), which downloads information from the HapMap 
website containing all of the tagSNPs for each gene. These are then cut down by 
using stringent cut-offs and design scores received from Illumina for each 
tagSNP. An r2 of 0.8 and a minor allele frequency of (MAF) of 0.15 were used to 
create the final lists. Within the HapMap, four populations have been used to 
capture information, Caucasian, Japanese, Chinese and Yoruban. In this case, 
with a Bangladeshi population, it was decided that we should utilize information 
from the Caucasian, Chinese and Japanese populations to try to ensure that we get 
maximal information from the Bangladeshi population. 
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2.3.3 Illumina experimental procedure 
The experimental procedure was carried out as per the manufacturers directions, 
summarised below. 
Day 1 
Single use DNA activation 
" Add 5µl of GS#-MS 1 to each well of GS#-SUD plate 
" Add 5 t1 of 50ng DNA to each well of GS#-SUD plate 
" Pulse centrifuge to 250 g 
" Vortex at 2300rpm for 20 seconds 
" Pulse centrifuge to 250 g 
" Heat GS#-SUD plate at 95°C for 30 minutes 
" Pulse centrifuge to 250 g 
" Add 5µl GS#-PS1 reagent to each well to the GS#-SUD plate and seal 
" Pulse centrifuge to 250 g, vortex at 2300 rpm for 20 seconds 
" Add l5gl 2-propanol to each well of the GS#-SUD plate 
" Vortex at 1600 rpm for 20 seconds 
" Centrifuge GS#-SUD plate for 3000 g for 20 minutes 
" Decant supernatant by inversion onto tissue, blot off excess supernatant 
" Invert GS#-SUD plate on tissue and centrifuge at 8g for 1 minute 
" Allow plate to dry at room temperature for 15 minutes 
" Add I Opl GS#-RS 1 reagent to each well of the GS#-SUD plate 
" Pulse centrifuge to 250 g 
" Vortex 2300 rpm for 1 minute 
Proceed to GoldenGate Hybridization. 
GoldenGate Hybridization 
" Add I Oµl GS#-OPA to each well of the GS#-ASE plate 
" Add 30pl GS#-OB 1 to each well of the GS#-ASE plate 
" Transfer I Ogl of activated DNA sample from the GS#-SUD plate 
" Heat seal GS#-ASE plate and pulse centrifuge to 250 g 
" Vortex GS#-ASE plate at 1600 rpm for 1 minute 
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" Place heat sealed GS#-ASE plate on heat block at 70°C 
" Immediately change the set temperature on the heat block to 30°C and 
allow the GS#-ASE plate to sit in the heat block until it cools to 30°C 
(approx. 2 hours) 
Day 2 
Extension and Ligation, GoldenGate Assay 
" Centrifuge GS#-ASE plate to 250 g 
" Place GS#-ASE plate on magnetic plate for -2 minutes or until beads are 
captured 
" Remove heat seal, remove all liquid and discard, leaving beads in wells 
" Leaving plate on magnetic plate add 50gl GS#-AM1 to each well of the 
GS#-ASE plate 
" Vortex GS#-ASE plate at 1600 rpm for 20 seconds 
" Place GS#-ASE plate on magnetic plate for -2 minutes 
" Remove GS#-AM 1 from each well 
" Repeat addition of GS#-AMI, vortexing and removal of buffer 
" Remove GS#-ASE plate from magnetic plate and add 50µ1 of GS#-UB 1 to 
each well 
" Place GS#-ASE plate on magnetic plate for -2 minutes 
" Remove GS#-UB 1 from each well 
" Repeat addition GS#-UB 1 and removal of buffer 
" Add 37µl of GS#-MEL to each well of the GS#-ASE plate 
" Seal plate and vortex plate at 1600 rpm for 1 minute 
" Incubate GS#-ASE plate on 45°C for 15 minutes 
PCR preparation 
" Add 64µl taq polymerase to GS#-MMP tube 
" Aliquot 30µl of mixture into each well of the GS#-PCR plate 
" Seal and centrifuge to 250 g 
" Place GS#-ASE plate on magnetic plate for -2 minutes 
" Remove and discard supernatant from all wells of the GS#-ASE plate 
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" Add 50pl of GS#-UB 1 to each well of the GS#-ASE plate and allow plate 
to rest on the magnetic plate for -2 minutes 
" Remove and discard supernatant from GS#-ASE plate 
" Add 35 gl GS#-IP 1 to each well of the GS#-ASE plate 
" Vortex at 1800 rpm for 1 minute 
" Place at 95°C for 1 minute 
" Remove plate from heat block and place on magnetic plate for -2 minutes 
" Transfer 30gl supernatant from first column of GS#-ASE plate into the 
first column of the GS#-PCR plate 
" Repeat transfer for each column of the GS#-ASE plate 
" Immediately transfer GS#-PCR plate to the thermal cycler 
o 37°C for 10 minutes, 95°C for 3 minutes, followed by 34 cycles of 
95°C for 35 seconds, 56°C for 35 seconds and 72°C for 2 minutes. 
Ending with 72°C for 10 minutes and 4°C for 5 minutes. 
" Proceed immediately to Prepare and hybridise to Array 
Prepare and hybridise to Array 
" Pulse centrifuge GS#-PCR plate to 250 g 
" Add 20pl of GS#-MPB into each well of the GS#-PCR plate 
" Pipette solution in each column up and down to mix the beads with PCR 
product the transfer the mixed solution into each column of the filter plate 
" Store at room temperature, protected from light for 60 minutes 
" Place filter plate containing bound PCR products onto filter plate adaptor 
" Centrifuge at 1000 g for 5 minutes at 25°C 
" Add 50 µl of GS#-UB2 to each well of the filter plate 
" Centrifuge at 1000 g for 5 minutes at 25°C 
" Add 301il of GS#-MH1 to all columns of the GS#-INT plate 
" Replace the waste plate with the GS#-INT plate 
" Add 30µ10.1N NaOH to all wells of the filter plate 
" Centrifuge at 1000 g for 5 minutes at 25°C 
" Gently mix the GS#-INT plate by moving from side to side 
" Using the humidity control template as a guide dispense 30µ1 of GS#-UB2 
to the indicated GS#-HYB plate wells 
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" Using the GS#-HYB plate template as a guide under the GS#-HYB plate, 
slowly pipette up and down several times to mix contents in the GS#-INT 
plate and then transfer 5041 of neutralized HYB solution from the first 
column of the GS#-INT plate into the first column of the GS#-HYB plate 
" Repeat for each column 
" Seal and centrifuge at 3000 g for 4 minutes at 25°C 
" Dispense 70m1 GS#-UB2 into first OmniTray 
" Dispense 60m1 NaOH into second OmniTray 
" Place SAM with fibre bundles facing down into the UB2 tray 
" Agitate SAM gently for 10 seconds to remove bubbles and set timer for 3 
minutes 
" After 3 minutes move SAM into NaOH tray and set timer for 30 seconds 
" After 30 seconds move SAM back into UB2 tray for at least 30 seconds to 
neutralized NaOH 
" Side GS#-HYB plate into cartridge frame 
" Place SAM slowly lowering until firmly seated on the GS#-HYB plate 
" Close SAM cartridge using gentle pressure on the lid when closing the 
latch 
" Place GS#-HYB plate/SAM pair into hybridization oven at 60°C for 30 
minutes 
" After 30 minutes, reset the oven to 45°C 
" Incubate overnight (at least 14 hours) 
Day 3 
Wash and Image Array 
" Add equal an equal mixture of 95% ethanol and 2-butanol to the GS#-ISI 
bottle 
" Separate Sam from GS#-HYB plate 
" Place SAM into GS#-UB2 and agitate for 1 minute at room temperature 
" Place SAM into 2°d UB2 tray and agitate for 1 minute at room temperature 
" Dip the SAM into the GS#-IS I tray for 5 minutes 
" Remove SAM and place on empty tray to air dry for 20 minutes, fibre 
bundles up 
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" Clean proximal ends of SAM bundles with canned air 
" Place SAM in scanner tray and begin scan. 
2.3.4 Illumina analysis 
Rigorous quality control of the Illumina data was performed after the 
experimental work. This was done using the Illumina beadstudio program to 
ensure proper clustering of the alleles. 
Actual gene analysis was performed using the Family Based Association Test 
(FBAT) program (see 2.4). This allowed us to generate global p-values for each 
tagSNP and see if there was any association with AE and other atopic phenotypes. 
2.4 Statistical analysis 
Statistical analysis was performed using a MySQL database which performed 
quality control checks such as signal intensity, allele frequency discrepancies, 
deviations from Hardy-Weinberg and Mendelian expectations. This database then 
outputs the data into the correct format for analysis using the FBAT program. 
FBAT is used to test for association using the phenotypes affected status and IgE 
levels as discontinuous and continuous traits. FBAT allows the use of dominant, 
recessive and co-dominant models for testing association (Laird et al., 2000). 
Phenotype files were also created documenting all allergic disease of all 
individuals in this study. Allergic disease phenotypes include - AE, Asthma, 
Hayfever and Food allergy. 
PBAT (Pedigree Based Association Test) was used to calculate the expected 
power of our study (Lange et al., 2004). 80 families with 2 or more affected 
individuals were modelled over a range of odds ratios to demonstrate the 
population's power to detect dominant and recessive effects. 
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LD maps were generated using the generated genotypes from the Illumina study 
and haploview (Barrett et al., 2005). 
2.4.1 Bonferroni correction 
The Bonferroni correction is a statistical method for correction when multiple 
statistical tests are being carried out. Therefore the significance level that a p- 
value is required to meet is more stringent and in theory would reduce the type 1 
error or the number of false positives. To calculate the bonferroni correction the 
significance level (usually 0.05) is divided by the number of tests being carried 
out (for example the number of SNPs being investigated). 
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Chapter 3 
Illumina Candidate Gene Association Study 
- Previously associated genes 
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3.1 Introduction 
A candidate gene association study was conducted using the Illumina Goldengate 
assay and newly available information from the HapMap project. Both previously 
associated genes and also novel genes were analysed. Novel genes are discussed 
in chapter four and this chapter focuses on the previously associated genes. 
3.1.1 Candidate gene selection 
A literature review was conducted to identify genes which had been previously 
associated and, from this, eleven genes were chosen which had been previously 
associated in several populations or were identified as being particularly relevant 
either through biological function or positioning within the genome. The eleven 
previously associated genes chosen for this study cover nine areas of the genome 
(Figure 3.1). These genes cover both immunological components as well as 
barrier function (Table 3.1). 
Of the eleven previously associated genes, six genes were associated with AE in 
the Bangladeshi population as discussed in sections 3.2.1 to 3.2.6. The genes 
which were not found to be associated are discussed in section 3.2.8. 
Phenotypic information for other allergic diseases, such as asthma, hayfever and 
food allergies, was also available for this specific population. Therefore all the 
Illumina candidate genes were analysed for association to these other allergic 
diseases. This analysis also allowed combinations of allergic disease to be 
analysed such as AE with asthma, AE with hayfever and AE with food allergy. 
Full p-value tables for each gene can be found in appendix A. 
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Figure 3.1 - Location of previously associated AE genes within the human 
genome. Schematic of areas of the genome covered by the previously associated 
genes picked for the Illumina candidate gene association study. Nine locations are 
indicated although eleven genes were included. CCLI and CCL5 are both located 
at 17g12 and SPINK5 and TIM3 are located at 5q32 and 5q33.3 respectively. 
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Gene Alias Chr References Previous Populations 
Linkage with 
association 
SPINK5 LEKTI 5q32 (Chavanas et al., 5g31, British 
(3.2.1) 2000; Kabesch et p=0.004 Japanese 
al., 2004; Moffatt, German 
2004; Walley et at., 
2001) 
NOD] CARD4 7p15.1 (Laitinen et al., 7p14, German 
(3.2.2) 2001; Weidinger et p=0.005 Finnish 
at., 2005) 
IL4RA CD 124 16p 12.1 (Hershey et al., American 
(3.2.3) 1997; Mitsuyasu et Japanese 
at., 1998; Ober et British 
al., 2000) German 
ST2 ILIRLI 2g12-14 (Li et al., 2000; Japanese 
(3.2.4) Lohning et al., 
1998; Moritz et at., 
1998; Shimizu et 
at., 2005) 
STAT6 IL-4-STAT 12g13.3 (Negoro et al., Japanese 
(3.2.5) 2006; Tamura et at., 
2001) 
TIM3 HAVCR2 5q33.3 (Graves et al., 2005; 5g31, American 
(3.2.6) Sabatos et at., 2003) p=0.004 
FCERI B MS4A2 11q12- (Banfield et al., British 
(3.2.8) 13 2001; Cookson, 
2004; Cox et at., 
1998) 
CMA1 CYH 14q 11.2 (Mao et al., 1998) Japanese 
(3.2.8) Italian 
British 
LOR Loricrin 1 q21 (Sugiura et at., 1 q21, Japanese 
(3.2.8) 2005) p=0.0005 
CCLI SCYA1 17g12 (Gombert et al., 17g21, German 
(3.2.8) 2005) p=7.4x104 
17q25, 
p=0.0004 
CCL5 RANTES 17g12 (Cookson and 17g21, German 
(3.2.8) Moffatt, 2002) p=7.4x104 Hungarian 
17q25, 
p=0.0004 
Table 3.1 - Previously associated AE genes. List of genes included in the 
Illumina candidate gene association study. Chr - chromosomal position. Each 
gene is discussed separately in this chapter and the section appropriate to each 
gene is listed under the gene name. Note FLG was not included in this specific 
study as it was studied separately (see chapter 5). 
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3.1.2 tagSNP picking for the candidate genes 
The HapMap project's goal was to produce a haplotype map of the human 
genome describing the common patterns of human sequence variation (The 
International HapMap, 2003; The International HapMap, 2005; The International 
HapMap, 2007) which can then be used by researchers to find genes affecting 
health and disease. As there is no linkage disequilibrium (LD) data currently 
available for the Sylheti population, data was selected from the HapMap project 
for 30 Caucasian trios, 30 Yoruban trios and 45 Han Chinese. To maximise the 
probability that variation in the Sylheti population was assayed, tagSNPs were 
selected from the three population groups. SNPs were picked using the HapMap 
tagSNP data available at www. hapmap. org. A custom MySQL database with 
tagger (de Bakker et al., 2005) implemented in Haploview (Barrett et al., 2005) 
was used with the default parameters of an r2 value of 0.8 and a minor allele 
frequency (MAF) of 0.15 plus 5kb upstream and downstream of each gene to try 
and capture some regulatory regions. These parameters provided extensive lists 
of SNPs which were used to construct the final 384 SNP list for the Goldengate 
assay. 
3.1.3 Goldengate genotyping 
The assay was performed using the protocol specified in the materials and 
methods section 2.2.3. Quality control statistics were used to assess the quality of 
the data before the start of the analysis. The number of SNPs on the array was 
384. Of these 384 SNPs, eight failed, giving a working total of 376 SNPs 
(97.9%). Of these 376 SNPs, a call rate of over 97% was seen in 98% of SNPs. 
Quality control statistics show that these data are of a high quality. SNPs and 
genes of interest were initially identified using a 0.05 p-value cut off. This 
allowed us to identify genes and SNPs of particular interest for further analysis. 
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3.1.4 Correction for multiple testing 
As discussed in Chapter 2 (2.4.1) there is a need to correct p-values for multiple 
testing. There are three main options for correction, these are listed below and all 
3 different methods give varying results. 
1. Correct p-values using total number of SNPs in the assay. 
2. Correct p-values using total numbers of SNPs in previously associated 
genes and likewise total number of SNPs in novel genes, as the probability 
that the previously associated SNPs are associated is much greater. 
3. Correct on a gene by gene basis. 
This means that in order for SNPs to be significant after multiple testing, specific 
thresholds should be met which are listed below. 
1.1.329x10'4 
2. Previously associated - 4.72x 10-4 
Novel -1.88x104 
3. Listed in each gene results section. 
The results of all three methods are shown and the merits of each discussed later 
in chapter 7 (section 7.1). 
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3.2 Results 
3.2.1 Power of study 
A power calculation was conducted to assess the likelihood that any associations 
would be observed. This was conducted using the statistical program PBAT 
which is specific for family based studies (Lange et al., 2004). These calculations 
are based on 80 families with two or more affected children. An odds ratio (OR) 
of two and four were specified and were assessed using dominant and recessive 
modes of inheritance. An OR of two would indicate a relatively minor genetic 
effect and an OR of four would indicate a mjor genetic effect. 
Odds Ratio 
Allele 
Fre uenc u 
2 
Dominant 
4 
Dominant 
2 
Recessive 
4 
Recessive 
0.05 0.321 0.419 0.344 0.941 
0.1 0.882 0.947 0.498 0.987 
0.2 1 1 0.572 0.990 
0.3 1 1 0.520 0.967 
0.4 1 1 0.412 0.880 
! 'able 3.2 - Power calculations based on 80 families with two or more affected 
children. Odds ratio's of two and four were specified and assessed using 
dominant and recessive modes of inheritance. This population could be used to 
assess both major and minor dominant effects and major recessive effects. 
The results of these power calculations indicate that within this population, both 
major and minor dominant effects and major recessive effects could be observed 
within this population. However this population would only be able to find 
common effects, minor allele frequency of over 10%, and not rare variants. This 
power calculation is quite optimistic as it assumes a p-value of 0.05 and quite a 
large OR. Smaller p-values have been used in this study to account for multiple 
testing and also realistic ORs are much smaller given that AE is a complex genetic 
disease. 
86 
3.2.2 SPINK5 
SPINK5 has been associated with AE in several different ethnic populations 
(Kabesch et al., 2004; Kato et al., 2003; Nishio et al., 2003; Walley et al., 2001). 
Autosomal recessive mutations in SPINK5 underlie the monogenic skin disease 
Nethertons syndrome (Chavanas et al., 2000) which has several overlapping 
symptoms with atopy such as high IgE levels and a predisposition to atopic 
diseases. 
3.2.2.1 Illumina candidate gene study 
SPINK5 had two SNPs (rs9325073 and rs4263489) out of the 25 SNPS which 
were genotyped, which reached the initial 0.05 significance level plus one SNP 
(rs17704764) which gave a borderline p-value of 0.06 (Table 3.3). On further 
analysis and after correction for multiple testing (method 3 (gene by gene) 
threshold of 0.002) none of these remained significant. Figure 3.2 shows a 
negative log of the p-value of SPINK5 and figure 3.3 shows the LD of the gene 
generated from the genotyping results. 
The SNP rs9325073 was also significant at p <_ 0.05 in the analyses with other 
allergic diseases however did not remain significant when corrected for multiple 
testing. 
SPINK5 SNP - 
Chromosome 5 
Chromosomal position Location, p-value 
rs9325073 147478845 Intron 0.007 
rs4263489 147496388 Intron 0.05 
rs17704764 147468847 Intron 0.06 
Table 3.3 - Significant tagSNPs in SPINK5. Three SPINK5 tagSNPs out of 25 
were significant at a p-value _< 
0.05 from the Goldengate genotyping assay. 
rs17704764 was just outside the significant cut off. 
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Figure 3.2 - SPINK5 significance level. -log of the p-value. Three tagSNPs 
reached the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red 
lines at 3.32 and 3.87 are equivalent to the previously associated gene threshold 
and also the all genes threshold. The SPINK5 gene position is also indicated at 
the base of the graph, with exons marked as vertical lines and introns marked as a 
peaked horizontal line. 
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Figure 3.3 - LD (r2) map of SPINK5 showing no large area of LD. Linkage 
disequilibrium maps were generated using Haploview and the data generated from 
the Illumina Goldengate assay to produce Bangladeshi specific LD maps. r2 is a 
measure of linkage disequilibrium. The distance from SNP one to SNP twenty- 
five is 82 kb. LD is defined by the level of grey colour within the square. A dark 
grey/black square indicates strong LD, a light/medium grey square is some LD 
and white indicates no LD. 
3.2.2.2 Further investigation 
As SPINK5 is a gene which has been investigated many times previously and 
even though the gene was not significant in this study after correction for multiple 
testing, it was chosen for further investigation by re-sequencing. 
Specific samples were picked to try to reduce the cost of the experiment and this 
was based on haplotypes generated. The haplotypes chosen had a frequency 
higher than 10% in the Bangladeshi population and these haplotypes were 
generated using the haplotype function within Haploview and the generated 
Illumina data. Using the major haplotypes in this AE population for SPINK5 
allows a targeted approach for finding any possible pathogenic SNPs within the 
coding region of SPINK5. 
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Haplotype % Total number of 
homozygous 
individuals 
% of AE 
affected 
individuals 
1 1122221222211111112222222 31.7 31 48.4 
2 1112211221122221112222211 10.5 7 42.8 
3 1112211221122121112212111 9.2 7 42.8 
Table 3.4 - Haplotypes generated for SPINK5. Using the 25 SNPs typed in the 
Illumina assay haplotypes were generated for the Bangladeshi population. 
Haplotypes over 10% were chosen, however it was decided to include the 
haplotype at 9.2%. 1 and 2 indicate the different alleles within each SNP. The 
total number of individuals within the population who were homozygous for the 
haplotypes is listed along with the percentage of AE affected individuals from this 
total number. 
Haplotyping, individual identification and primer design were carried out by 
myself and the PCR and sequencing reactions were carried out by Rauda Al- 
Kuwaiti (A PhD student within the lab also studying AE). Further bioinformatic 
analysis was also carried out using PolyPhen to try to predict if SNPs could be 
causative. 
In total, nineteen other SNPs were identified in the targeted SPINK5 sequencing 
(Table 3.5). This included one Illumina tagSNP, three previously associated 
SNPs, nine intronic SNPs, five synonymous SNPs and three non-synonymous 
SNPs. All SNPs had been previously identified and were found in online SNP 
databases. The three non-synonymous SNPs were then genotyped by Taqman in 
all 80 Bangladeshi families (Table 3.6) but none were found to be associated. 
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SNP Location Variant Change No. of 
Individuals 
(N) 
% AE 
affected 
rs34482796 Exil C/T Missense, 
Val-Ala 
2 (3) 50 
rs2303066 Int13-14 A/G PA 3(4) 33.3 
rs2303067 Ex14 A/G PA, 
Missense, 
Glu-Lys 
3 (4) 33.3 
rs2303068 Intl4-15 A/G PA 3(4) 33.3 
rs6896303 Ex15 A/G Synonymous, 
G1 -Gl 
5 (7) 40 
rs880687 Ex17 C/A Synonymous, 
Gl ly 
3 (5) 0 
rs41291431 Intl 7-18 C/T 2(4) 50 
rs1353655 Ex18 C/T Synonymous, 
Val-Val 
2(6) 50 
rs56820817 Int2O-21 -/T 5 (8) 40 
rs3777134 Ex23 G/A Missense, 
Gin-Arg 
8 (12) 50 
rs60006978 Int23-24 A/G 2 (3) 0 
rs9325073 Int24-25 C/G 3 (3) 0 
rs59729667 Int24-25 A/G 1 (3) 0 
rs2303070 Ex26 A/C Missense, 
As -Glu 
2 (3) 100 
rs2052537 Int27 -/A/AA/T 
mixed 
8(9) 50 
rs6895434 Int3l-32 T/C 8(12) 50 
rs2400478 Ex32 C/T Synonymous, 
Gly-Gly 
4 (12) 50 
rs4349706 Ex34 T/C 3'UTR 2 (4) 0 
rs3088193 Ex34 C/G 3'UTR 2(4) 0 
Table 3.5 - Summary of SNPs found in the targeted AE population by 
sequencing. In total nineteen other SNPs were found within the AE population. 
All of these had been previously identified and described in SNP databases. The 
three SNPs highlighted in red were then genotyped in all 80 Bangladeshi families. 
PA - Previously associated SNP. (N) - is the total number of individuals 
sequenced for this fragment. The three PA SNPs highlighted in blue were 
genotyped when previously associated SNPs were investigated and can be found 
in 3.2.7. 
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SNP Location p-value 
rs34482796 Exon 11 0.883 
rs3777134 Exon 23 0.707 
rs2303070 Exon 26 0.364 
Table 3.6 - Three non-synonymous SNPs identified in the targeted 
sequencing were not found to associated with AE. Genotyped using Tagman 
probes. 
All non-synonymous SNPs were analysed using the PolyPhen program, SNP data 
collection (Ramensky et al., 2002) which allows prediction of a mutations impact 
on protein structure and function. This program has collected data on all known 
non-synonymous SNPs which can be found in dbSNP build 126. All of the non- 
synonymous SNPs found in table 3.4 were scored as benign and therefore thought 
to have little impact on SPINK5 structure or function. 
3.2.2.3 Summary 
Three SNPs within SPINKS were found to be associated with AE through the 
Illumina candidate gene study however none of these remained significant when 
corrected for multiple testing. Sequencing of the major haplotypes within 
SPINK5 identified several other SNPs, however none of these were novel. 
Further analysis of the non-synonymous SNPs using PolyPhen indicated that these 
SNPs were unlikely to have an effect on SPINKS structure or function. 
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3.2.3 NOD! 
NOD] has been previously associated in two separate AE studies (Laitinen et al., 
2001; Weidinger et al., 2005). Mutations within NOD] have been shown to 
disrupt the activation of NFiB and therefore NODI is implicated in inflammatory 
and apoptotic pathways. 
3.2.3.1 Illumina study 
NOD] had only one SNP (rs2075820) out of sixteen SNPs which were genotyped, 
which showed evidence of association at p<0.05 (Table 3.7). After correction 
for multiple testing (method 3- p-value = 0.0031) this did not remain significant. 
Figure 3.4 shows the negative log of the p-value for the whole gene. Figure 3.5 
shows the generated LD (r2) from the genotypes. Interestingly this SNP is non- 
synonymous, with one allele encoding a Glutamic acid residue and the other a 
Lysine residue. 
SNP rs2075820 was significant in almost all analyses for the other allergic 
diseases. Interestingly several other SNPs appeared to be associated in the 
combination analyses. When the AE and asthma combination was analysed 
rs2284358, rs1558066 as well as rs2075820 were associated, and when the AE 
and hayfever combination was analysed four different tagSNPs were associated 
(rs1558068, rs2906773, rs2529440 and rs2256023). Again none of these 
remained significant when corrected for multiple testing. 
-"NOD 1 SNP. - Chromosomal Location,, ', '"p-value 
Chromosome 7, ` position 
rs2075820 30265477 Exon 6 0.016 
Non- 
synonymous 
Glu-Lys 
Table 3.7 - Significant tag SNPs in NOW. One NODI tagSNP out of sixteen 
was significant at p-value < 0.05 from the Goldengate genotyping assay. 
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Figure 3.4 - NOD] significance level with AE. -log of the p-value. One tagSNP 
reached the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red 
lines at 3.32 and 3.87 are equivalent to the previously associated gene threshold 
and also the all genes threshold. The NODI gene position is also indicated at the 
base of the graph, with exons marked as vertical lines or filled blocks and introns 
marked as a peaked horizontal line, UTRs are unfilled boxes. 
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Figure 3.5 - LD (r2) of NODI showing one block of LD. The LD in NODI 
appears as one big block indicated by the large amount of medium to dark grey 
and black squares, indicating that this is not an area of the genome prone to 
recombination events in recent history. Linkage disequlibrium maps were 
generated using Haploview and the data generated from the Illumina Goldengate 
assay to produce Bangladeshi specific LD maps. r` is a measure of linkage 
disequilibrium. The distance from SNP one to SNP sixteen is 44.5 kb. Probable 
blocks of LD are marked inside red triangles. LD is defined by the level of grey 
colour within the square. A dark grey/black square indicates strong LD, a 
light/medium grey square is some LD and white indicates no LD. 
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Analysis using PolyPhen into the significant coding tagSNP rs2075820 indicates 
that this amino acid substitution is likely to be benign as it is not highly conserved 
in many species (Figure 3.6). 
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Figure 3.6 - Polyphen alignment of NODI around SNP rs2075820. Only three 
species maintain the Glutamic acid (H. Sapiens, M. Musculus and P. Troglodytes). 
3.2.3.2 Summary 
A non-synonymous coding SNP was found to be significantly associated at p< 
0.05 through the Illumina Goldengate assay. However this did not remain 
significant when corrected for multiple testing. No further resequencing was 
carried out, however previously associated SNPs were investigated and these 
results can be found in 3.2.7. 
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3.2.4 IL4RA 
Three separate studies have found genetic association to IL4RA with atopy and 
atopic phenotypes (Hershey et al., 1997; Mitsuyasu et al., 1998; Ober et al., 2000) 
and IL4RA has a role in the induction of IgE production and high IgE levels are 
linked with atopic phenotypes (Bacharier and Geha, 2000) 
3.2.4.1 Illumina study 
IL-IRA has one SNP (rs2239346) out of the fourteen genotyped which was 
significant at p<0.05 and one SNP (rs3024622) which gave a p-value of 0.06 
(Table 3.8). Correction for multiple testing (method 3- p-value = 0.0035) 
indicates that SNP rs2239346 is still significant when using method 3 p-value 
correction. Figure 3.7 shows a negative log of the p-value graph for the whole 
gene and figure 3.8 shows the LD (r2) map of the gene. 
SNP rs2239346 was significant in all other analyses except for food allergy but 
when food allergy and AE were combined it was still significant. On correction 
for multiple testing AE only, AE and hayfever and AE and food allergy, remained 
significant on a gene by gene level. The asthma and AE combination was 
significant on a previously associated gene level. 
IL4RA SNPs - 
Chromosome 16 
Chromosomal 
position 
Location p-value 
rs2239346 27266562 Intron 0.0005 
rs3024622 27272954 Intron 0.06 
Table 3.8 - Significant tagSNPs in IL4RA. Two tagSNPs out of fourteen were 
significant at p-value < 0.05 from the Goldengate genotyping assay. rs3024622 
was just outside the significant cut-off. 
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Figure 3.7 - IL4RA significance level. -log of the p-value. Two tagSNPs 
reached the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red 
lines at 3.32 and 3.87 are equivalent to the previously associated gene threshold 
and also the all genes threshold. The IL4RA gene position is also indicated at the 
base of the graph, with exons marked as vertical lines or filled boxes and introns 
marked as a peaked horizontal line, UTRs are unfilled boxes. 
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FS 
Figure 3.8 - LD (r2) of IL4RA showing one large area of LD. Linkage 
disequilibrium maps were generated using Haploview and the data generated from 
the Illumina Goldengate assay to produce Bangladeshi specific LD maps. r2 is a 
measure of linkage disequilibrium. The distance from SNP one to SNP fourteen 
is 27.5 kb. The probable block of LD is marked inside a red triangle. LD is 
defined by the level of grey colour within the square. A dark grey/black square 
indicates strong LD, a light/medium grey square is some LD and white indicates 
no LD. 
3.2.4.2 Further investigation 
IL-IRA was chosen for further analysis because of its significant association in this 
study. Specific samples were picked to try to reduce the cost of the experiment 
and to do this haplotypes were generated. The haplotypes chosen had a frequency 
higher than 10% in the Bangladeshi population and these haplotypes were 
generated using the haplotype function within Haploview and the generated 
Illumina SNP data. 
99 
Haplotype % Total number of 
homozygous individuals 
% of AE 
affected 
individuals 
1 1121222211221 28.6 18 38.8% 
2 2122111212112 27.8 35 54.3% 
3 1121111221221 8.6 4 75% 
Table 3.9 - Haplotypes generated for IL4RA. Using the fourteen SNPs typed 
in the Illumina assay, haplotypes were generated for the Bangladeshi population. 
Haplotypes with a population frequency of over 10% were chosen, however it was 
decided to include the haplotype at 8.6% as the next largest haplotype group was 
only 3.6%. 1 and 2 indicate the different alleles within each SNP. The total 
number of individuals within the population who were homozygous for the 
haplotypes is listed along with the percentage of AE affected individuals from this 
total number. 
3.2.4.2.1 Sequencing 
The samples chosen for analysis, for all exons, were amplified by PCR and 
sequenced using standard protocols. These samples were then analysed using the 
PhredPhrap software. All sequences were clean and no heterozygous or 
homozygous mutations were found. The primers used encompassed the 
intron/exon boundaries and coding sequence and primers were also designed to 
encompass the 3' UTR. 
3.2.4.3 Summary 
IL4RA was found to have one intronic tagSNP which was significant at p: 5 0.05 
which remained significant when corrected on a gene by gene level. This SNP 
became more significant when the analysis was combined with asthma. Further 
sequencing analysis was carried out, using targeted individuals, to try and identify 
any possible causative mutations or SNPs. No sequence variants were identified 
within the exons, intron/exon boundaries or 3'UTR of IL4RA. 
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3.2.5 ST2 
ST2 has only been previously associated in a Japanese population and this was 
with a promoter SNP which was 30,000 bp upstream of the gene (Shimizu et al., 
2005). ST2 production has been reported in mast cells (Moritz et al., 1998), 
which are effector cells in the acute stages of AE. 
3.2.5.1 Illumina study 
ST2 had seven SNPs (rs13019081, rs3821204, rs1921622, rs950880, rs12712142, 
rs13015714 and rs1420101) out of the sixteen SNPs genotyped in this study 
which were significant at p <_ 0.05 and one which gave a p-value of 0.076 (Table 
3.10). When corrected for multiple testing SNPs rs13019081 and rs3821204 are 
still significant when using a gene by gene correction (p-value = 0.003 1). Figure 
3.9 shows a negative log of the p-value for the whole ST2 gene. Figure 3.10 
shows an LD (r) plot of the genotyping. Multiple SNPs showing association 
within the gene shows that there must be SNPs within the gene locus that are 
associated with disease susceptibility SNP(s). 
rs13019081 showed stronger association with asthma and hayfever and in 
particular asthma and AE, where all the associations remained significant on a 
previously associated gene threshold. rs3821204 also maintained its significance 
at a gene by gene cut-off in all other allergic disease analysis. All other tagSNPs 
which showed association only continued to show association when the allergic 
diseases were combined with AE which emphasises ST2's specific association to 
AE. 
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ST2 SNPs - 
Chromosome 2 
Chromosomal 
position 
Location p-value 
rs13019081 102409340 Intron 0.001 
rs3821204 102418799 Intron 0.002 
rs1921622 102424585 Intron 0.0098 
rs950880 102391080 Intron 0.032 
rs 12712142 102419102 Intron 0.032 
rs13015714 102430383 Downstream 0.035 
rs 1420101 102416234 Intron 0.039 
rs953934 102390811 Intron 0.076 
Table 3.10 - Significant tagSNPs in ST2. Eight ST2 tagSNPs out of sixteen 
were significant at p-value < 0.05 from the Goldengate genotyping assay. 
rs13019081 and rs3821204 remain significant after correction for multiple testing 
on a gene by gene level. rs953934 was just outside the significant cut-off. 
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Figure 3.9 - ST2 significance level. -log of the p-value. Eight tagSNPs reached 
the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red lines at 
3.32 and 3.87 are equivalent to the previously associated gene threshold and also 
the all genes threshold. The ST2 gene position is also indicated at the base of the 
graph, with exons marked as vertical lines or filled boxes and introns marked as a 
peaked horizontal line, UTRs are unfilled boxes. 
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Figure 3.10 - LD(r2) plot of ST2 showing one large area of LD. The LD plot of 
ST2 shows one large area of strong LD. The probable block of LD is marked 
inside a red triangle. This indicates that there is little recombination in this area of 
the genome and therefore there could be many conserved sites. Linkage 
disequilibrium maps were generated using Haploview and the data generated from 
the Illumina Goldengate assay to produce Bangladeshi specific LD maps. r2 is a 
measure of linkage disequilibrium. The distance from SNP one to SNP sixteen is 
39.5 kb. LD is defined by the level of grey colour within the square. A dark 
grey/black square indicates strong LD, a light/medium grey square is some LD 
and white indicates no LD. Missing squares indicate a lack of data. 
3.2.5.2 Further investigation 
ST2 was chosen for further analysis because of the many SNPs which were 
significant at a 0.05 level and also the two SNPs which remained significant when 
corrected on a gene by gene level. This was performed using sequence analysis 
for identification of mutations and SNPs. Samples were picked on the basis of 
haplotypes as described previously (3.2.1.2). 
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Haplotype % Total number of 
homozygous individuals 
% of AE 
affected 
individuals 
1 2221122222222-12 38.6 50 46% 
2 1112212211112-11 29.1 34 38.2% 
3 1212112122221-21 6.7 1 100% 
Table 3.11 - Haplotypes generated for ST2. Using the sixteen SNPs typed in 
the Illumina assay haplotypes were generated for the Bangladeshi population. 
The three major haplotypes of ST2 were selected for further analysis. I and 2 
indicate the different alleles within each SNP, a dash indicates that the data was 
missing for this SNP. The total number of individuals within the population who 
were homozygous for the haplotypes is listed along with the percentage of AE 
affected individuals from this total number. 
3.2.5.2.1 Sequencing 
All eleven exons were amplified by PCR and then sequenced in the chosen 
individuals to try and identify any mutations. The PCR primers encompassed the 
intron/exon boundaries and also the full coding region, the 3'UTR was also 
covered. The sequencing did not identify any mutations in any of the individuals. 
The primers used encompassed the intron/exon boundaries and coding sequence 
and primers were also designed to encompass the 3' UTR. However the 
mutations may be many bp away as demonstrated in the Japanese study of ST2 
(Shimizu et al., 2005). 
3.2.5.3 Summary 
ST2 was found to have eight tagSNPs which were significant at p<0.05 of which 
two remained significant when corrected for multiple testing on a gene by gene 
level. Further sequencing analysis was carried out, using targeted individuals, to 
try and identify any possible causative mutations or SNPs. However no sequence 
variants were identified within the exons, intron/exon boundaries or 3'UTR. 
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3.2.6 STATE 
SNPs within the STAT6 locus in a Japanese population have been associated with 
allergic disease, including asthma and AE (Negoro et al., 2006; Tamura et al., 
2001). 
3.2.6.1 Illumina study 
STAT6 had one SNP (rs324019) out of the 8 SNPs genotyped which was 
significant at p: 5 0.05 (Table 3.11), which was not significant when corrected for 
multiple testing (p-value = 0.0062). Figure 3.11 shows the negative log of the p- 
value for the whole gene and figure 3.12 shows an LD (r) map of STATE. 
The STAT6 tagSNP did not maintain its significance in the further analyses with 
any of the other allergic diseases. One other tagSNP (rs10783813) showed a p- 
value of 0.046 when analysed against food allergy. 
STAT6 SNPs - 
Chromosome 12 
Chromosomal 
position 
Location p-value 
rs324019 55772914 Intron 0.048 
Table 3.11 - Significant tagSNPs in STATE. One STAT6 tagSNP out of 8 was 
significant at p-value < 0.05 from the Goldengate genotyping assay. This did not 
remain significant when corrected for multiple testing. 
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Figure 3.11 - STAT6 significance level. -log of the p-value. One tagSNP 
reached the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red 
lines at 3.32 and 3.87 are equivalent to the previously associated gene threshold 
and also the all genes threshold. The STAT6 gene position is also indicated at the 
base of the graph, with exons marked as vertical lines or filled boxes and introns 
marked as a peaked horizontal line, UTRs are unfilled boxes. 
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Figure 3.12 - LD(r2) plot of STAT6 showing one large area of LD. There is 
one LD block within STA T6, however there is some missing information indicated 
by no boxes. The probable block of LD is marked inside a red triangle. This 
would indicate that there has been little recombination at this specific locus over 
time. Linkage disequilibrium maps were generated using Haploview and the data 
generated from the Illumina Goldengate assay to produce Bangladeshi specific 
LD maps. r2 is a measure of linkage disequilibrium. The distance from SNP one 
to SNP eight is 17.5 kb. LD is defined by the level of grey colour within the 
square. A dark grey/black square indicates strong LD, a light/medium grey square 
is some LD and white indicates no LD. Missing squares indicate a lack of data. 
3.2.6.2 Summary 
STAT6 had one tagSNP which was significant at p<0.05. This SNP did not 
remain significant when corrected for multiple testing, therefore this gene was not 
chosen for any further analysis. 
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3.2.7 TIM3 
Three SNPs in TIM3 have been found to be previously associated to atopy and AE 
(Graves et al., 2005). Due to the involvement of the TIM family in allergy 
associated immune responses this was considered a good previously associated 
candidate gene. 
3.2.7.1 Illumina study 
TIM3 had one SNP (rs6861025) of the two SNPs genotyped that was significant at 
p<0.05 (Table 3.13) which was still significant when corrected for multiple 
testing using a gene by gene basis (p-value = 0.025). Figure 3.13 shows a 
negative log of the p-value for the whole gene. As this gene only contained two 
tagSNPs which were genotyped to capture all the information within TIM3, it was 
not necessary to do an LD map, as it will only show one block. 
SNP rs6861025 maintained its significance on a gene by gene basis in all the 
further analyses with the other allergic diseases. 
TIM3 SNPs - 
Chromosome 5 
Chromosomal 
position 
Location p-value 
rs6861025 156451675 Intron 0.0075 
Table 3.13 - Significant tagSNP in TIM3. One TIM3 tagSNP out of two was 
significant at p-value < 0.05 from the Goldengate genotyping assay. This did not 
remain significant when corrected for multiple testing. 
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Figure 3.13 - TIM3 significance level. -log of the p-value. One tagSNP reached 
the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red lines at 
3.32 and 3.87 are equivalent to the previously associated gene threshold and also 
the all genes" threshold. The TIM3 gene position is also indicated at the base of 
the graph, with exons marked as vertical lines or filled boxes and introns marked 
as a peaked horizontal line, UTRs are unfilled boxes. 
3.2.7.2 Summary 
TIM3 had one tagSNP which was significant at p<0.05. This SNP did not 
remain significant when corrected for multiple testing, therefore this gene was not 
chosen for any further analysis. 
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3.2.8 Previously associated SNPs 
Previously associated SNPs in the associated genes SPINK5, IL4RA, ST2, STAT6 
and NOD] (sections 3.2.2-3.2.6 respectively) and also the unassociated genes 
FCERIB and CMA1 were further investigated in the Bangladeshi families. These 
genes provided either the most positive associations or in the case of the negative 
genes were well replicated in other studies and therefore it was prudent to 
investigate. A comprehensive literature search was performed to identify all 
previously associated SNPs (performed by myself and Rauda Al-Kuwaiti) and 
then these SNPs were analysed using Taqman probes. 
Thirty-eight SNPs were found to be previously associated within the seven genes. 
These are listed in table 3.14. Several of the SNPs were found to be in complete 
LD with SNPs from the Illumina study and therefore did not need to be 
reanalysed. These were the NODJ SNP rs2235099 which is in complete LD (r2 
=1, in all 3 HapMap populations, Caucasian, Chinese and Japanese) with 
rs2075820 and had a p-value of 0.0163, and also the SPINK5 SNP rs2303064 
which is in complete LD with rs1422987 and had a p-value of 0.439. As the 
SNPs all had an r2 of 1 in all three HapMap populations it is reasonable to assume 
that the SNP will be in complete LD in the Bangladeshi population. 
There were also several SNPs listed in table 3.14 that were analysed on the 
Illumina array. These included the IL4RA SNP rs1801275 which had a p-value of 
0.408, the STAT6 SNPs rs324015 (p-value = 0.325), rs703817 (p-value = 0.759), 
rs324011 (p-value = 0.771) and rs167769 (p-value = 0.719), and the NOD] SNPs 
rs2907749 (p-value = 0.691) and rs2075818 (p-value = 0.072). Of the 29 
remaining SNPs which were tested for association none reached any level of 
significance. This means although none of the previously associated SNPs are 
associated in the Bangladeshi population there should be other variants within the 
Bangladeshi population which are causative and are yet to be identified. The 
heritability of AE, Atopy and IgE variation is discussed in section 1.3.6. 
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Gene RS number Taqman LD(r2) with SNP previously 
typed 
Illumina 
SPINK5 rs2303061 Yes No No 
rs2303062 Yes No No 
rs2303063 Yes No No 
rs2303065 Yes No No 
rs2303066 Yes No No 
rs2303067 Yes No No 
rs2303068 Yes No No 
rs2303064 No Yes (rs 1422987) No 
IL4RA rs 1805010 Yes No No 
rs 1805011 Yes No No 
rs 1805012 Yes No No 
rs 1805013 Yes No No 
rs 1805014 Yes No No 
rs1805015 Yes No No 
rs 1801275 No No Yes 
ST2 rs6543 116 Yes No No 
STAT6 rs2598483 Yes No No 
rs3001428 Yes No No 
rs3024974 Yes No No 
rs 1059513 Yes No No 
rs4559 Yes No No 
rs324015 No No Yes 
rs703817 No No Yes 
rs324011 No No Yes 
rs 167769 No No Yes 
NODI rs2736726 Yes No No 
rs2075817 Yes No No 
rs2975632 Yes No No 
rs2075822 Yes No No 
rs2907748 Yes No No 
rs5743368 Yes No No 
rs3020207 Yes No No 
rs2907749 No No Yes 
rs2075818 No No Yes 
rs2235099 No Yes (rs2075820) No 
CMAI rs1800875 Yes No No 
FCeRI B rs2583476 Yes No No 
rs2847655 Yes No No 
Table 3.14 - Thirty-eight SNPs were found to be previously associated with 
AE from genes within the Illumina study. Five positively associated genes 
(SPINK5, IL4RA, ST2, STAT6 and NOD]) and two negatively associated genes 
(CMAI and FCcR1 B) had previously associated SNPs analysed. The SNP rs 
number is listed along with if they were analysed using Taqman, LD or they were 
analysed using the original Illumina study data. 
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3.2.9 Negative associations 
In addition to the genes which were found to be associated in the Illumina 
Goldengate assay (sections 3.2.1-3.2.6) five additional previously associated 
genes were also analysed using the Illumina Goldengate assay. These were 
CMA1, Loricrin, CCLI, CCL5 and FCERJB. These genes did not show any 
evidence of genetic association in the Bangladeshi population, with no tagSNPs 
reaching the initial significance level of p <_ 0.05. In the case of CMA1 and 
FCeRIB, no previously associated SNPs were found to be associated in the 
Bangladeshi population. These genes were included for analysis for the reasons 
below. 
CMA1 is a glycosylated chymostrypsin like serine protease which is present in the 
secretory granules of human skin mast cells. It was previously associated with 
AE (Mao et al., 1998; Mao et al., 1996) in a Japanese population. 
Loricrin is a key protein in the stratum corneum, which is crosslinked by 
transglutaminases once a granular layer cell is terminally differentiated and this, 
along with several other proteins, makes cells into corneocytes. It was not 
actually associated in a genetic study but was found to be down regulated in a 
gene expression microarray using normal and AE patient skin (Sugiura et al., 
2005). 
CCL1 is a chemokine found in dendritic cells, mast cells and dermal epithelial 
cells. CCLI serum levels are significantly higher in AE patients than normal 
controls and also when compared to other allergic inflammatory disease such as 
psoriasis and cutaneous lupus erythematosus (Gombert et al., 2005). 
CCL5 is a chemokine which has been previously associated and a functional 
mutation was discovered in a proximal promoter. However, chemokine 
expression is often upregulated in allergic and atopic diseases (Cookson and 
Moffatt, 2002). CCL5 is located on chromosome 17, where there has been a 
previous region of linkage to AE and psoriasis. Though the gene itself is some 
distance away from this area. 
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IgE dysregulation is a major feature of AE and other allergic disease. Allergens 
which are complexed to IgE bind via the FCeRI receptor located on the surface of 
epidermal Langerhans cells, mast cells and basophils. This binding then triggers 
the release of inflammatory mediators. The gene for the ß subunit of the FCER1 
gene is located in a region which has been linked to atopy previously, 11g12-13 
(Hill and Cookson, 1996). This gene has also been linked to asthma (Shirakawa 
et al., 1996) and AE (Cox et al., 1998; Fölster-Holst et al., 1998; Söderhäll et al., 
2001). 
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3.3 Discussion 
3.3.1 Overview 
Eleven genes were selected as genes for replication. They had been previously 
associated by multiple groups or shown strong association by only one group. Of 
these eleven genes, six came out with positive associations after the Illumina 
assay. 
Gene Associated 
with AE 
Best AE 
p-value 
Other association? 
SPINK5 Yes 0.0076 Asthma, Hayfever, Food Allergy 
NOD] Yes 0.016 Asthma, Hayfever, Food Allergy 
IL4RA Yes 0.000509 Asthma, Hayfever, Food Allergy 
ST2 Yes 0.00107 Asthma, Hayfever, Food Allergy 
STAT6 Yes 0.048 Food Allergy 
TIM3 Yes 0.0075 Asthma, Hayfever, Food Allergy 
CMA1 No 0.126 - 
Loricrin No 0.063 Asthma, Food Allergy 
CCL1 No 0.223 - 
CCL5 No 0.214 - 
FCeRl B No 0.065 Hayfever, Food Allergy 
Table 3.14 - Summary of association found in the previously associated 
candidate genes. 
3.3.2 SPINK5 
SPINK5 is the gene which is mutated in the monogenic recessive skin disease 
Netherton syndrome. The features of this disease are bamboo hair (trichorrhexis 
invaginata), congenital ichthyosiform erythroderma and atopic diatheses. It is 
notable that patients with Nethertons syndrome display greatly elevated levels of 
IgE in their serum similar to that of patients with atopy and AE. This gene has 
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been associated with AE and atopy several times and the results have been 
rigorously replicated (Chavanas et al., 2000; Kabesch et al., 2004; Moffatt, 2004; 
Walley et al., 2001). 
The result from the Illumina assay has shown that this gene could play a role in 
the susceptibility of AE in the Bangladeshi population. The SNP rs9325073 has a 
p-value of 0.007633 and two other SNPs almost reach a level of significance 
(rs4263489 and rs17704764), however none of these remain significant after 
correction for multiple testing, even on a less stringent gene by gene basis. 
Although none of these are coding SNPs which could be identified as disease 
causing, they are tagSNPs and therefore there could be other SNPs in the gene 
region which are disease causing. Nineteen SNPs were identified in the targeted 
sequencing. Three of these were known non-synonymous SNPs, however none of 
these were found to be associated to AE when they were genotyped in the all 80 
Bangladeshi families. Further analysis of these SNPs using PolyPhen indicates 
that none of them are likely to be detrimental to the SPINK5 protein. Seven 
previously associated SNPs were also investigated using Taqman probes and 
again none were found to be associated and so therefore there must be other 
variants in the Bangladeshi population. One previously associated SNP 
(rs2303064) was in LD with a SNP which was analysed on the Illumina assay 
(rs1422987) which was not found to be significant. 
The combination analysis, using the Illumina tagSNPs and the known allergic 
diseases within this population are very interesting. rs9325073 remains 
significant in all analyses and becomes more significant when analysed for 
association with AE and Asthma and Hayfever. This is not surprising since 
SPINK5 has been previously associated with atopy and therefore the immune 
response of allergic diseases. However these do not remain significant when 
corrected for multiple testing. 
3.3.3 NOD! 
NOD] lies in a region which has been linked to atopy and shares many structural 
and functional features with NOD2 and because of this it has been classified as a 
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very good candidate gene. Two studies have previously associated NOD] 
haplotypes with AE (Laitinen et al., 2001; Weidinger et al., 2005). The study by 
Laitinen et al (2001) was a linkage study for asthma and atopy and revealed that 
an area of linkage to atopy and elevated IgE levels was in the 7p 15 region where 
NOD] lies. The study by Weidinger et al (2005) was the first to show NOW 
polymorphisms and haplotypes that were associated with atopy susceptibility. 
The results from the Illumina assay are interesting. Only one SNP rs2075820 
came up as significant however as there are previously associated SNPs these 
were also investigated by TaqMan. The SNP which was found to be significant in 
the Illumina study, rs2075820 is a coding non-synonymous SNP which changes a 
Lysine residue to a Glutamic acid residue, which is a significant amino acid 
change from a polar basic to a polar acidic. One previously associated coding 
SNP, rs2235099, was found to be in complete LD with rs2075820. It is therefore 
likely that the synonymous SNP is a tagging SNP for the non-synonymous SNP 
and it is the SNP rs2075820 which is possibly causative. However analysis using 
PolyPhen indicates that this amino acid is likely to be benign within the protein. 
Therefore it is possible that there are other causative SNPs. Two other previously 
associated SNPs were already on the Illumina assay and these were not 
significant. Seven other previously associated SNPs were analysed using Taqman 
probes and again none were found to be significant. As these results did not 
maintain significance with AE, when corrected for multiple testing, no further 
investigation was carried out. 
The results from the combination analyses with the other known allergic disease 
phenotypes in the Bangladeshi population provide some of the most significant 
results in this gene. The two original studies which showed association to NODJ 
were primarily focussed on atopy and asthma. When the tagSNPs were analysed 
against asthma many more tagSNPs became significant and this significance was 
maintained when Asthma and AE phenotypes were combined. This enhances the 
probability that this result is real, especially when there is overlap from two 
previous studies from different populations which have also found association or 
linkage to this region. 
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3.3.4 IL4RA 
The production of IgE is initiated by antigen presenting B cells interacting with 
antigen specific type 2T helper cells (Bonnefoy et al., 1996). Binding of IL4 to 
its receptor (IL4RA) on the B cell delivers the first signal for isotype switching 
and induces the production of IgE antibodies (Bacharier and Geha, 2000). 
Associations with atopy and atopic phenotypes have been reported in 2 case- 
control studies (Hershey et al., 1997; Mitsuyasu et al., 1998) and in one family 
based study (Ober et al., 2000). Specifically the ile50 (rs1805010) allele has been 
associated to atopic asthma and the arg551 (rs1805014) allele has been associated 
with hyper IgE syndrome and atopy. 
The result from the Illumina assay showed that one tagSNP was associated with 
AE. The SNP rs2239346 had a p-value of 0.000509 and is an intronic SNP within 
IL4RA. When IL4RA was investigated further by sequencing no coding SNPs or 
mutations were identified in the small but highly selected population, intron/exon 
boundaries and the 3' UTR were also included in this sequencing. One previously 
associated SNP was genotyped within the Illumina Goldengate assay however this 
was not significant. Six other previously associated SNPs were analysed in the 
Bangladeshi families and none of these reached significance either. It is therefore 
possible that the causative mutations are yet to be located and could reside in 
regulatory regions. 
When the tagSNPs were analysed using the other allergic disease phenotype 
information from this Bangladeshi population, they also managed to emphasize 
the involvement of IL4RA in allergic disease. When AE was combined with 
asthma, hayfever and food allergies it became more significant. This is especially 
true in the case of AE and asthma, where SNP rs2239246 reached the previously 
associated gene correction level. Several other tagSNPs became significant in the 
other analysis which also emphasizes the probability that the IL4RA association is 
real. 
The expression of filaggrin (FLG) has been found to be reduced in keratinocytes 
which were differentiated in the presence of IL4 and IL13 and also in skin 
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biopsies from AE patients but without FLG mutations (Howell et al., 2007). It is 
therefore possible that IL4 is having an effect through the atopic immune response 
on the skin barrier. The reduced FLG expression, without the presence of 
mutations, shows that IL4 and IL 13 have a modulatory effect on FLG and patients 
gain a defect in FLG. This is particularly interesting due to the well replicated 
finding that FLG is involved in AE and Ichthyosis Vulgaris. This is discussed in 
more detail in chapter 5. 
3.3.5 ST2 
ST2 is an orphan receptor which has relevance to AE due to its expression in type 
2T helper cells and not type 1 (Yanagisawa et al., 1997). ST2 production has also 
been reported in mast cells (Moritz et al., 1998), which are effector cells in the 
acute stages of AE. A SNP in a distal promoter to ST2, rs6543116 (-26999G/A) 
(Shimizu et al., 2005) was found to be associated to this gene in a Japanese 
population. This SNP was found to regulate transcriptional activity of ST2, and 
with that, the -26999A allele seemed to contribute to higher levels of serum ST2 
and also IgE. Other genes within the 2g12-14 region, which is predominantly an 
ILIR gene cluster, have also been associated with asthma (Karjalainen et al., 
2002; Mao et al., 2000; Wjst et al., 1999) and therefore genes in this region seem 
to be involved in the immune response to allergic disease and could therefore be 
involved in AE. The SNP in the distal promoter could in fact be having an effect 
elsewhere in this gene region. 
The results of the Illumina study indicate the ST2 is a strong candidate gene for 
AE with seven of the 16 tagSNPs typed in this study showing levels of 
significance. P-values ranged from rs13019081 = 0.001066 to rs1420101 = 
0.039013. After correction for multiple testing two SNPs remain significant when 
using the gene by gene correction (rs13019081 and rs3821204). When this gene 
was further analysed by sequencing, no mutations or SNPs were identified in the 
coding regions, intron/exon boundaries and 3'UTR. There is however a high 
degree of association to ST2 and therefore it is thought likely that pathogenic 
SNPs located in the gene region are present. These are yet to be elucidated and the 
previously associated SNP (rs6543116) was not associated with AE in the 
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Bangladeshi families. It is possible that, like the previously associated SNP, the 
pathogenic SNP or SNPs could be located in regulatory regions. 
The SNP, rs13019081 showed a stronger association with asthma, hayfever and 
AE and asthma combined. ST2 has been shown to be essential to immune 
responses within the lung mucosa (Coyle et al., 1999), so it is not unexpected that 
association can be seen with asthma. However what is most interesting is the 
association when AE and asthma is combined. A stronger association when AE 
and asthma traits are combined really does emphasize that ST2 is involved in the 
immune response of both AE and asthma and therefore mutations within ST2 
could lead to an increased probability of allergic disease within an individual. 
3.3.6 STAT6 
STAT6 carries out a number of cellular functions. It is responsible for signal 
transduction as well as activation of transcription and it is involved in IL4 
activation (Takeda et al., 1996). SNPs in a Japanese population have been 
associated with allergic disease in particular asthma and AE (Negoro et al., 2006; 
Tamura et al., 2001). The STAT6 variant (G2964A) was found be to linked to 
eosinophilia in local inflammatory sites, especially in the population of patients 
with peripheral blood eosinophilia (Negoro et al., 2006). Tamura et al, (2001) 
discovered a novel dinucleotide repeat in exon one, which is non-coding, of the 
STAT6 gene which when further analysed allowed them to class individuals into 
four groups depending on the number of repeats in the GT repeat (13 repeats to 16 
repeats). The 1t group with 13 GT repeats was found to have a higher frequency 
in the number of children with allergic disease compared with controls although 
this did not reach statistical significance. Another association to allergic disease 
was found in group one (13 GT repeats) and group three (15 GT repeats) 
heterozygotes. This was not linked to IgE levels. Group three previously had no 
association to the G2964A variant and this gives a mixed message as to the 
importance of STATE in AE and atopy. 
Only one tagSNP was associated in the Illumina study of STATE. The SNP 
rs324019 had a p-value of 0.048799. This significant SNP did not maintain 
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significance when analysed against any other allergic disease phenotype. This 
would indicate that STAT6 is not associated with atopy and therefore the 
pathogenesis of atopic diseases in the Bangladeshi population. Four previously 
associated SNPs were included on the Illumina Goldengate assay and none of 
these reached any level of significance. Five other previously associated SNPs 
were analysed in the Bangladeshi population using Taqman probes. None of these 
reached any level of significance either. 
3.3.7 TIM3 
TIM3 is located at 5g33.3 and encodes a T-cell Immunoglobulin and Mucin 
domain 3. TIM3 is expressed on type 1T helper cells (Thl) but not type 2T 
helper cells (Th2) and a mouse model has shown that abrogation of interaction 
between TIM3 and its ligand leads to heightened Thl responses (Sabatos et al., 
2003). Three SNPs in TIM3 have been found to be previously associated to atopy 
and AE (Graves et al., 2005). Due to the involvement of the TIM family in 
allergy associated immune responses this was considered a good previously 
associated gene. The results of the Illumina study indicate that TIM3 could indeed 
be involved in AE. Only two taeSNPs were needed to canture all of the 
information in this region and of these two SNPs, rs6861025 (an intronic SNP) 
reached a significance of 0.007504. This SNP also maintained its significance 
with all other analyses with allergic disease phenotypes. In mice, it has been 
shown that Tim-3 has a beneficial effect by skewing Th2 responses towards Thl 
responses during pulmonary inflammation (Kearley et al., 2007). It is therefore 
hypothesised that the same effect could occur in humans and that TIM3 has an 
important role in the regulation of Th2 disease responses. 
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3.4 Summary and conclusions 
This candidate gene study investigating previously associated genes for AE has 
provided a significant advance in the understanding of the genetic variation within 
AE through the use of a different ethnic population. Generally, previous AE 
studies have focussed on Northern European Caucasian, American Caucasian and 
Japanese populations and whilst these ethnicities provide worthwhile insights into 
these specific populations, little comparison has occurred with other ethnicities, 
which provides greater insight into the variability of complex diseases between 
populations. 
Of the eleven previously associated genes chosen for this study, there is a large 
amount of variation of the genetic association seen in populations. In the 
Northern European Caucasian population, seven of the eleven genes have shown 
association. Two of the eleven genes were associated in the American Caucasian 
population and six of the eleven in the Japanese population. Six out of the eleven 
previously associated genes were found to be associated in the Bangladeshi 
population. There is no direct overlap between ethnicities and the genes found to 
be associated. Even when comparing the Bangladeshi population and the 
Japanese population, which are relatively close by location, only four (SPINK5, 
114R, 4, ST2 and STATE) of the six genes were replicated. This implies that even in 
populations which are close by distance there is a certain element of genetic 
variation in common complex diseases which has evolved in fairly recent times. 
This study does however have a small sample size and this means that the power 
to detect realistically sized effects is reduced. 
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Chapter 4 
Illumina Candidate Gene Association Study 
-- Novel genes 
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4.1 Introduction 
In the previous chapter (3), the analysis of eleven previously associated AE genes 
was discussed. The focus of this chapter is the novel genes which were analysed 
in the same experiment using the Illumina Goldengate assay. 
4.1.1 Novel gene selection 
Fifteen putative candidate genes for AE were analysed in the Illumina candidate 
gene study. They were selected based on their position in the genome (Figure 4.1) 
and/or possible biological function in AE either in skin barrier formation or the 
immunological component of AE (Table 4.1). 
The tagSNP picking for candidate genes, goldengate genotyping and correction 
for multiple testing as described in Chapter 3 sections 3.1.2,3.1.3 and 3.1.4 apply 
to these genes also. 
For ease of reference the P-values used for multiple testing correction are listed 
below. 
4.1.329x10"4 
5. Previously associated - 4.72x104 
Novel -1.88x104 
6. Listed in each gene results section. 
Phenotypic information for other allergic diseases, such as asthma, hayfever and 
food allergies, was also available. Therefore all the Illumina candidate genes 
were analysed for association to these other allergic diseases. This analysis also 
allowed combinations of allergic disease to be analysed such as AE with asthma, 
AE with hayfever and AE with food allergy. Full p-value tables for each gene can 
be found in appendix B. 
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Eight of the fifteen genes selected on the basis of position and/or biological 
function showed some evidence of association with AE with the result shown in 
sections 4.2.1 to 4.2.9. Genes which did not show any association are discussed 
in section 4.2.10. 
14 15 16 17 18 19 
Lý@ «» 
20 21 22 XY MT 
Figure 4.1 - Location of novel genes chosen for analysis within the human 
genome. Schematic of areas of the genome covered by the novel genes picked for 
the Illumina candidate gene association study. Ten locations are indicated 
although fifteen genes were included. KYNU, ACVRJ and FAP are located at 
2q22.3,2q23-24 and 2q23 respectively. WASIP and NRAMP at 2g31.1 and 2q35. 
TNC and PTGDS are located at 9q33 and 9q34. 
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Gene Alias Chr Reason Linkage 
Peak 
SLC9A3R1 EBP50 17g25.1 BIOLOGICAL FUNCTION 
(4.2.1) - Immune system (Helms et at., 2003) 
CD86 3g21 BIOLOGICAL FUNCTION AE 
(4.2.2) - Immune system (Lee et al., 2000) 3q21 
POSITIONAL CANDIDATE LOD = 3.65 
TNC Tenascin-C 9q33 BIOLOGICAL FUNCTION 
(4.2.3) - Structural (Ogawa et at., 2005) 
KYNU Kynureninase 2q22.3 BIOLOGICAL FUNCTION IgE 
(4.2.4) - Immune system (Ito et al., 2004) 2q24-q32 
POSITIONAL CANDIDATE LOD = 1.85 
ACVR1 2q23-24 BIOLOGICAL FUNCTION IgE 
(4.2.5) - Proliferation (Karagiannidis et al., 2006) 2q24-q32 
POSITIONAL CANDIDATE LOD = 1.85 
CCR4 3p24 BIOLOGICAL FUNCTION 
(4.2.6) - Immune System 
JAKS 19p13.1 BIOLOGICAL FUNCTION 
(4.2.7) 1 - Immune System (Matsumoto et at., 1999) 
IL10RA I1g23.3 BIOLOGICAL FUNCTION 
(4.2.8) - Immune system (Dunstan et at., 2005) 
PTGDS 9q34 BIOLOGICAL FUNCTION 
(4.2.9) - Immune system (Pierzchalska et at., 2003; 
Sugimoto et at., 2007) 
HRF TPT1 13g14.1 BIOLOGICAL FUNCTION 
(4.2.10) 3 - Immune system (Budde et al., 2002) 
COL7AJ 3p21.1 BIOLOGICAL FUNCTION AE 
(4.2.10) - Expression within the skin 3p14-3p24 
POSITIONAL CANDIDATE LOD = 1.75 
PTPN22 1p13.2 BIOLOGICAL FUNCTION 
(4.2.10) - Immune System (Duffy, 2007; Rieck et 
al., 2007) 
WASIP WIPF1 2g31.1 BIOLOGICAL FUNCTION IgE 
(4.2.10) - Structure 2q24-q32 
POSITIONAL CANDIDATE LOD = 1.85 
FAP 2q23 BIOLOGICAL CANDIDATE IgE 
(4.2.10) - Epithelium formation 2q24-q32 
POSITIONAL CANDIDATE LOD = 1.85 
NRAMPI SLC1 IA1 2q35 BIOLOGICAL CANDIDATE IgE 
(4.2.10) - Pathogen resistance (Bellamy, 1999) 2q24-q32 
POSITIONAL CANDIDATE LOD = 1.85 
Table 4.1 - Novel genes included on the Illumina candidate gene association 
study. Linkage peaks are from the previous whole genome microsatellite scan 
performed in sixty of the Bangladeshi AE families. The results for each gene are 
discussed separately except in the cases of negative associations and the sections 
are indicated below the gene name. 
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4.2 Results 
4.2.1 SLC9A3R1 
Immunohistochemistry has shown that this protein is expressed both in 
keratinocytes within the granular layer where terminal differentiation and barrier 
formation occurs and also in T cells (Helms et al., 2003). It has been suggested 
that SLC9A3R1 is a negative regulator of T-cell activation (Itoh et al., 2002). 
Therefore SLC9A3R1 may be involved in the immune response linked to AE. 
4.2.1.1 Illumina study 
SLC9A3R1 had one significant SNP (rs 1054131) out of the six genotyped at p <_ 
0.05 (Table 4.2) which when corrected for multiple testing was significant under 
all 3 models of correction (method 3- p-value = 0.0071). Figure 4.2 shows a 
schematic of the negative log p-value for the whole gene and figure 4.3 shows the 
LD (r2) of the gene. 
rs1054131 remained significant at an all gene level for all other phenotypes 
analysed (appendix B). 
SLC9A3R1 
Chromosome 17 
Chromosomal 
position 
Location p-value 
rs1054131 70254797 5' near gene 0-14 
Table 4.2 - Significant tagSNPs in SLC9A3RJ. One SLC9A3R1 tagSNP out of 
six was significant at a p-value <_ 0.05 from the Goldengate genotyping assay. 
This SNP remained significant when corrected for multiple testing. 
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Figure 4.2 - SLC9A3R1 significance level. -log of the p-value. One tagSNP 
reached the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red 
lines at 3.73 and 3.87 are equivalent to the novel gene threshold and the all gene 
threshold (novel gene and all gene threshold shown as thick red line due to 
proximity). The SLC9A3R1 gene position is also indicated at the base of the 
graph, with exons marked as vertical lines and introns marked as a peaked 
horizontal line. 
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Figure 4.3 - LD(r2) map of SLC9A3RI showing one large area of LD. The LD 
in SLC9A3RJ is strong (many dark grey/black squares) and therefore there have 
been few recombination events occurring in this gene locus in history. The 
probable block of LD is marked inside red triangles. Linkage disequilibrium 
maps were generated using Haploview and the data generated from the Illumina 
goldengate assay to produce Bangladeshi specific LD maps. r2 is a measure of 
linkage disequilibrium. LD is defined by the level of grey colour within the 
square. A dark grey/black square indicates strong LD, a light/medium grey square 
is some LD and white indicates no LD. The distance from SNP I and SNP 6 is 23 
kb. 
4.2.1.2 Further investigation 
rs1054131 in SLC9A3R1, which had a p-value of 1.305x10"14, was found to have 
abnormal Illumina Beadstudio clustering (Figure 4.4). Normal clustering is 
shown in figure 4.5. A clustering of four groups would indicate a possible mis- 
calling problem. Plate specific clustering was ruled out as there was good mixture 
of all 4 plates in each cluster. It is however possible that there is another SNP 
underneath one of the primers and this would affect the clustering. On this basis it 
would indicate that the clusters could be as follows (where x would indicate 
another SNP influencing the clustering). 
128 
Cluster at 0 norm theta = AA 
Cluster at 0.5 norm theta = AB 
Cluster at 0.7 norm theta = ABX 
Cluster at I norm theta = BB 
In order to confirm this clustering, five samples from each of the clusters were 
sequenced. The five samples picked are shown in figure 4.6. When sequenced 
the samples were analysed using the PhredPhrap software. It was then found that 
two of the clusters were in fact homozygous. This is shown in figure 4.7. 
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Figure 4.4 - rs1054131 Beadstudio Clustering. Unusual clustering of this SNP. 
It is normal to have three clusters not four. The current clustering would indicate 
that the group at 0 norm theta are AA homozygotes, clusters at 0.5 and 0.7 norm 
theta are AB heterozygotes and the cluster at norm theta I is BB homozygote 
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Figure 4.5 - Normal Beadstudio clustering. Normal clustering in the Illumina 
Beadstudio package. 3 clusters are present. Homozygotes AA are clustered at 0 
norm theta, heterozygotes AB are clustered approximately at 0.5 norm theta and 
homozygotes BB are clustered at 1 norm theta. 
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Figure 4.6 - Five samples from each cluster picked. Five samples were picked 
from each cluster for sequencing to confirm the initial clustering in Beadstudio. 
Samples picked are in yellow. Cluster one is on the far left hand side and runs 
from left to right and ending with cluster four on the far right hand side. 
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AGCTCTGCCGGCCTGGAGGGGAGAGGGGGAGGAAG 
4 
A 
Figure 4.7 - Sequencing for confirmation of rs1054131 clustering. Sequence 
1, is from an individual in cluster one (theta 0). rs1054131 is indicated by an 
arrow and is homozygous A. Sequence 2, from an individual in cluster two (theta 
0.5) is heterozygous A/G. Sequence 3, from an individual in cluster three (theta 
0.7) is homozygous G. Sequence 4, from an individual in cluster four (theta 1). 
rs1054131 is indicated by an arrow and is homozygous G. 
So in actual fact the clustering is as in figure 4.8. The new p-value is 0.114593 
making it non-significant. 
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Figure 4.8 - Actual clustering of rs1054131. Cluster one was homozygous AA, 
cluster two was AB and clusters three and four were found to be Homozygous 
BB. 
4.2.1.3 Summary 
One tagSNP within SLC9A3RI was found to be associated with AE in the 
Bangladeshi population through the Illumina candidate gene study. After 
investigation into the clustering of this SNP (rs1054131), it was found that the 
clustering was incorrect and therefore this gene is not associated with AE in the 
Bangladeshi population. 
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4.2.2 CD86 
CD86 interacts with CD28 to provide co-stimulatory signals for T cell activation 
and has been implicated in the activation of the Th2 subset of CD4+ T helper 
lymphocytes that are thought to have a pivotal role in mediating allergic 
inflammation (Lanier et al., 1995). Linkage to the 3g21 region, where CD86 is in 
the genome, has also been previously described (Lee et al., 2000). Therefore 
CD86 is a positional and biological candidate gene. 
4.2.2.1 Illumina study 
CD86 had one significant SNP (rs2715276) in this study out of the 18 SNPs 
genotyped at p _< 
0.05 (Table 4.3). When corrected for multiple testing this SNP 
did not remain significant (method 3, threshold - 0.0027). Figure 4.9 shows the 
negative log of the p-value for the whole gene and figure 4.10 shows the LD for 
the gene. 
Although only one tagSNP was significant within CD86 for AE phenotype, 
several other tagSNPs became significant particularly when other phenotypes 
were combined with AE. For example rs2255214, rs2715267 and rs4308217 
became significant when a combined asthma and AE analysis was conducted, 
giving p-values of 0.0074,0.0034 and 0.0045 respectively. When food allergy 
and AE was combined rs2255214 and rs2715267, again, gave p-values of 0.0019 
and 0.0068. With rs2255214 remaining significant after correction for multiple 
testing on a gene by gene level (method 3). 
CD86 SNPs 
Chromosome 3 
Chromosomal 
position 
Location p-value 
rs2715276 123264076 Intron 0.01 
Table 4.3 - Significant tagSNPs in CD86. One CD86 tagSNP out of 18 was 
significant at p-value < 0.05 from the Goldengate genotyping assay. This SNP did 
not remain significant when corrected for multiple testing. 
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Figure 4.9 - CD86 significance level. -log of the p-value. One tagSNP reached 
the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red lines at 
3.73 and 3.87 are equivalent to the novel gene threshold and the all gene threshold 
(novel gene and all gene threshold shown as thick red line due to proximity). The 
CD86 gene position is also indicated at the base of the graph, with exons marked 
as vertical lines, introns marked as a peaked horizontal line, unfilled boxes as 
UTR's. 
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Figure 4.10 - LD(r2) map of CD86 showing no area of LD. There is no large 
area of LD within this locus. Linkage disequilibrium maps were generated using 
Haploview and the data generated from the Illumina goldengate assay to produce 
Bangladeshi specific LD maps. LD is defined by the level of grey colour within 
the square. A dark grey/black square indicates strong LD, a light/medium grey 
square is some LD and white indicates no LD. No area of LD indicates a large 
number of recombination events at this locus in history. r` is a measure of linkage 
disequilibrium. The distance from SNP I and SNP 18 is 72.5 kb. 
4.2.2.2 Summary 
One tagSNP (rs2715276) within CD86 was found to be specifically associated 
with AE in the Bangladeshi population through the Illumina candidate gene study. 
However this tagSNP did not remain significant when corrected for multiple 
testing. However other tagSNPs (rs2255214, rs4308217) when analysed against 
other phenotypes and phenotype combinations gave significant p-values, one of 
which remained significant after correction for multiple testing at method three. 
Further analysis of this gene is warranted with regard to atopic disease. 
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4.2.3 Tenascin-C 
Tenascin-C has been found to be upregulated in the lesional skin of AE patients 
but was not found to be upregulated in normal skin or psoriatic skin (Ogawa et al., 
2005). 
4.2.3.1 Illumina study 
Tenascin-C had four significant SNPs (rs3748166, rs7029844, rsl 1793430 and 
rs11794797), associated specifically with AE, in this study out of 45 at p-0.05 
(Table 4.4) which again when corrected for multiple testing did not remain 
significant (Method 3- p-value = 0.0011). Figure 4.11 shows the negative log of 
the p-value for the whole gene and figure 4.12 shows the LD (r2) map of the gene. 
These four significant tagSNPs remained significant when tested against the other 
phenotypes. rs11793430 remained significant only when combined with AE 
specifically in the cases of asthma and hayfever. However it was significant when 
analysed against food allergy and this dropped out when combined with AE. 
rs11794797 also remained significant for all other phenotypes, but was more 
significant when the analysis was combined with AE, again except in the case of 
food allergy. rs7029844 remained significant when analysed against asthma and 
AE however did not remain significant when AE was combined with hayfever and 
food allergy. rs3748166 remained significant in all other analysis. 
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Tenascin-C 
Chromosome 9 
Chromosomal 
position 
Location p-value 
rs3748166 114959703 Intron 0.0097 
rs7029844 114958465 Intron 0.010 
rs l 1793430 114887674 Intron 0.011 
rs11794797 114894827 Intron 0.016 
Table 4.4 - Significant tagSNPs in Tenascin-C associated specifically with 
AE. Four Tenascin-C tagSNPs out of 45 were significant at a p-value < 0.05 from 
the Goldengate genotyping assay. None of these SNPs remained significant after 
correction for multiple testing. 
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Figure 4.11 - Tenascin-C significance level. -log of the p-value. Four tagSNPs 
reached the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red 
lines at 3.73 and 3.87 are equivalent to the novel gene threshold and the all gene 
threshold (novel gene and all gene threshold shown as thick red line due to 
proximity). The Tenascin-C gene position is also indicated at the base of the 
graph, with exons marked as vertical lines, introns marked as a peaked horizontal 
line, unfilled boxes as UTR's. 
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Figure 4.12 - LD(r2) map of Tenascin-C showing two LD blocks. Tenascin-C 
looks to have 2 distinct blocks of LD. Probable blocks of LD are marked inside 
red triangles. The point between the 2 blocks is where recombination has 
occurred and therefore where much variation occurs. The extent of LD decreases 
in proportion to the number of generations since an LD generating event, such as a 
mutation or a recombination event. Therefore this recombination looks to have 
been in relatively recent history. Linkage disequilibrium maps were generated 
using Haploview and the data generated from the Illumina goldengate assay to 
produce Bangladeshi specific LD maps. LD is defined by the level of grey colour 
within the square. A dark grey/black square indicates strong LD, a light/medium 
grey square is some LD and white indicates no LD. r2 is a measure of linkage 
disequilibrium. The distance from SNP I and SNP 45 is 106.5 kb. 
4.2.3.2 Further investigation 
Tenascin-C has four tagSNPs which were significant at p-value < 0.05 and when 
there are multiple SNPs associated within one gene the chances that the 
association is real is much greater. Therefore Tenascin-C was chosen for further 
investigation. 
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Specific samples were picked to try to reduce the cost of the experiment. Briefly 
samples were picked on the basis of haplotypes. The haplotypes chosen were 
identified as the major haplotypes generated using the haplotype function within 
Haploview and the generated Illumina data (Figure 4.13). Using the major 
haplotypes in this AE population for Tenascin-C allows a targeted approach for 
finding any possible pathogenic SNPs within the coding region of Tenascin-C. 
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Figure 4.13 - Haplotype blocks generated for Tenascin-C using Haploview 
and the generated Illumina data. Major haplotypes are joined with thick black 
lines when over 10% and thin black lines when under I%. 
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Haplotype % Total % of AE 
number of affected 
individuals individuals 
1 122212211222111211222- Block 1 (24.4%) 
221112211222111- Block 2 (44.5%) 5 40 
212122211 Block 3 (31.3%) 
2 221112211222111- Block 2 (44.5%) 
111211221 Block 3 (25.2%) 5 40 
3 112221222112122- Block 2 (30.3%) 
221111122 Block 3 (26.0%) 13 53.8 
Table 4.5 - Haplotypes generated for Tenascin-C. Using the 45 SNPs typed in 
the Illumina assay haplotypes were generated for the Bangladeshi population. 
Haplotypes joined by thick lines (Figure 4.13) (indicating over 10% frequency) 
were chosen. 1 and 2 indicate the different alleles within each SNP. 
Haplotyping, individual identification and primer design was carried out by 
myself and the PCR and sequencing reactions were carried out by Rauda Al- 
Kuwaiti. Further bioinformatic analysis was also carried out by myself using 
PolyPhen to try to predict if SNPs could be causative. 
4.2.3.2.1 Sequencing 
Samples were sequenced using primers which encompass the intron/exon 
boundaries, the coding sequence as well as the 3'UTR. Several previously 
identified variants were detected as well as two novel variants (Table 4.6). 
tan 
SNP Location Variant Change No. of 
Individuals 
rs3748166 Intron 1 C/T 2(5) 
rs3833490 Intron 1 Ins A 2 (5) 
rs1757095 Exon 3 C/T Non-synonymous 
Gln-Arg 
3 (8) 
rs1617917 Intron 3 A/T 3(8) 
rs2210108 Intron 9 A/G 3(8) 
rs45602433 Exon 10 C/T Non-synonymous 
Arg-His 
2 (7) 
Novel Exon 15 C/T Non-synonymous 
Pro-Ser 
1 (8) 
rs2274750 Exon 19 G/A Non-synonymous 
Thr-Ala 
l (q) 
rs35141770 Intron 19 +TGTG Insertion 5(9) 
rs13321 Exon 24 C/G Non-synonymous 
Glu-Gln 
5 (9) 
Novel Intron 24 G/C 1 (8) 
Table 4.6 - Summary of SNPs found in TNC in the targeted AE population by 
sequencing. In total 11 other SNPs were found within the AE population. All of 
these had been previously identified and found in SNP databases. Two of these 
SNPs had not been identified before, one of which was non-synonymous. (N) 
indicates the number of individuals sequenced in total for this exon. 
Two of the variants found were genotyped in the AE Bangladeshi families. The 
result of this analysis is shown in table 4.7. Genotyping was carried out by 
Taqman (Rauda Al-Kuwaiti, a PhD student with the lab also working on AE) and 
I performed the FBAT analysis. 
SNP Location p-value 
rs45602433 Exon 10 0.233 
rs35141770 Intron 19 0.085 
l able 4.7 - SNPs identified in the AE population, genotyped in the full AE 
population. Neither of these known SNPs were found to be significant. 
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The novel SNP found in exon 15 is also predicted to be benign, using PolyPhen, 
within TNC (Figure 4.14) and it is also not conserved between species (4.15) 
which backs up the predicted benign effect. 
AA2 Description 
S SubName. FuII=Tenascm C (Hexabrachion); LENGTH 2201 AA 
Figure 4.14 - PolyPhen analysis on the novel TNC mutations found in Exon 
15 indicates it is benign. The sequence was inputted and the amino acid change 
was identified in order for the analysis to occur. 
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Prediction Available data Prediction basis Substitution effect Prediction data 
benign alignment alignment WA PSIC score difference 0 063 
Fragment of multiple alignment around position 1499: 
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Figure 4.15 - PolyPhen multiple alignment showing that amino acid 1499 is 
not conserved between species. 
4.2.3.3 Summary 
Four significant tagSNPs, within TNC, were identified in the initial Illumina study 
for association with AE. When further analysis was carried out these SNPs 
remained significant when AE was combined with other allergic phenotypes. As 
there were multiple SNPs found to be associated with AE this gene was chosen 
for further analysis. Eleven SNPs were identified in the sequencing analysis. Of 
these eleven, two were novel, one of which results in an amino acid change. 
When this change was analysed using PolyPhen it was not predicted to have an 
effect on the protein folding or structure. 
143 
4.2.4 KYNU 
It has been found that kynureninase mRNA is upregulated in skin lesions in AE 
patients in comparison with involved skin in AE patients and normal controls (Ito 
et al., 2004). T cell proliferation is inhibited by changes in the tryptophan 
degradation pathway and therefore this pathway may be involved in the 
pathogenesis of AE. 
4.2.4.1 Illumina study 
KYNU had one significant SNP (rs13024113) out of the 53 SNPs genotyped in 
this study at p<0.05 (Table 4.8) which when corrected for multiple testing was 
significant under all 3 correction strategies. Figure 4.16 shows the negative log of 
the p-value for the whole gene and figure 4.17 shows the LD map of the gene. 
The original Illumina Beadstudio clustering of rs 13024113 is shown in figure 
4.18. 
rs13024113 remained significant under all 3 correction strategies for other 
phenotypes analysed. rs2304700 was borderline under the AE analysis however 
became significant at p<0.05 for the asthma, hayfever and food allergy analysis. 
This was not maintained when combined with AE. 
KYNU SNPs 
Chromosome 2 
Chromosomal 
position 
Location p-value 
rs13024113 143544737 Intron 0.000067 
Table 4.8 - Significant tagSNPs in KYNU. One KYNU tagSNP out of 53 was 
significant at p-value < 0.05 from the Goldengate genotyping assay with the AE 
phenotype. This SNP remained significant after correction for multiple testing. 
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Figure 4.16 - KYNU significance level. -log of the p-value. One tagSNP 
reached the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red 
lines at 3.73 and 3.87 are equivalent to the novel gene threshold and the all gene 
threshold (novel gene and all gene threshold shown as thick red line due to 
proximity). The KYNU gene position is also indicated at the base of the graph, 
with exons marked as vertical lines, introns marked as a peaked horizontal line, 
unfilled boxes as UTR's. 
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Figure 4.17 - LD(r2) map of KYNU showing two LD blocks. KYNU appears to 
have two very jumbled block of LD possibly due to past recombination events. 
Probable blocks of LD are marked inside red triangles. Linkage disequilibrium 
maps were generated using Haploview and the data generated from the Illumina 
goldengate assay to produce Bangladeshi specific LD maps. LD is defined by the 
level of grey colour within the square. A dark grey/black square indicates strong 
LD, a light/medium grey square is some LD and white indicates no LD. r` is a 
measure of linkage disequilibrium. The distance from SNP 1 and SNP 53 is 164.5 
kb. 
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Figure 4.18 - Illumina Beadstudio clustering of rs13024113. No samples are 
seen at homozygous AA. 244 samples are homozygous at this SNP. 110 samples 
are homozygous BB. Please note that this SNP is under further investigation due 
to the lack of AA homozygotes which should be located at 0 theta. 
4.2.4.2 Further investigation 
KYNU was chosen for further analysis as it had one tagging SNP which remained 
significant after correction for multiple testing using all 3 methods. Therefore it 
was chosen for further investigation in the form sequencing to try and identify any 
mutations. 
Specific samples were picked to try to reduce the cost of the experiment. Briefly 
samples were picked on the basis of haplotypes. The haplotypes chosen had a 
frequency higher than 10% in the Bangladeshi population and these haplotypes 
were generated using the haplotype function within Haploview and the generated 
Illumina data. Using the major haplotypes in this AE population for KYNU allows 
a targeted approach for finding any possible pathogenic SNPs within the coding 
region of KYNU. 
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Haplotype % Total % of AE 
number of affected 
homozygous individuals 
individuals 
1 2111211212111111122211111122122 18.8 13 16.7 
1211221211121222121121 
2 1212112121212221211221122111221 11 2 0 
1111221222122212122121 
3 1221121221222222222112211222222 5.9 2 100 
2211122111211121211221 
Table 4.9 - Haplotypes generated for KYNU. Using the 53 SNPs typed in the 
Illumina assay haplotypes were generated for the Bangladeshi population. 
Haplotypes over 10% were chosen, however it was decided to include the 
haplotype at 5.9% as all of the haplotypes tended to have small numbers. 1 and 2 
indicate the different alleles within each SNP. The total number of individuals 
within the population who were homozygous for the haplotypes is listed along 
with the percentage of AE affected individuals from this total number. 
4.2.4.2.1 Sequencing 
The samples for KYNU exons one to fourteen were amplified by PCR and then 
sequenced using standard protocols. The sequences were then analysed using the 
PhredPhrap software. All sequences were clean and no heterozygous or 
homozygous mutations were found. The primers encompassed the intron/exon 
boundaries, coding sequence and the 3'UTR. 
4.2.4.3 Summary 
One tagSNP within KYNU was found to be associated with AE in the Bangladeshi 
population through the Illumina candidate gene study. This SNP remained 
significant even when corrected using all three methods. Further analysis was 
carried out using a targeted sequencing approach. However no mutations were 
identified in the coding regions. 
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4.2.5 ACVR1 
Activin-A (ACVR1) seems to be structurally and functionally similar to TGF-ß 
and like TGF-ß it has been found to be involved in the pathogenesis of asthma 
(Karagiannidis et al., 2006). Human mast cells are an abundant source of Activin- 
A and these cells are well known for their role in allergy and inflammation. 
4.2.5.1 Illumina study 
ACVRI had one significant SNP (rs6756964) out of the 23 SNPs genotyped in this 
study at p<0.05 (Table 4.10) which was not significant when corrected for 
multiple testing (method 3- p-value = 0.0022). Figure 4.19 shows the negative 
log of the p-value for the whole gene and figure 4.20 shows the LD(? ) map of the 
gene. 
rs6756964 remained significant with the asthma and AE, food allergy and food 
allergy and AE analysis, but not for hayfever. 
ACVR1 SNPs 
Chromosome 2 
Chromosomal 
position 
Location p-value 
rs6756964 158471046 Intron 0.011 
Table 4.10 - Significant tagSNPs in ACVRI. One ACVRI tagSNP out of 23 was 
significant at p-value < 0.05 from the Goldengate genotyping assay. This SNP did 
not remain significant after correction for multiple testing. 
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Figure 4.19 - ACVR1 significance level. -log of the p-value. One tagSNPs 
reached the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red 
lines at 3.73 and 3.87 are equivalent to the novel gene threshold and the all gene 
threshold (novel gene and all gene threshold shown as thick red line due to 
proximity). The ACVRI gene position is also indicated at the base of the graph, 
with exons marked as vertical lines, introns marked as a peaked horizontal line, 
unfilled boxes as UTR's. 
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Figure 4.20 - LD(r2) map of ACVRI showing two LD blocks. ACVRI looks to 
have 2 separated blocks of weak LD and the area where there is little LD is where 
recombination events have occurred. This could indicate that this is region of 
common recombination in history. Probable blocks of LD are marked inside red 
triangles. Linkage disequilibrium maps were generated using Haploview and the 
data generated from the Illumina goldengate assay to produce Bangladeshi 
specific LD maps. A dark grey/black square indicates strong LD, a light/medium 
grey square is some LD and white indicates no LD. r2 is a measure of linkage 
disequilibrium. The distance from SNP I and SNP 23 is 138.5 kb. 
4.2.5.2 Summary 
One tagSNP within ACVRI was found to be associated with AE in the 
Bangladeshi population through the Illumina candidate gene study. However this 
SNP did not remain significant when corrected for multiple testing and therefore 
this gene was not chosen for further investigation. 
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4.2.6 CCR4 
CCR4 expressing cells have been found at sites of allergic inflammation (Banwell 
et al., 2003). The chemokines also play fundamental roles in the development, 
homeostasis, and function of the immune system. Therefore CCR4 could be 
involved in the immune aspect of AE. 
4.2.6.1 Illumina study 
CCR4 had one significant SNP (rs2228428) out of the three SNPs genotyped in 
this study at p<0.05 (Table 4.11) which did not remain significant when 
corrected for multiple testing (method 3- p-value = 0.016). Figure 4.21 shows 
the negative log of the p-value for the whole gene. 
rs2228428 became more significant at a gene by gene level through the asthma, 
hayfever and food allergy analysis and did remain significant at p <_ 0.05 for the 
combined analysis of these phenotypes with AE. rs7612287 also became 
significant through the asthma, hayfever and food allergy analysis. 
CCR4 SNPs Chromosomal Location p-value 
Chromosome 3 position 
Exon 2 
rs2228428 32970932 Synonymous 0.022 
Table 4.11 - Significant tagSNPs in CCR4. One CCR4 tagSNP out of three was 
significant at p-value < 0.05 with AE from the Goldengate genotyping assay. This 
SNP did not remain significant after correction for multiple testing. 
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Figure 4.21 - CCR4 significance level. -log of the p-value. One tagSNP reached 
the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red lines at 
3.73 and 3.87 are equivalent to the novel gene threshold and the all gene threshold 
(novel gene and all gene threshold shown as thick red line due to proximity). The 
CCR4 gene position is also indicated at the base of the graph, with exons marked 
as vertical lines, introns marked as a peaked horizontal line, unfilled boxes as 
UTR's. 
4.2.6.2 Summary 
One tagSNP (rs2228428) within CCR4 was found to be associated with AE in the 
Bangladeshi population through the Illumina candidate gene study. However this 
SNP did not remain significant when corrected for multiple testing. This SNP 
along with one other (rs7612287) showed association with other atopic 
phenotypes even after correction for multiple testing at a gene by gene level. 
Further investigation into the gene is required in relation to other atopic 
phenotypes. 
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4.2.7 JAKS 
JAK3 is a tyrosine kinase of the non-receptor type, involved in the interleukin-2 
and interleukin-4 signalling pathway and seems to play a role in IgE receptor/mast 
cell response (Ghoreschi et al., 2009). The NC/Nga mouse established in 1957 
seems to show similar AE like symptoms and is often used as a model for AE 
(Matsumoto et al., 1999). These mice show AE-like skin lesions and markedly 
upregulated IgE levels. In these mice it has been found that enhanced tyrosine 
phosphorylation of JAK3 mediated by IL-4 results in hyper-IgE production 
(Matsumoto et al., 1999). It has therefore been proposed as a mechanism for the 
pathogenesis of AE. 
4.2.7.1 Illumina study 
JAKS has five significant SNPs (rs722429, rs2286662, rs10421916, rs7255931 
and rs11086080) out of the 21 SNPs genotyped in the Illumina study at p <_ 0.05 
and three SNPs (rs11086080, rs2110586 and rs7409343) which gave p-values of 
0.057,0.059 and 0.075 respectively (Table 4.12), when corrected for multiple 
testing, rs722429 remained significant using all 3 correction strategies and 
rs2286662 which remained significant using the gene by gene method (p-value = 
0.0024). Figure 4.22 shows the negative log of the p-value for the whole gene and 
figure 4.23 shows the LD(r2) map of the gene. The original Illumina Beadstudio 
clustering of rs 13024113 is shown in figure 4.24. 
rs722429 remained significant after correction for multiple testing when analysed 
against asthma, hayfever, hayfever and AE. It also remained significant at a gene 
by gene level for the analysis with AE and asthma, food allergy and food allergy 
and AE. The other AE significant tagSNPs remained significant at p: 5 0.05 for all 
atopic phenotypes. 
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JAKS SNPs 
Chromosome 19 
Chromosomal 
position 
Location p-value 
rs722429 17785753 5' near JAK3 0.000102 
rs2286662 17793138 
5' near JAK3 
Exon 1 of INSL3 
Non-synonymous 0.00239 
rs10421916 17789987 Intron 0.00387 
rs7255931 17799844 Intron 0.022 
rs11086080 17788041 5' near JAK3 0.058 
rs2110586 17818309 Intron 0.059 
rs7409343 17787385 5' near JAK3 0.075 
Table 4.12 - Significant tagSNPs in JAKS. Seven JAKS tagSNPs out of 21 were 
significant at a p-value <_ 0.05 from the Goldengate genotyping assay. rs722429 
remained significant when corrected for multiple testing using all three methods. 
rs22186662 remained significant when correct for multiple testing using the gene 
by gene method. rsl 1086080, rs2110586 and rs7409343 were just outside the cut- 
off. 
155 
JAK3 
4.5 
4 
3.5 
3 
2.5 
c) 
2 
1.5 
1 
0.5 
40 
Chromosomal Position (bp) 
Figure 4.22 - JAKS significance. -log of the p-value. Seven JAKS tagSNPs 
reached the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red 
lines at 3.73 and 3.87 are equivalent to the novel gene threshold and the all gene 
threshold (novel gene and all gene threshold shown as thick red line due to 
proximity). The JAKS gene position is also indicated at the base of the graph, 
with exons marked as vertical lines, introns marked as a peaked horizontal line, 
unfilled boxes as UTR's. 
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k. 
Figure 4.23 - LD(r2) map of JAKS showing no blocks of LD. JAKS locus 
displays little LD. Probable blocks of LD are marked inside red triangles. It is 
likely that because of the lack of LD that so many SNPs have demonstrated 
positive associations with atopic disease and if proved correct then there must be 
SNPs within JAKS which contribute to disease susceptibility. Linkage 
disequilibrium maps were generated using Haploview and the data generated from 
the Illumina goldengate assay to produce Bangladeshi specific LD maps. A dark 
grey/black indicates strong LD, a light/medium grey is some LD and white 
indicates no LD. r` is a measure of linkage disequilibrium. The distance from 
SNP I and SNP 21 is 35.8 kb. 
157 
tr 
7. 
1" 
Ih 
ä 
00 
0k 
0. 
0r 
2121 
u" 
022429 
65 193 98 
. ý_, 
Norm Theo 
v~ _... 
Figure 4.24 - Illumina Beadstudio clustering of rs722429.65 samples are seen 
at homozygous AA. 193 samples are heterozygous at this SNP. 98 samples are 
homozygous BB. 
4.2.7.1.1 JAK3/INSL3 
JAKS was chosen for further analysis as it had one tagging SNP which remained 
significant after correction for multiple testing using all 3 methods, plus other 
tagSNPs which showed some positive association. Further investigation into 
JAKS revealed that there was another gene (INSL3) lying very close to the 5' end 
of JAKS and the tagSNPs used to investigate JAK3 covered JNSL3 also. INSL3 
(Insulin-like 3) belongs to the insulin-like hormone family. It seems to be 
produced predominantly in the testicular Leydig cells and the ovarian theca cells 
(Tomboc et al., 2000). Theca cells are endocrine cells within the ovary which 
have an effect on fertility (Magoffin, 2005). Knock-out experiments have 
identified a role for INSL3 in initiating testes descent during fetal development but 
also an important role in mediating male and female germ line cells (Rosengren et 
1k al., 2006). Little is known about INSL3 expression within skin. 
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Figure 4.25 - Location of JAKS and INSL3 on chromosome 19. INSL3 can be 
seen to lie closely to JAKS. 
4.2.7.2 Further investigation 
As one of the significant tagSNPs is located in the exon of INSL3 and also results 
in a non-synonymous change from an Alanine residue to a Threonine residue it 
was decided to target INSL3 for further investigation in the form of sequencing to 
try and identify any other mutations. Further bioinformatic analysis was also 
carried out using PolyPhen to try to predict if SNPs could be causative. 
Samples were identified as in section 4.2.4.2. 
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Haplotype % Total number 
of homozygous 
individuals 
% of AE affected 
individuals 
1 11112 28.9 31 54.8 
2 21221 27.7 23 60.8 
3 11111 12.7 5 40 
4 22221 9.9 2 50 
5 11222 9.4 3 66.7 
6 21222 7.9 1 100 
Table 4.13 - Haplotypes generated for INSL3. Using five SNPs typed in the 
Illumina assay, which encompasses INSL3, haplotypes were generated for the 
Bangladeshi population. The haplotypes chosen encompass 96.5% of all 
haplotypes for these five SNPS within this population. 1 and 2 indicate the 
different alleles within each SNP. The total number of individuals within the 
population who were homozygous for the haplotypes is listed along with the 
percentage of AE affected individuals from this total number. 
4.2.7.2.1 Sequencing 
The samples for INSL3 exons one and two were amplified by PCR and then 
sequenced using standard protocols. The sequences were then analysed using the 
PhredPhrap software. The primers encompassed the intron/exon boundaries, 
coding sequence and the 3'UTR. No mutations were found in exon two. 
Within exon one, three novel sequence variants were identified along with the 
original Illumina genotyped non-synonymous coding SNP. 
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Change Location Sequence Samples Figure 
G/A Intron GCTTGGCCCCNGCGCC 136 - unaffected 4.26 
ACCCACC 
C/A Intron GCGCCACCCANCACCA 13 - unaffected 4.27 
TGGACC 145 - affected 
353 - affected 
367 - unaffected 
386 - unaffected 
387 - affected 
433 - unaffected 
505 - affected C/A Exon 1 CCCGCCTGGGNGCTGG 13 - unaffected 4.28 
Alanine- TGCTGCT 121 - unaffected 
Glutamic 145 - affected 
Acid 378 - unaffected 
353 - affected 
367 - unaffected 
387 - affected 
433 - unaffected 
479 - affected 
505 - affected 
Table 4.14 - Novel sequence variants found in INSL3 samples. Three novel 
mutations found in the selected population which was screened by sequencing; 
two intronic mutations and one coding mutation. The start codon is indicated in 
red in the second intronic variant sequence. 
7U ivy ++A 
CCCCGCTTGGCCCCGCGCCACCCACCACCA 
Bcccc 
90 100 110 
Figure 4.26 - Intronic G/A heterozygous mutation found in one AE 
unaffected sample. (A) Sample 136. G/A heterozygote can clearly be seen at 97 
bp. (B) Control DNA. No change can clearly be seen at the same position. 
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m 
A 
B 
100 110 12( 
CCGGCGCCACCCANCACCATGGACCCC 
Figure 4.27 - Intronic C/A heterozygous found in eight samples. (A) Sample 
145. C/A heterozygote can clearly be seen at 107 bp. (B) Sample 136. Wild-type 
sequence at 108 bp. The variant indicated by N at the beginning of this sequence 
is the other intronic variant identified as can be seen in figure 4.26. 
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CCNGCGCCACCCAPCACCATGGACCCC 
A 
B 
140 150 
TCTGCCCGCCTGGGCTGGTGCTGCTGG 
Figure 4.28 - Coding C/A mutation resulting in an Alanine to Glutamic acid 
amino acid change. (A) Sample 43. The red arrow indicates the novel 
heterozygous C/A at base pair 145. The black arrow indicates rs2286663 which is 
a known synonymous SNP. The sample in panel A is homozygous A at this 
position, wild-type is G. This mutation does not affect the novel non-synonymous 
SNP found as the change from GCG or GCA to GAG or GAA both result in a 
change from Alanine to Glutamic acid. (B) Control DNA. Homozygous for the 
wild-type C at position 138bp. 
4.2.7.2.2 PolyPhen 
The significant tagSNP which was in fact non-synonymous in INSL3 was not 
predicted to have an effect on the protein using the PolyPhen algorithm. The 
novel non-synonymous SNP identified was also predicted to be benign (Figure 
4.29). 
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TC7GCCCGCCTGGG r- ý, CTGGTGCTGCTGG 
Acc number Position AAi AA2 Description 
ENST00000379695 9AE peptide ENSP00000369017 pep KNOWN protein_codmg 
Scorel Seon2 ISeon1 Scon21 Obswvadons Dlsgnostles 
+1149 -0.303 1A62 7 calculated 
Figure 4.29 - PolyPhen analysis of the novel amino acid change found in 
INSL3 exon I which is predicted to be benign. 
4.2.7.3 Summary 
Seven tagSNPs out of 21 within . IAK3 were 
found to be associated with AE in the 
Bangladeshi population through the Illumina candidate gene study. rs722429 
remained significant using all 3 correction strategies and rs2286662 which 
remained significant using the gene by gene method. Another gene was found to 
lie very close to . JAKS and rs2286662 which lies 
downstream of JAK3 was found 
to be a non-synonymous SNP within INSL3. For this reason further analysis of 
INSL3 was conducted by sequencing. Three novel mutations were found within 
INSL3, two of which were intronic and one of which was a non-synonymous 
coding SNP. The non-synonymous novel SNP was not predicted to have an effect 
on the protein. 
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4.2.8 IL10RA 
The allergic responses of young children were characterised and it was found that 
the production of IL-10 was found to be impaired when stimulated with food, 
vaccines and staphylococcus aureus which is a pathogen known to cause many 
infections in AE lesions (Dunstan et al., 2005). Impairment of the IL10 receptor 
could be involved in AE due to the observation that IL10 is impaired in atopic 
patients. 
4.2.8.1 Illumina study 
ILJORA has two significant SNPs (rs11216666 and rs11216667) out of eleven 
SNPs which were genotyped, which showed evidence of association at pS0.05 
(Table 4.15), after correction for multiple testing (method 3- p-value = 0.0045) 
none of which remained significant. There were also two tagSNPs (rs2282496 
and rs2282494) which gave borderline p-values of 0.06 and 0.07 respectively. 
Figure 4.30 shows the negative log of the p-value for the whole gene and figure 
4.31 shows the LD(r2) map of the gene. 
rsl 1216666 and rsl 1216667 were also significant with the asthma phenotype of 
this population. However this did not remain significant through any other 
analysis. 
IL10RA SNPs - 
Chromosome 11 
Chromosomal 
position 
Location p-value 
rs11216666 117381245 Downstream 0.0312 
rsl 1216667 117381408 Downstream 0.0312 
rs2282496 117370189 Intron 0.0610 
rs2282494 117372078 Intron 0.0708 
Table 4.15 - Significant tagSNPs in IL1ORA. Four ILIORA tagSNPs out of 11 
were significant at a p-value <_ 0.05 from the Goldengate genotyping assay. 
rs2282496 and rs2282494 were just outside the significant cut-off. None of these 
remained significant after correction for multiple testing. 
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Figure 4.30 - IL10RA significance. -log of the p-value. Four ILIORA tagSNPs 
reached the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red 
lines at 3.73 and 3.87 are equivalent to the novel gene threshold and the all gene 
threshold (novel gene and all gene threshold shown as thick red line due to 
proximity). The ILIORA gene position is also indicated at the base of the graph, 
with exons marked as vertical lines, introns marked as a peaked horizontal line, 
unfilled boxes as UTR's. 
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Figure 4.31 - LD(r2) map of ILIORA showing one block of LD. There looks to 
be one main block of LD within IL1ORA however this is not strong indicated by a 
lack of black/dark grey squares. Probable blocks of LD are marked inside red 
triangles. This indicates that this area of the genome has undergone 
recombination however this may not be recent history as the amount of LD 
decreases in relation to the length of time since recombination. Linkage 
disequilibrium maps were generated using Haploview and the data generated from 
the Illumina goldengate assay to produce Bangladeshi specific LD maps. r2 is a 
measure of linkage disequilibrium. The distance from SNP I and SNP II is 22.5 
kb. 
4.2.8.2 Summary 
Four tagSNPs within ILIORA were found to be associated with AE in the 
Bangladeshi population through the Illumina candidate gene study. However 
these SNPs did not remain significant when corrected for multiple testing and 
therefore this gene was not chosen for further investigation. 
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4.2.9 PTGDS 
PTGDS has been shown to play a role in the inhibition of itching in mice with 
atopic like dermatitis. Scratching as a reaction to itching causes injury to the skin, 
which, in-turn further increases the itching, the so called itch-scratch cycle 
(Sugimoto et al., 2007). 
4.2.9.1 Illumina study 
PTGDS had two significant SNPs (rs3814501 and rs4880082) out of four SNPS 
which were genotyped, which showed evidence of association at p<0.05 (Table 
4.16) none of which remained significant after multiple testing (method 3- p- 
value = 0.013). Figure 4.32 shows a negative log of the p-value for the whole 
gene. 
Neither of these tagSNPs maintained the significance with any of the other 
allergic phenotypes. 
PTGDS SNPs - 
Chromosome 9 
Chromosomal 
position 
Location p-value 
rs3814501 137145950 Upstream 0.026 
rs4880082 137154665 3'UTR 0.038 
Table 4.16 - Significant tagSNPs in PTGDS. Two PTGDS tag SNPs out of four 
were significant at a p-value <_ 0.05 from the Goldengate genotyping assay. None 
of these remained significant after correction for multiple testing. 
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Figure 4.32 - PTGDS significance. -log of the p-value. Two PTGDS tagSNPs 
reached the p-value cut-off of 0.05 as indicated by the red line at 1.30. The red 
lines at 3.73 and 3.87 are equivalent to the novel gene threshold and the all gene 
threshold (novel gene and all gene threshold shown as thick red line due to 
proximity). The PTGDS gene position is also indicated at the base of the graph, 
with exons marked as vertical lines, introns marked as a peaked horizontal line, 
unfilled boxes as UTR's. 
4.2.9.2 Summary 
Two tagSNPs within PTGDS were found to be associated with AE in the 
Bangladeshi families through the Illumina candidate gene study. However these 
SNPs did not remain significant when corrected for multiple testing and therefore 
this gene was not chosen for further investigation. 
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4.2.10 Negative associations 
In addition to the novel genes which were found to be associated in the Illumina 
Goldengate assay (sections 4.2.1-4.2.9) six additional novel genes were also 
analysed using the Illumina Goldengate assay. These were HRF, COL7A, 
PTPN22, WASIP, FAP and NRAMP. These genes did not show any evidence of 
genetic association in the Bangladeshi family based study, with no tagSNPs 
reaching the initial significance level of p: 5 0.05. These genes were included for 
analysis for the reasons below. 
HRF or IgE dependent Histamine Releasing Factor is located at chromosome 
13g14.13. This was first identified in 1995 (MacDonald et al., 1995). It is a 
unique molecule in the manner that it does not have any homology to any known 
interleukin or chemokine, however studies have shown that it stimulates the 
production of IL-4 and IL-13 from basophils (Schroeder et al., 1997). It is 
therefore a reasonable assumption that a gene dependent on IgE and stimulating 
IL-4 and IL-13 could be involved in the susceptibility to AE. 
COL7A encodes the alpha chain of type VII collagen. The gene expression is 
restricted to the basement zone just beneath the stratified squamous epithelia. 
Mutations in this gene are associated with all forms of dystrophic epidermolysis 
bullosa (Ryynanen et al., 1991). This was considered a potential candidate gene 
due to its location within the skin and also to its chromosomal positioning at 
3p21.1. 
PTPN22 encodes a protein tyrosine phosphatase N22. This gene has been linked 
to a wide array of autoimmune diseases previously such as type 1 diabetes (Duffy, 
2007), rheumatoid arthritis (Orozco et al., 2008), systemic lupus erythematosus 
(Chung and Criswell, 2007) and Graves' disease (Heward et al., 2007). One 
single base change has been associated to all these diseases. It has also been 
hypothesised that this single base change could result in T cell hyper 
responsiveness (Rieck et al., 2007). Therefore this seemed a very appropriate 
gene to study with the Illumina due to its possible biological function. 
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WASIP or Wiskott-Aldrich Syndrome Interacting Protein is located at 2g24-31 
which is a previous area where linkage was found in the whole genome 
microsatellite scan. This gene encodes a protein which plays an important role in 
the organisation of the actin cytoskeleton in cells. It is also known to bind to the 
Wiskott-Aldrich Syndrome Protein (Anton et al., 2007) which is mutated in 
Wiskott-Aldrich syndrome which is an X-linked recessive disorder and also has 
an eczema component. 
Fibroblast Activation Protein (FAP) is also located at 2q23 which again is within 
a linkage region found in the whole genome microsatellite linkage scan. The 
protein encoded is a homodimeric integral membrane gelatinase belonging to the 
serine protease family (Huber et al., 2003). It is involved in epithelial cancers, 
granulation tissue of healing wounds and soft tissue sarcomas (Henry et al., 2007). 
It is thought to be involved in the control of fibroblast growth or epithelial- 
mesenchymal interactions during development, tissue repair and epithelial 
carcinogenesis. 
NRAMPI is located at 2q35, again an area of linkage from the previous 
microsatellite genome study. Its function is a divalent transition metal transporter 
which is involved in iron metabolism and also host resistance to certain 
pathogens. It has been associated to leprosy susceptibility and also tuberculosis 
susceptibility in 2 separate populations (Takahashi et al., 2008). In Bangladeshi 
families it is postulated that exposure to tuberculosis stimulates an immune 
response which seems to be protective to AE (von Hertzen and Haahtela, 2004). 
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4.3 Discussion 
Fifteen genes were selected as novel candidate genes. These genes were picked 
because of their possible biological function and/or their position in the genome 
with reference to the whole genome microsatellite scan completed previous to this 
study. Of these fifteen genes, nine showed positive association though this was 
reduced to eight due to genotyping artefact. The six candidates which did not 
show association were HRF, COL7A, PTPN22, WASIP, FAP and NRAMP. These 
genes were interesting because they were either positional candidates or biological 
candidates however it was expected that many of these would not show 
association. 
Gene Associated 
with AE 
Best p-value Other association? 
CD86 Yes 0.01 Asthma, Hayfever, Food Allergy 
TNC Yes 0.0097 Asthma, Hayfever, Food Allergy 
KYNU Yes 0.000067 Asthma, Hayfever, Food Allergy 
ACVRI Yes 0.011 Asthma, Food Allergy 
CCR4 Yes 0.022 Asthma, Hayfever, Food Allergy 
JAK3 Yes 0.0001 Asthma, Hayfever, Food Allergy 
IL10RA Yes 0.031 Asthma, Hayfever 
PTGDS Yes 0.026 Asthma 
SLC9A3R1 No 0.114 - 
HRF No 0.222 Asthma, Food Allergy 
COL7A No 0.365 - 
PTPN22 No 0.097 Asthma 
WASIP No 0.144 - 
FAP No 0.243 - 
NRAMP No 0.108 Asthma, Hayfever, Food Allergy 
Table 4.17 - Summary of association found in the novel candidate genes. 
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4.3.1 SLC9A3R1 
The results of the Illumina candidate gene study have indicated that this gene is 
associated to AE in the Bangladeshi population. The SNP rs1054131 reached a 
significance level of 1.305x10-14, which is very significant. However further 
investigation into this p-value has shown that this gene is not in fact associated. 
As can be seen with the ABCA12 SNP (chapter 6) rs4571054, the clustering 
within the Illumina beadstudio computer package was wrong and after further 
analysis and sequencing of some individuals it was found that this SNP was no 
longer significant and had a p-value of 0.114. Even with the quality control 
checks in place there have still been a number of false positive associations and 
therefore associations found need to be checked and replicated in another 
population for complete confidence in a true association. 
4.3.2 CD86 
The Illumina candidate gene study showed some association to CD86. Only one 
tagSNP out of eighteen was significant. The SNP rs2715276 had a p-value of 
0.010. This shows that CD86 could be involved in the pathogenesis of AE but it 
is doubtful that it has a large effect. However when the analysis of AE was 
combined with either asthma or food allergy, several other SNPs became 
significant giving good p-values and one even reaching the correction level set on 
a gene by gene level. The fact that other SNPs within CD86 become more 
significant when the analysis of allergic diseases is combined emphasizes the 
probability that this gene has a role in atopic part of these diseases. CD86 is 
known to be involved in T cell activation, specifically Th2 CD4+ lymphocytes 
which have a major role in the mediation of allergic inflammation. It specifically 
interacts with CD28 which provide co-stimulatory signals for the activation of T- 
cells. Therefore any impairment in the ability of CD86 to interact with CD28 
would influence the mediation of the inflammatory reaction. 
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4.3.3 Tenascin-C 
The results of the Illumina study indicate that Tenascin-C could be a gene which 
has a significant contribution to the pathogenesis of AE. Four SNPs within the 
Tenascin-C gene region were found to be significant. The SNPs rs11793430, 
rs11794797, rs7029844 and rs3748166 had p-values of 0.011,0.016,0.011 and 
0.0097 respectively. Most of the SNPs also remained significant when the 
analysis was combined with other allergic disease phenotypes within this known 
population. This again emphasises the possible role of Tenascin-C within AE, as 
when multiple SNPs within a gene region are significant, the probability that the 
association is real is increased. 
Tenascin-C has been shown to be upregulated in lesional skin of AE patients 
(Ogawa et al., 2005). In normal skin, generally, the expression of Tenascin-C is 
low but during wound healing has been shown to be upregulated (Latijnhouwers 
et al., 1996). Previously the role of cytokines and the stress response has also 
been shown to regulate the expression of Tenascin-C in human epidermal 
keratinocytes (Latijnhouwers et al., 1998). However the role of Tenascin-C in the 
development of AE has not been proven. It is possible that the stress response 
within lesional skin of AE patients may be contributing to the upregulation in 
expression of Tenascin-C, however these results indicate that Tenascin-C is 
involved at an earlier stage. One possible novel causative SNP was identified 
however through PolyPhen analysis, it is not thought to have a detrimental effect 
within the protein. However, it is possible that even mild mutations could be 
having an effect as PolyPhen is only a predictive tool. 
4.3.4 KYNU 
The result of the Illumina study indicates the KYNU could be involved in the 
pathogenesis of AE. One SNP within the KYNU gene showed significance. The 
SNP rs13024113 had a p-value of 0.000067. This is a strong p-value and 
therefore indicates that KYNU could have a significant effect. This tagSNP also 
remained significant when analysed with all other allergic phenotypes. This SNP 
is undergoing further investigation due to its skewing towards heterozygotes and 
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BB homozygotes. No AA homozygotes were observed. However rs2304700 
which was not significant with AE, was significant when tested against asthma, 
hayfever and food allergy. This indicates that KYNU may be having independent 
effects in AE, asthma, hayfever and food allergy. No possible causative SNPs 
were found in the targeted sequencing. 
KYNU, like Tenascin-C, has been found to be upregulated in the lesional skin of 
AE patients (Ito et al., 2004). The tryptophan degradation pathway has also been 
shown to have a role in controlling T cell responsiveness and proliferation 
(Widner et al., 2000) and therefore could have a role in AE through this manner. 
4.3.5 ACVR1 
One SNP in the Illumina study showed significance. The SNP rs6756964 had a p- 
value of 0.011. This SNP also remained significant when analysed with the other 
known allergic diseases. However when corrected for multiple testing it did not 
remain significant. 
ACVR1 is structurally and functionally similar to TGF-ß which is involved in the 
pathogenesis of asthma (Karagiannidis et al., 2006). Mast cells, which have a 
well characterised role in allergy and inflammation, are an abundant source of 
ACVR1. Therefore as ACVR1 is functionally similar to TGF-ß it may well have 
a very similar role in the pathogenesis of allergic diseases. ACVR1 has also been 
shown to induce apoptosis in cells involved in growth and development (Shav-Tal 
and Zipori, 2002), and it has also been shown to promote proliferation in 
fibroblasts (Cho et al., 2003). 
4.3.6 CCR4 
The Illumina study had one significant SNP. The SNP rs2228428 had a p-value 
of 0.022. This SNP also become more significant when tested for association 
with asthma, hayfever and food allergy, which when corrected for multiple testing 
was significant at a gene by gene level. This SNP is actually a synonymous 
coding SNP and could therefore be involved itself in AE. It is possible that this 
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SNP could be having an effect on splicing factors or binding factors within the 
gene. Further study is needed to elucidate if such an effect is occurring. 
It is not unusual that a gene such as CCR4 could be involved in several allergic 
diseases as it is involved in the immune response and is found at sites of allergic 
inflammation (Banwell et al., 2003). 
4.3.7 JAKS 
There are five significant SNPs in JAK3 and three that have borderline 
significance. These SNPs rs722429, rs7409343, rsl1086080, rs10421916, 
rs2286662, rs7255931 and rs2110586 had p-values ranging from 0.00010 to 
0.075. The number of SNPs associated in JAK3 with AE gives a good case for the 
involvement of JAK3 in AE. JAK3 is involved in the IL-2 and IL-4 signalling 
pathway and also seems to play a role in the IgE receptor/mast cell response. As 
mast cells are well known to be part of the immune response in allergy, it is 
therefore proposed that it is through this mechanism that JAK3 is involved in AE. 
Interestingly there is another gene which lies close to JAK3. The SNP rs2286662, 
which downstream of JAK3, lies within exon 1 of INSL3. This SNP is actually a 
non-synonymous coding SNP which changes an Alanine residue to a Threonine 
residue, which in turn is the transition of a non-polar neutral residue to a polar 
neutral residue. It is possible that through the tagSNP picking strategy for JAK3, 
information from INSL3 has inadvertently been captured and that INSL3 is the 
gene with some disease association. Very little is known about INSL3 expression 
within the skin, however it does seem very unlikely that a gene which produces a 
hormone which has been shown to be associated with cryptorchidism (Tomboc et 
al., 2000) would be involved in AE. 
Further investigation into INSL3 was carried out. This involved targeted 
sequencing of the major haplotypes found within INSL3, using the Illumina 
tagSNPs which map around and within INSL3. Interestingly three novel 
mutations were identified. Two were intronic and one was a non-synonymous 
mutation which resulted in an Alanine to Glutamic amino-acid change. When this 
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novel non-synonymous change was analysed using PolyPhen to predict the effect 
on INSL3 protein, it was not predicted to have an effect. However, because 
through the SNP tagging of JAK3 the information from INSL3 was also captured 
it is very difficult to tell if the association signal is from JAK3 or INSL3. The SNP 
with the strongest association (rs722429) actually lies closer to INSL3 than JAK3. 
4.3.8 IL10RA 
Two significant SNPs were found in the Illumina study, the SNPs rs 11216666 and 
rsl 1216667 had a p-value of 0.03 1, however these did not remain significant 
when corrected for multiple testing. The two significant tagSNPs were also found 
to be associated with asthma but not with any other allergic disease within this 
population and these SNPs were not significant when asthma and AE were 
combined. These results would indicate that IL1ORA impairment is independent 
in AE and asthma. This does seem unlikely since generally genes involved in 
atopy have effects within the allergic response of many allergic diseases. ILIORA 
was not chosen for further analysis by sequencing because there was not enough 
evidence to substantiate that these observations are real. 
4.3.9 PTGDS 
The Illumina study results indicate that PTGDS may indeed be associated with AE 
susceptibility in the Bangladeshi family based study. This 5 kb gene contains 11 
exons, however to capture all the variation in this gene only four tagSNPs needed 
to be typed. Of these four tagSNPs, two had a positive association. The SNPs 
rs3814501 and rs4880082 had p-values of 0.025625 and 0.038596 respectively. 
Neither of these SNPs remained significant when corrected for multiple testing 
and also when the Illumina tagSNPs were analysed for association to the other 
allergic diseases within this population. As for IL10RA this gene was not chosen 
for further investigation by sequencing because it was thought that there was not 
enough evidence to substantiate that this association was indeed real. 
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4.4 Summary and conclusions 
This candidate gene study investigating novel genes for AE has provided a 
significant advance in the understanding of the genetic variation within AE. Eight 
of fifteen genes within this study showed association to AE. This is a significant 
amount. In theory if twenty genes had been chosen at least one would have been 
significant by chance. So therefore to have nine out of fifteen showing 
association indicates that many of these associations could be real and it also 
emphasizes the wealth of genes that seem to have an effect in the pathogenesis of 
AE. 
These eight genes have never been associated with AE before. Six out of the 
eight candidates which were found to associated with AE were involved in the 
immune system response, one (ACVR1) is involved in proliferation of fibroblasts, 
and one gene (TNC) which is involved in skin structure and wound healing. The 
variation in the type of genes found to be associated with AE in this Bangladeshi 
family study also emphasizes the variation and involvement of different biological 
systems in AE. It would be interesting to discover if these associations are 
specific to the Bangladeshi population or if they are also found in other Atopic 
populations through a replication study. 
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Chapter 5 
Filaggrin variants in Atopic Eczema 
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5.1 Introduction 
5.1.1 Filaggrin in skin 
Filaggrin (filament aggregating protein - FLG) rapidly aggregates the keratin 
cytoskeleton causing the collapse of the granular cells into flattened anuclear 
squames. Keratohyalin granules in the granular layer of the epidermis contain 
profilaggrin which is a 400 kDa protein which is composed of 10-12 FLG repeats 
(Gan et al., 1990). The profilaggrin is cleaved into singular repeats of the FLG 
peptide which are 37 kDa each. Once the cytoskeleton is condensed by the FLG 
peptides it is crosslinked with transglutaminases forming the cornified envelope. 
The cornified envelope keeps out allergens and infections plus retains water in 
skin (Candi et al., 2005; Smith et al., 2006). 
Filaggrin has long been known to be implicated in the formation of the stratum 
corneum (Dale et al., 1985; Steinert et al., 1981). Early immunoblotting studies 
showed that profilaggrin was absent in Ichthyosis Vulgaris (IV) keratinocyte 
extracts from IV patients when compared with controls (Fleckman et al., 1987; 
Penabad et al., 1998). Through electron microscopy, keratohyalin granules, which 
contain profilaggrin, were found to be absent in several IV patients and markedly 
reduced in several others (Sybert et al., 1985). Additionally mRNA of 
profilaggrin in IV patients was more unstable and had a much shorter half-life 
when compared to controls (Nirunsuksiri et al., 1998). All of these early studies 
have indicated FLG to be involved in IV which is often found associated with 
Atopic Eczema (AE). 
5.1.2 Flaky tail mouse -a model for IV 
In 1958 a spontaneous mutation arose in a mouse cross creating the "flaky tail" 
mouse. It is an autosomal recessive mutation that leads to dry, flaky skin and 
annular tail and paw restrictions in young mice (Lane, 1972; Presland et al., 2000; 
Rothnagel et al., 1994). Generally the phenotype appears at age 2-4 days. 
Lesions begin to clear up by the age of 3-4 weeks and by the age of 6 weeks the 
phenotype is no longer distinguishable from wild-type mice. The flaky tail mouse 
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phenotype was linked to polymorphic markers on the mouse chromosome 3, 
which is where the Epidermal Differentiation Cluster (EDC) lies in the mouse 
genome (Lane, 1972). In humans the EDC maps to chromosome 1g21 (Mischke 
et al., 1996). Immunofluorescence and western blot studies found that 
profilaggrin, which maps within the EDC, is markedly reduced in comparison to 
wild-type controls and shows a similar appearance to that of the early 
immunoblotting studies in humans with IV (Sybert et al., 1985). Recently a 
mutation which is analogous to FLG mutations found in humans has been 
identified in the flaky tail mouse (Fallon et al., 2009). This emphasizes the 
possibility for use of the flaky tail mouse as a model for FLG loss and therefore 
the mechanisms in which FLG is in involved in AE, though there is no 
heterozygous phenotype. 
5.1.3 Filaggrin in ichthyosis vulgaris 
Ichthyosis Vulgaris is a skin disorder causing dry, scaly skin and affects 
approximately 1 in 250 people. This incidence rate was calculated from an 
English school children cohort in 1966 (Wells and Kerr, 1966). More recently a 
study looking at FLG in childhood eczema in an North England population also 
looked at numbers of children with IV and found a prevalence of 1 in 80 (Brown 
et al., 2008). Phenotypically, patients have palmer hyperlinearity (HLP), keratosis 
pilaris (KP) and fine scaling on the lower abdomen, legs and arms (Figure 5.1) 
and symptoms manifest themselves within the first year of life but not at birth. 
Symptoms are more prominent in winter. Skin cells in IV grow at a normal rate, 
however they do not shed as quickly as they should and result in a build up or fine 
scaling on the skin. 
There are varying levels of IV. Severe and obvious IV is distinguished by 
prominent scaling on the skin all over the body, although flexural regions tend to 
be less affected. This scaling is often flaky due to the prolonged shedding cycle 
(Oji and Traupe, 2006). Milder and less obvious IV still shows scaling on the 
skin but it is often much less defined and less obvious to the eye. There is also a 
different form of IV where keratosis pilaris (rough bumps present around follicles 
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on the skin) is present, fine scaling is less obvious and when put together with 
HLP a diagnosis of IV is formed (Figure 5.2). 
Initially mutations in FLG were found to be associated with IV (Smith et al., 
2006) and subsequently the same two mutations were found to be associated with 
AE (section 5.1.4). The pattern of inheritance of IV seems to be semi-dominant 
manner with homozygous and compound heterozygous FLG mutations underlying 
the severe form of IV and heterozygous FLG mutations underlying the milder 
form of IV with variable penetrance. 
I If) 
Figure 5.1 - Scaling in IV and HLP. (1) - Scaling such as this on a lower leg is 
normally seen on the legs, abdomen and arms in IV patients. (2) - Hyper Linear 
Palms can be clearly seen on the palm of this hand. (3) - Magnified image of the 
palm in 2. Lines can be clearly seen. (Clinical pictures courtesy of Prof. E. 
O'Toole). 
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3 
Figure 5.2 - Varying phenotypes of IV. (1) - Obvious IV. Note the scale like 
pattern on the skin and flakiness of the skin. (2) - Less obvious IV. Scaling 
is 
still present but it is not as pronounced as in (1). (3) - Different IV. Keratosis 
pilaris (rough bumps present around follicles) is present and scaling is not 
pronounced. HLP is also present on palms. (Clinical pictures courtesy of Prof. E. 
O'Toole). 
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5.1.4 Filaggrin in atopic eczema 
Loss-of-function mutations in the gene encoding FLG are major pre-disposing 
factors for AE in families with IV and in case-control studies (Palmer et al., 
2006). The population in this initial study was a Northern European, Caucasian 
population. In this population group, there are high incidences of IV and AE, 
often occurring together. Subsequent studies have replicated these findings again 
in Northern European, Caucasian populations (Barker et al., 2006; Brown et al., 
2008; Ekelund et al., 2008; Marenholz et al., 2006; Morar et al., 2007; Rogers et 
al., 2007; Ruether et al., 2006; Sandilands et al., 2006; Sandilands et al., 2007b; 
Stemmler et al., 2006; Weidinger et al., 2006; Weidinger et al., 2007), in Japanese 
populations (Hamada et al., 2007; Nomura et al., 2008; Nomura et al., 2007) and 
also in a Singaporean Chinese population (Chen et al., 2008) (Figure 5.3). These 
studies have given strength to the involvement of FLG in AE. The FLG role in 
AE in other ethnicities has yet to be investigated, so therefore with the strength of 
association already seen it is prudent to investigate this in the Bangladeshi 
population. 
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5.2 Results 
5.2.1 Common mutations in a family based study 
Two mutations in the gene encoding FLG have been reported to be the cause of 
moderate to severe IV (Smith et al., 2006) and as strong predisposing factors for 
Atopic Eczema (Palmer et al., 2006). These two mutations R501X and 2282de14 
both lead to complete loss of processed FLG product and are the common FLG 
mutations in Northern European populations. These mutations were genotyped in 
the Bangladeshi AE families and control population. Restriction sites are created 
by the mutations and so therefore a restriction digest was used, examples of 
restriction gels are found in figures 5.4 and 5.5. Six families out of 80 were found 
to be carrying these two mutations (Tables 5.1 and 5.2) and these individuals were 
then re-examined clinically and it was found that some of the individuals also had 
IV (11 individuals with IV had FLG mutations versus 16 individuals with FLG 
mutations and no IV). Pedigrees of the six families found with these mutations 
are shown in figure (5.6,5.7 and 5.8). 
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186 bp 
131 bp 
105 bp 
Figure 5.4 - Restriction digest of R501X PCR products. R501X creates an 
Mu/I1 restriction site. In a Wildtype individual the NIu11I restriction fragment 
sizes are 186bp, 105bp and 2l bp. A heterozygous individual would have 
fragments 186bp. 131 bp, 105bp, 55bp and 21 bp. An individual that is 
homozygous for the mutation would have fragments 131 bp. 105bp, 55bp and 
21 bp. The 55bp and 21 bp fragments are not seen as they have been run off the gel 
in order to get clear separation of the other fragments. No patients were fiOund 
with homozygous R501 X mutation. Lane I- 100 hp ladder. Lane 2.3 - tail, 
Lane 4-5 - patient samples, homozygous no mutation. Lane 6- patient sample, 
heterozygous for mutation. Lane 7-24 - patient samples, homozygous no 
mutation, Lane 25 - negative control. Lane 26 - 100 
bp ladder. 
200 bp 
100 bp 
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Heterozygous Homozygous 
No mutation 
R501X Genotype frequency Allele 
Frequency 
No of 
Samples 
11 12 22 1 2 
Affected 161 155 6 0 316 6 
Unaffected 149 148 1 0 297 1 
Total 310 303 7 0 613 7 
Chi Squared = 3.27, P=0.07 
Table 5.1 - R501 X genotyping. Family based study genotyped by PCR and 
restriction enzyme analysis, scored by 2 separate individuals. Analysed for 
association using a Chit test. Allele I= wild-type, allele 2= R501 X. No 
association is shown with the R501X mutation in the Bangladeshi families as a p- 
value of 0.07 was calculated from the genotypes. This analysis does not take into 
account the relatedness between some individuals which was used as a first pass 
analysis. If some association had been shown then the same method of analysis 
using FBAT would have been better. 
811 bp 
688 bp 
Figure 5.5 - Restriction digest of 2282de14 products. 2282de14 creates a Dra111 
restriction site. In a wildtype individual the Drauf restriction fragments are the 
same as a normal PCR product, 811 bp. In a heterozygous individual the fragment 
sizes are 811 bp, 668bp and 143bp. An individual that is homozygous (or the 
mutation has restriction fragments of 668bp and 143bp. Lanes 1 and 26 - 100 bp 
ladder (Invitrogen, USA), Lane 2- negative control, Lanes 3,5,7,9 and 24 - 
heterozygous for mutation, Lanes 4,6,8,10-20,23 and 25 - homozygous, no 
mutation, Lane 21 - fail, Lane 22 - homozygous with mutation. 
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Homozygous Homozygous Heterozygous 
No mutation mutation 
2282del4 Genotype frequency Allele frequency 
No of 
Samples 
11 12 22 1 2 
Affected 157 145 8 4 298 16 
Unaffected 133 125 8 0 258 8 
Total 290 270 16 4 556 F 24 
Chi squared = 3.52, P=0.172 
Table 5.2 - 2282de14 genotyping. Family based study genotyped by PCR and 
restriction enzyme analysis, scored by 2 separate individuals. Analysed for 
association using a Chit test. Allele 1= wild-type, allele 2= 2282de14. No 
association is shown with the 2282de14 mutation in the Bangladeshi families as a 
p-value of 0.172 was calculated from the genotypes. This analysis does not take 
into account the relatedness between some individuals which was used as a first 
pass analysis. If some association had been shown then the same method of 
analysis using FBAT would have been better. 
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From these six families there also seems to be a common haplotype on which the 
2282de14 mutations are carried (Table 5.3). 
SNP - Family 
4 4 35 18 45 81 
rs12730241 G G G G G G 
rs3814300 C C C C C C 
rs2065958 A A A A A A 
2767insT wt wt wt wt wt wt 
rs2184953 A A A A A A 
R826X wt wt wt wt wt wt 
2282de14 mutation mutation mutation mutation mutation mutation 
R501X wt wt wt wt wt wt 
rs11582620 A G G G A A 
Table 5.3 - Observed haplotypes carrying the 2282de14 mutation. All five 
families which were found to have the 2282de14 mutation seem to have a 
haplotype in common in four of the tagSNPs. The tagSNP rsl 1582620 shows 
variation which would indicate no LD. 
5.2.2 Analysis of R501X/2282del4 mutations in a case-control population 
A control Bangladeshi population also from the East London area (provided by 
Prof. GA Hitman) was then screened for these two mutations. Screening in a 
control population will give an estimation of the frequency of the mutation in a 
general population. The control population was not clinically examined for the 
presence of AE or IV. A case population of the parents of each family from the 
Bangladeshi AE family study was used to compare with the control population 
results. Using only the parents of each family for analysis gives an un-related 
population and the combined R501X/2282de14 genotyping results are shown in 
table 5.4. 
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Combined 
R501X/2282de14 
Genotype frequency Allele 
frequency 
No of 
Samples 
11 12 22 1 2 
Parents 108 102 6 0 210 6 
Controls 162 153 9 0 315 9 
Total 270 255 15 0 525 15 
uni ýiquarect = u, Y=I 
Table 5.4 - Combined R501X/2282deI4. A case control analysis of the 2 
filaggrin mutations R501X and 2282de14 using a control Bangladeshi population 
and the parents from each family. Allele 1= wild-type, allele 2= R501X or 
2282del4. The p-value calculated indicates that there is no association with FLG 
mutations in this case control population. 
5.2.3 tagSNP association with FLG 
To further investigate if FLG mutations were associated with AE in the 
Bangladeshi population a tagSNP approach was used which has been previously 
described (Chapter 3,3.1.2). Briefly, tagSNPs were picked using three of the four 
HapMap populations, Caucasian, Chinese and Japanese. A MAF of 0.15, r2 of 0.8 
and FLG plus 5 kb upstream and downstream were used. The only difference in 
this case was that the tagSNPs were picked using tagger which is implemented in 
Haploview. Five tagSNPs were picked to try to capture all the information in this 
region. These five SNPS are located within exon 3 of FLG and the 3' 
untranslated region (UTR) (Figure 5.9). These SNPS were then analysed using 
Taqman probes and the data was analysed using a custom MySQL database (Mr. 
Richard Dobson) to quality control the data and then further analysed using 
FBAT. 
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12.6 kb 
EXO T 
2282del4 
Figure 5.9 - Schematic of Filaggrin. The five tagSNPs are shown in black and 
the two mutations R501X and 2282de14, which have been screened in this 
population, are shown in red. The 3'UTR is shown in light blue. 
SNP p-value AE 
rs11582620 0.590 
rs2184953 0.146 
rs2065958 0.848 
rs3814300 0.405 
rs12730241 0.813 
Table 5.5 - Five HapMap tagSNPs investigated for FLG association to AE. 
Results were analysed under both dominant and recessive models and also under 
two different traits, affected status for AE and also their measured IgE levels. P- 
values were generated using FBAT. 
No association was found with AE using this tagSNP approach in the Bangladeshi 
population. This data together with the previous mutation data indicates that FLG 
is perhaps not a strong AE gene in the Bangladeshi population. 
As other atopic phenotype data was also available, this was also analysed as in 
chapters 3 and 4 (see sections 3.1.1 and 4.1.1). No association was observed with 
any of the other atopic phenotypes. 
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SNP,, - Asthma AE+Asthma Hayfever AE+Hayfever FA AE+FA 
rs11582620 0.556 0.279 0.891 0.316 0.893 0.288 
rs2184953 0.611 0.426 0.115 0.053 0.183 0.103 
rs2065958 0.947 0.899 0.720 0.502 0.772 0.757 
rs3814300 0.527 0.739 0.674 1.00 0.121 0.208 
rs12730241 0.652 0.432 0.576 0.322 0.659 0.519 
Table 5.6 - HapMap tagSNPs investigated for FLG association to other 
known atopic phenotypes in the Bangladeshi population. FA - Food Allergy. 
5.2.4 Sequencing of FLG in two families 
Two probands that were found to be heterozygous for the 2282de14 mutation in 
the initial screening of the R501X and 2282de14 mutations (Figure 5.6, Families 4 
and 35), were then sent to Prof. Irwin McLeans laboratory in Dundee for FLG 
mutation screening. These two individuals were chosen for further analysis as 
they were both found to have IV as well as AE and therefore they should be 
compound heterozygous for mutations in FLG. 
Filaggrin screening is very difficult because of the nature of the gene. It consists 
of 10-12 repeats of 384 bp, this means that a special high fidelity PCR kit must be 
used and often sequencing fails. It is very difficult to design primers to amplify 
small pieces of FLG as primers are often specific to more than one repeat within 
FLG and therefore would not be specific enough to use for mutation screening. 
However when the sequence was examined through bioinformatic analysis, at the 
base level, some sequence differences were found within each of the repeats. 
These differences are just a few bases but are enough to be able to design specific 
primers (Sandilands et al., 2007b). Primers have now been designed, by Prof. 
McLeans laboratory, to be specific to these regions of difference and it is possible 
to amplify each repeat and screen for mutations. As these protocols have been 
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optimised in Prof. McLeans laboratory it was sensible to send the samples there 
for analysis. 
Two further mutations, leading to a predicted full loss of FLG, were identified. 
R826X, which leads to a premature stop codon, was found in the proband 
individual in family 4 and 2687insT, a frameshift mutation, was found in the other 
proband individual in family 35 sent for sequencing analysis. These two 
additional mutations were then screened in the parental population by PCR and 
sequencing. A parental population was chosen for screening as this drastically 
reduces the cost of screening and if the mutation is present then it would be found 
in the parental population unless the mutations occurred de novo. After 
genotyping of these two mutations they were not found to be present in any other 
family other than the one it had already been identified in. All members of these 
two families were screened for these two mutations. The pedigrees of these two 
families (4 and 35) are found in figure 5.6 and the sequencing traces of the two 
new mutations compared with controls are shown in figure 5.10. 
Family 35 contains AE affected individuals with the genotypes 
2282de14/2767insT (also affected with IV and HLP), 2282de14/wt and wt/wt and 
also an unaffected individual with the genotype 2282de14/2767insT (also affected 
with IV and HLP). Family 4 contains AE affected individuals with the genotypes 
2282de14/R826X, 2282de14/2282del4 who are also both affected with IV and 
HLP, but also has two unaffected AE individuals with the genotypes 
2282del4/R826X and 2282de14/wt. These 2 families indicated that there is no 
mutation segregation with AE but there does seem to be with IV although with 
reduced penetrance. 
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5.3 Discussion 
5.3.1 Linkage to 1g21 
From the whole genome microsatellite scan performed previous to this study 
(Chapter 1,1.3.8), the marker D1S498, which lies approximately 1 Mb from FLG 
in the epidermal differentiation complex at 1g21, gave a LOD score of 0 which is 
regarded as an inconclusive result, where a LOD >3 is significant linkage and 
LOD S -2 is an excluded region (Lander and Kruglyak, 1995), and therefore 
further investigation was required to elucidate if FLG is involved in AE in the 
Bangladeshi population. 
5.3.2 Association with atopic eczema 
The two probands from families 4 and 35 only had one identified FLG mutation 
and these two samples were sent to Dundee (Prof Irwin McLeans' Laboratory) for 
sequencing, and two further mutations were found, R826X and 2767insT (Figure 
5.10). When all the genetic information for these mutations is placed onto the 
pedigrees it is clear that the FLG mutations do not segregate with AE. The 
pedigrees (Figure 5.6) for families 4 and 35 show quite a mixture of affected AE 
individuals with compound heterozygous mutations, and unaffected individuals 
also with compound heterozygous mutations. The fact that there are AE 
unaffected individuals with homozygous and compound heterozygous mutations 
within families with AE affected individuals with FLG mutations definitely 
indicates that FLG is not significantly associated in this family based Bangladeshi 
population study. 
The 2767insT has been previously detected in another Bangladeshi American 
individual (Irwin McLean unpublished data) and it was thought that this mutation 
could be prevalent in this population. These two mutations were then screened in 
the parental population of our 80 families and were not found in any other 
families. 
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Carrier rates in the Bangladeshi population are very low in comparison to other 
studies. Only 1.87% of AE affected individuals carried one or more R501X 
alleles and only 5.1% of AE affected individuals carried one or more 2282de14 
alleles. This is in stark contrast to other populations' frequency of carriage of one 
or more FLG null alleles. In a Danish population 17.5% of AE individuals carried 
one or more FLG null alleles (Palmer et al., 2006), in another European 
population of 163 AE affected individuals, 42% carried one or more FLG null 
alleles (Barker et al., 2006), in yet another European population 21.3% of AE 
affected individuals were found to carry one or more FLG null alleles (Stemmler 
et al., 2006), in a North of England population a similar result of 18.4% was found 
(Brown et al., 2008) and in a Japanese population 25% of AE population were 
found to carry one or more FLG null alleles (Nomura et al., 2008). In the North 
of England population only 4.2% of 190 AE individuals had 2 null mutations 
(Brown et al., 2008) and therefore only this percentage have AE caused by only 
FLG mutations and 95.8% of cases still have other factors (genetic or 
environmental) yet to be determined. In this population only 3.8% of the AE 
cases can be explained by two null FLG mutations and therefore this leaves 96.2% 
still to be explained by other factors. It is possible that Bangladeshi specific 
mutations may reside within these Bangladeshi families, though there is no 
evidence for high carrier frequencies given the frequencies for the common 
mutations and the two new mutations in this population. 
Five tagSNPs were also screened in this population to try and detect any possible 
association. The five SNPs were not found to be significant. All these different 
tests for association indicate that although there may be rare mutations in the 
Bangladeshi population there is no major genetic association with AE 
susceptibility in the Bangladeshi population. 
This study is the first in an Indian subcontinent population and it has been found 
that there is no evidence for association to AE and the FLG locus in the 
Bangladeshi population. Although there are FLG mutations in this population 
there is no major association with AE but there does appear to be an association 
with IV albeit with variable penetrance. An overview of all FLG mutations found 
to date, including Bangladeshi, can be seen in figure 5.3. 
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A large meta-analysis (Baurecht et al., 2007) has sought to remove much of the 
variability between the studies, such as study design and strength of association, 
and try to give a clearer view of the actual contribution of FLG to AE. The meta- 
analysis used nine studies which met the inclusion criteria. Articles were 
excluded for not providing data on the effect of the genetic variations on AE risk. 
Articles included were (Barker et al., 2006; Marenholz et al., 2006; Morar et al., 
2007; Palmer et al., 2006; Ruether et al., 2006; Sandilands et al., 2006; Sandilands 
et al., 2007b; Stemmler et al., 2006; Weidinger et al., 2006; Weidinger et al., 
2007). There has been much variation in the quoted odds ratio for FLG in AE and 
the meta-analysis recalculated this to give a global odds ratios. For case-control 
studies an odds ratio (OR) of 4.09 was calculated and for family based studies an 
OR of 2.06 was calculated. This means that, with these odds ratios and our 
previous power calculations, which indicated that the power of this Bangladeshi 
family based study would allow major and minor dominant effects and major 
recessive effects to be found, if FLG has a major effect on AE susceptibility this 
would be detected in the Bangladeshi population. 
Candidate gene investigation into AE has mainly concentrated on immune system 
related genes with only three of twenty candidate genes being involved in the skin 
barrier. The investigations into these genes, SPINK5 (Walley et al., 2001), SCCE 
(Vasilopoulos et al., 2003) and now FLG, are now indicating that epithelial 
disruption could be the primary event which leads to full AE. These three genes 
all result in impaired skin barriers through different modes. SCCE mutation leads 
to an impaired stratum corneum integrity and therefore disrupted function. 
SPINK5 mutation results in altered stratum corneum cohesion. FLG mutation 
leads to transepidermal water loss. It is already known that keratinocytes are 
active within the adaptive immune system and that severe barrier disruption alone 
can stimulate keratinocyte proliferation and cytokine production even in the 
absence of immune cell signals (Djalilian et al., 2006; Vickery, 2007). 
It is currently thought that FLG mutations have a recessive mode of inheritance 
with reduced penetrance within mild to moderate AE case (Brown et al., 2008) 
rather than the initial proposed semi-dominant pattern initially reported for 
moderate to severe AE case (Palmer et al., 2006). However this is still very 
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unclear as the pattern of inheritance does not seem to be classical recessive 
inheritance. This is clearly seen in the Bangladeshi population where even 
unaffected individuals can harbour two FLG mutations. There have also been 
suggestions that the high frequency of mutant FLG alleles in the general 
population (-. 10%) could not be explained by normal genetic drift and is 
consistent with heterozygote advantage (Irvine and McLean, 2006). It is possible 
that barrier disruption could be beneficial and aid in so called natural 
immunisation. Perhaps FLG mutants have been selected for, during historical 
pandemics of disease, where sensitisation leads to better survival of heterozygous 
individuals. 
Recently a whole genome association study has been conducted into AE using a 
Northern European population (Esparza-Gordillo et al., 2009). This study sought 
to identify new loci that contribute to AE pathogenesis, however during this 
chromosome 1 q21 was also identified as associated to AE. They then went on to 
genotype four of the known European FLG mutations and also used this to 
identify if the associated SNP was in LD with these mutations in FLG. LD was 
observed between the FLG mutations and the associated SNP which was some 
156 kb away. Removal of the FLG mutations also removed the association. This 
indicates that the association within l q21 was indeed a result of FLG mutations. 
However another set of markers surrounding HRNR (hornerin) gene, 78 kb away 
from FLG, was also showing an association signal, even after exclusion of the 
FLG mutations. This emphasizes that other risk factors may be located within the 
EDC on chromosome 1g21, as had been suggested in previous report (Morar et 
al., 2007). 
5.3.3 Association with ichthyosis vulgaris 
FLG mutations seem to be semi-dominant with variable penetrance, with 
homozygous and compound heterozygous mutations leading to severe IV with or 
without AE and heterozygous mutations leading to milder IV. 
Six Bangladeshi families of the 80 AE families harboured the two common 
European FLG mutations, R501X and 2282de14. These six families were 
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clinically re-assessed specifically looking for signs of IV as IV is actually a 
relatively rare condition in the Bangladeshi population. All four R501X 
heterozygotes from family 13 (Figure 5.7) had no evidence of IV. However, the 
four 2282de14 homozygotes and four of the eleven 2282de14 heterozygotes 
(Figures 5.6,5.7 and 5.8) had clinical evidence of IV presenting as fine scaling on 
the arms and lower legs and hyperlinear palms. There may be more patients with 
IV in this cohort but they were not investigated clinically. 
Heterozygous FLG mutations were found in affected (AE and IV) individuals in 
two families (4 and 35). The DNA from these individuals was used for 
sequencing in order to try and find any other FLG mutations. Two further novel 
FLG mutations were identified, R826X and 2767insT (Figure 5.10). The 
mutation 2767insT has been previously found in an individual of Bangladeshi 
American descent (Prof Irwin McLean, unpublished data). These two mutations 
were then screened in the parental population of the 80 families. This approach 
would have detected the mutation if present in any other family. The two 
mutations were found to be only within the two families, 4 and 35, in which they 
were initially identified (Figure 5.6). The two compound heterozygotes for the 
2282del4/R501X mutations both had clinical signs of IV. One 2282de14/R826X 
compound heterozygote showed signs of IV however the other individual with the 
same genotype within the same family did not. This indicates that there is variable 
disease expression but it is not clear why there is a difference in clinical 
presentation. It is possible that the difference in clinical presentation could be due 
to the fact that IV is often seen as a seasonal disease as it is often more identifiable 
in winter months. The families were re-examined for IV in April and it is possible 
that some of the individuals' symptoms may have improved significantly due to 
the change in weather. 
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5.4 Summary and conclusions 
A cohort of 80 families was investigated for filaggrin mutations in relation to 
Atopic Eczema. Initially the 2 prevalent northern European mutations were 
investigated and no association was found, however six families were identified as 
having FLG mutations. These families were then clinically re-assessed for any 
signs of IV and it was found that the four 2282de14 homozygotes all had signs of 
IV along with six of the fourteen 2282de14 heterozygotes. A tagSNP approach, 
using Taqman probes, was then used to identify any association to the region and 
again no association was found to the FLG locus. Two proband heterozygotes 
DNA was sent to Prof. McLeans laboratory, Dundee, UK, for further analysis and 
sequencing and these individuals were found to have two new novel mutations 
making them compound heterozygotes. The cohort was then investigated for 
these two new mutations and it was found that these mutations were family 
specific. 
The work in this chapter is a significant contribution to the on-going investigation 
into FLGs contribution to AE and IV (Sinclair et al., 2009). Currently there is no 
indication that FLG contributes to AE in the Bangladeshi population, however 
there is an indication that it is involved in IV although with variable penetrance. 
It is still possible that rare variants are found within this population and 
contributing to the pathogenesis of AE. These could again only be found by 
sequencing of a large number of the individuals within this population. Due to the 
complexity of FLG sequencing and investigation this would be a very large and 
difficult task to undertake. 
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Chapter 6 
ABCA12 in Atopic Eczema 
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6.1 Introduction 
6.1.1 ABCA12 
ABCA12 (chr 2q33.3-q36.1) is a member of the Adenosine triphosphate Binding 
Cassette (ABC) superfamily which are active membrane-bound transporters of a 
range of substrates across intra-cellular and extra-cellular membranes. There are 
seven subfamilies of ABC transporters and 48 different ABC genes in total, 
although a number of pseudogenes have been located in the genome (Dean et al., 
2001). They can transport lipids, proteins, saccharides and/or metal ions. The 
ABCA12 (ABC superfamily A gene 12) gene consists of 53 exons and there are 2 
known expressed isoforms (Lefevre et al., 2003). ABCA12 is implicated in 
epidermal lipid transport. Recessive mutations in ABCA12 lead to the severe skin 
disease Harlequin Ichthyosis (HI) (Akiyama et al., 2005; Kelsell et al., 2005). 
HI is a recessive disease in which the barrier function of the skin is severely 
disrupted. ABCA12 is also implicated in 2 other less severe barrier function 
diseases, Lamellar Ichthyosis type 2 (L12) (Lefevre et al., 2003) and Non-Bullous 
Congenital Ichthyosiform Erythoroderma (NBCIE) (Natsuga et al., 2007). The 
variation in severity of each of these diseases indicates that ABCA12 mutations 
can have wide ranging effects and so minor amino acid changes in ABCA12 could 
have a less dramatic effect on the skin barrier and be involved in AE. Other genes 
involved in both monogenic skin barrier disease and with AE, such as FLG 
(Palmer et al., 2006; Smith et al., 2006) and SP1NK5 (Chavanas et al., 2000; Kato 
et al., 2003; Moffatt, 2004), have been described. 
There are three reasons ABCA12 was investigated for a role in AE: - 
1) A compromised skin barrier is a feature of AE (Proksch et al., 2006) 
2) The whole genome microsatellite scan gave a LOD = 2.15 (Non-parametric 
analysis) at marker D2S364 which is located at 2g31.3-g32.1. Although this 
marker is located approximately 32 Mb away from ABCA12, it is possible for a 
causative gene to be some distance away from a linkage peak due to the distance 
between markers in a whole genome microsatellite scan and the informativeness 
of these markers is specific families or populations. For example, in the initial 
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mapping of the BRCA1 locus the informative marker was some 30 cM away from 
the gene (Hall et al., 1992). 
3) Genes with roles in monogenic skin barrier disorders have been found to be 
associated with AE, for example SPINK5 is the causative gene in Nethertons 
syndrome and has been associated with AE in multiple studies in different 
ethnicities, FLG is associated with Ichthyosis Vulgaris (IV) as well AE. 
6.1.2 ABCA12 associated diseases 
HI is a severe, often lethal, autosomal recessive skin disorder. It is typified by 
hard, thick skin covering the body. The skin forms large diamond shaped plaques 
separated by deep fissures that restrict movement. These skin abnormalities also 
affect the eyes, lips, hands and feet. The impaired barrier also means the infants 
struggle to regulate water loss, temperature and also fight off infections. HI has 
been reported in both sexes and in various ethnic groups. Mutations have been 
found in almost all HI patients (Akiyama et al., 2005; Kelsell et al., 2005; Thomas 
et al., 2006; Thomas et al., 2007). The mutations are mostly frameshift, nonsense 
or result in single or multiple whole exon deletions. 
Lamellar Ichthyosis type 2 (L12) belongs to a subgroup of the non-syndromic 
autosomal recessive congenital ichthyoses (Lefevre et al., 2003). The disease has 
been found only in North African population and is known to be very rare as very 
few patients have been identified since the locus was first identified in 1998 
(Lefevre et al., 2003). Patients are generally born with a tight shiny covering 
which during the first few weeks of life is replaced with large, dark or plate like 
scales (Oji and Traupe, 2006). LI type 2 has been associated with missense 
mutations located in exons 28 to 32 in the ABCA12 gene (Lefevre et al., 2003). 
Non-Bullous Congenital Ichthyosiform Erythoroderma (NBCIE) is also an 
autosomal recessive skin disorder which is characterised by erythroderma and fine 
white superficial scales. Heterozygous non-synonymous changes were found in 
two patients with NBCIE and these bases also seemed to be conserved across 
several species (Natsuga et al., 2007). The conservation through species could 
indicate that the specific residues mutated are essential for normal function. 
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Figure 6.1 - ABCA12 associated skin disease. (1) - Harlequin Ichthyosis on 
birth. Hard, thick skin covering the body which restricts movement. Large 
diamond shaped plaques separated by deep fissures can be seen all over the body. 
The skin abnormalities also affect the eyes, mouth and fingers and toes. (2) - An 
older HI sufferer where the phenotype has begun to resemble NBCIE. (3) - An 
NBCIE sufferer. Similar to the phenotype shown in B, however NBCIE has 
erythroderma. (Clinical pictures courtesy of Prof. E. O'Toole). 
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6.2 Results 
6.2.1 ABCA12 microsatellite genotyping 
Five microsatellites flanking both the 5' and 3' ends of ABCA12 were selected. 
These markers were chosen as they flanked ABCA12. The position of these 
markers is shown in figure 6.2. These markers were selected on the basis of their 
location in relation to ABCA12 and they were not initially studied in the whole 
genome microsatellite scan. The markers are approximately 25 Mb away from the 
marker with LOD = 2.15 (D2S364) and span a 14 Mb region. 
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Figure 6.2 - Location of ABCA12 microsatellite markers in relation to 
linkage peak of IgE with marker D2S364. Parametric analysis of chromosome 
2 in the whole genome microsatellite scan gave this overview of linkage in 
relation to IgE. The location of ABCA12 is marked on the chromosome with this 
area expanded out to show the specific location of the markers tested in this study. 
DZS126 
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Using both dominant and recessive models in the FBAT program, association 
with AE was computed. Data was initially quality controlled using a custom 
MySQL database, created by Richard Dobson and Timothy Nugent, where 
scoring and mendelian inconsistencies are highlighted and resolved. The results 
are shown in table 6.1. 
Marker ChiSq P ChiSq P 
Dominant model Recessive model 
D2S1345 1.653 0.79 2.422 0.79 
D2S126 1.300 0.93 5.933 0.43 
D2S128 5.866 0.44 4.854 0.43 
D2S325 6.351 0.096 8.322 0.22 
D2S2382 13.667 0.034 8.142 0.23 
Table 6.1 - FBAT Chi Squared test identifying a significant marker with AE 
under a dominant model. Results of the FBAT analysis on the microsatellite 
markers. ChiSq - Chi squared value. P- p-value. Analysis was done using both 
dominant and recessive models. 
The marker D2S2382 is statistically significant at P<0.05 level in the dominant 
model. This marker (Figure 6.2) is the marker closest to the 3' end of ABCA12, 
approximately 1 Mb away. An example of the microsatellite profile for D2S2382 
can be seen in figure 6.3. This preliminary analysis supported ABC'A12 as a 
candidate gene for AE and was investigated further in the Illumina candidate gene 
study. 
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Figure 6.3 - D2S2382 microsatellite profiles. Several different profiles 
for 
D2S2382 were observed. In the top panel there is a heterozygote (alleles 
308/318), the next panel shows a 308/308 homozygote. The 3"h panel shows a 
318/318 homozygote. The 4`h panel shows a 318/334 heterozygote and finally a 
314/334 heterozygote can be seen in the bottom panel. These show the variation 
within this microsatellite. 
6.2.2 ABCA12 in the Illumina candidate gene study 
ABCA12 has two significant SNPs, out of 37 analysed, at p<0.05 (Table 6.2). 
SNP selection for the Illumina study is discussed in Chapter 3, section 3.1.2. 
Figure 6.4 shows the negative log of the p-value for the whole gene which shows 
these two SNPs as peaks above the red p-value cut-offs. Figure 6.5 shows the LD 
(r`) map of the gene. rs4571054 was found to be very significant and remained 
significant when corrected for multiple testing (Chapter 3,3.1.4) at a global level 
(P = 1.329x 10-4), novel gene level (P = 1.88x 104) and on a gene by gene basis (P 
= 0.0013). 
For completeness of study there were five additional tagSNPs which were 
analysed by Taqman. It was not possible to place these SNPs on the Goldengate 
assay because they were within 60 bp of other SNPs on the assay or they had very 
low design scores and so indicating that they would have been likely to fail in the 
assay. The five SNPs rs12472691, rs12998290, rs7576757, rs956133 and 
rs7579031 were analysed and none reached any level of significance. 
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Phenotypic information for other allergic diseases, such as asthma, hayfever and 
food allergies, was also available for this specific population. Therefore, as in 
chapters 3 and 4, ABCA12 was analysed for association to these other allergic 
diseases. This analysis also allowed combinations of allergic disease to be 
analysed such as AE with asthma, AE with hayfever and AE with food allergy. 
Full p-value tables for each gene can be found in appendix C. 
rs4571054 remained significant in all analysis even when corrected for multiple 
testing under all three methods. rs6737076 was also significant under all other 
analysis except for with Hayfever and AE. However this did not remain 
significant when corrected for multiple testing. 
ABCA12 SNPs - 
Chromosome 2 
Chromosomal 
position' 
Location p-value -`, 
rs4571054 215748628 Intron 1.9429x10" 
rs6737076 215618682 5' near gene 0.017 
Table 6.2 - ABCA12 significant tagSNPs. tagSNPs placed on the Illumina 
goldengate genotyping assay which were significant after the first pass analysis at 
P=0.05. Analysed using FBAT which generated the p-values. Data was quality 
controlled with a custom MySQL database looking for mendelian errors and call 
errors. 
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Figure 6.4 - ABCA12 significance showing the two tagSNPs which were 
significant in the study. -log of the p-value using the data from the Illumina 
goldengate assay for the 37 tagSNPs. Significance threshold of -log (p) 1.30 
which equals p=0.05 is marked with a red line across the graph to visually show 
the significance cut-offs using the three differing multiple testing correction 
methods, along with significance thresholds of 2.88 (p = 0.0013, threshold on a 
gene basis) 3.72 (p = 0.00019, Novel gene threshold) and 3.87 (p = 0.00013, All 
gene threshold). ABCA12 is superimposed onto the graph to show the location of 
the peaks over the actual gene. Exons are indicated by red vertical lines and 
introns by red horizontal lines. 
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looks to have three blocks of LD, suggesting points of recombination with areas 
of high genetic variation. Linkage disequilibrium maps were generated using 
Haploview and the data generated from the Illumina goldengate assay to produce 
Bangladeshi specific LD maps. r2 is a measure of linkage disequilibrium. The 
distance from SNP 1 and SNP 37 is 210 kb. Probable blocks of LD are marked 
inside red triangles. 
6.2.2.1 rs4571054 investigation 
One particular SNP in the ABCA12 gene, rs4571054, gave a p-value of 
1.9429x10-9 and was subsequently linked to abnormal clustering of the genotypes 
of this particular SNP in the Illumina bead studio (Figure 6.6). A normal cluster 
is shown in figure 6.7. A clustering of five would indicate a possible mis-calling 
problem. Plate specific clustering was ruled out as there was good mixture of all 
four plates in each cluster or it is possible that there is another SNP underneath 
one of the primers and this would affect the clustering. If the latter is occurring it 
would indicate that the clusters could be as follows, where x indicates another 
SNP :- 
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Figure 6.5 - LD (r2) map of ABCA12. ABCA12 in the Bangladeshi population 
Cluster at 0 norm theta = AA 
Cluster at 0.3 norm theta = AXB 
Cluster at 0.5 norm theta = AB 
Cluster at 0.7 norm theta = ABX 
Cluster at I norm theta = BB 
In order to confirm this clustering, five samples from each of the clusters were 
sequenced. The five samples picked are shown in figure 6.8. These samples were 
then sequenced and analysed by Anna Thomas (a PhD student working on cellular 
and genetic aspects of ABCA12) and myself to confirm the actual genotypes. 
When sequenced the five clusters were analysed using the PhredPhrap software. 
It was then found that three of the clusters were in fact homozygous. This is 
shown in figure 6.9. 
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Figure 6.6 - rs4571054 Beadstudio Clustering. Unusual clustering of this SNP, 
with five clusters instead of three. The current clustering would indicate that the 
group at 0 norm theta are AA homozygotes, clusters at 0.3,0.5 and 0.7 norm theta 
are AB heterozygotes and the cluster at norm theta 1 is BB homozygote. 
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Figure 6.7 - An example of normal Beadstudio clustering (SNP rs4519912). 
Normal clustering in the Illumina Beadstudio package. Three clusters are present. 
Homozygotes AA are clustered at 0 norm theta, heterozygotes AB are clustered 
approximately at 0.5 norm theta and homozygotes BB are clustered at I norm 
theta. 
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Figure 6.8 -5 samples from each cluster picked (SNP rs4571054). five 
samples were picked from each cluster for sequencing to confirm the initial 
clustering in Beadstudio. Samples picked are in yellow. Cluster 1 is on the far 
left hand side and runs from left to right and ending with cluster 5 on the far right 
hand side. 
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Figure 6.9 - Sequencing for confirmation of rs4571054 clustering. rs44 36957 
was found to lie underneath a primer but is in complete LD with rs4571054. (1) 
An individual in cluster I (theta 0). rs4571054 is shown highlighted in red on the 
right hand side of the trace and is homozygous A. (2) An individual in cluster 2 
(theta 0.3). rs4571054 is shown highlighted in blue on the right hand side of the 
trace and is homozygous A. (3) An individual in cluster 3 (theta 0.5). rs4571054 
is shown highlighted in blue on the right hand side of the trace and is homozygous 
A. (4) An individual in cluster 4 (theta 0.7). rs4571054 is shown highlighted in 
pink on the right hand side of the trace and is heterozygous A/G. (5) An 
individual in cluster 5 (theta 1). rs4571054 is shown highlighted in blue on the 
left hand side of the trace and is homozygous G. 
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rs4436957 7s4571054 
Genotypes were reassigned after the sequencing analysis and the likely clustering 
is as in figure 6.10. This gives a p-value of 0.878 and is therefore not significant. 
Another SNP was found when the fragment was sequenced. This was 17 bases 
upstream of rs4571054 and upon further analysis this was indeed found to lie 
underneath the primer used within the Illumina goldengate assay for analysis of 
rs4571054. However this SNP was found to be in complete LD with rs4571054 
and so therefore would not have accounted for the clustering variation seen within 
rs4571054. 
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Figure 6.10 - Predicted clustering of rs4571054 after sequence analysis of 
selected samples. Clusters 1,2 and 3 were found to be Homozygous AA. 
Cluster 4 was the real AB heterozygotes and cluster 5 remained homozygous BB. 
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6.2.3 ABCA12 mutations in harlequin ichthyosis 
12 new Harlequin Ichthyosis families were investigated by Anna Thomas, Nadiya 
Mahmud (a technician within the Genome Centre, QMUL) and myself for 
ABCA12 mutations. This involved PCR amplification of all 53 exons, including 
intronic boundaries. These PCRs were then sequenced and analysed using 
PhredPhrap software. Where patient DNA was not available, parent samples were 
analysed, as in the case of parents 9 and 10. Analysis of the parental DNA 
focussed on the identification of heterozygous mutations as the parents were both 
unaffected with HI. 
Mutation analysis revealed three new small deletions, a novel insertion, three 
novel premature stop codon nonsense mutations, three novel splice site mutations 
along with the recurrent 7322delC Pakistani mutation (Table 6.3). 
The ethnicity of patients, both in the 12 new families and also previously 
published work (Kelsell et al., 2005; Thomas et al., 2006; Thomas et al., 2007) 
was examined by Anna Thomas and myself. Mutations were found in several of 
the families with the same ethnicity. Therefore it was possible to construct 
putative founder mutations (Table 6.4). 
Mutation 7322delC has only ever been found in patients of Pakistani origin. The 
mutation is predicted to cause a frameshift and is therefore likely to produce a 
non-functional protein. Of the ten patients analysed of Pakistani origin, 80% 
carried this mutation. Further analysis was carried out using a microsatellite 
haplotype analysis, performed by Anna Thomas and analysed by myself, using the 
markers D2S128, D2S1345 and D2S2382 which were previously used in the 
ABCA12 and AE study (section 6.2.1). DNA was only available from three 
individuals of the 10 patients of Pakistani/Indian origin and this showed that two 
unrelated individuals were identical for these markers and the third individual 
only shared marker D2S2382 (Table 6.5). These results support a possible 
founder mutation in this population. Additionally one further Pakistani mutation 
was found, W 1294X. The two individuals harbouring this mutation inherited it in 
the homozygous form as a result of consanguinity. 
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Two apparently unrelated Caucasian patients from the UK were found to be 
heterozygous for the 2025de1G located in exon 16. This mutation is also 
predicated to cause a frameshift which would again likely result in a non- 
functional protein. Also, two unrelated Navajo American patients were found to 
harbour the W1744X mutation in exon 34. This mutation changes a tryptophan 
residue to a premature stop codon and is predicted to produce a truncated protein. 
A possible founder mutation may have been identified in the two analysed Balkan 
families. The first patient, from Scandinavia but is in actual fact of Bosnian 
descent, was a compound heterozygote with both the Y1090X (exon 23) and 
R1225X (exon 25). The second unrelated patient was from Albania and was 
homozygous for the Y1090X mutation. This mutation results in a tyrosine to a 
premature stop codon change and is predicted to produce a truncated protein. 
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Patient Mutation type Ethnicity Exon 
1 Frameshift Canadian Caucasian 2 
107insT 
2 Splice site Unknown 26 
c. 3829+1 -+a 
3 Frameshift Syrian 33 
Heterozygous 
5125_5128de1GATG 
Unknown second mutation 
4 Frameshift French 29 
4262de1G 
5 Frameshift Swiss 44 
6443 6445de1CAC 
6 Splice site Eritrean/Jamaican 37 
Heterozygous 
Unknown second mutation 
7 Nonsense substitution Middle Eastern/Arab 15 
W601X 
8 Nonsense substitution Bosnian 25 
Compound heterozygote 23 
R1225X Y1090X 
Parents 9 and Nonsense substitutions British Pakistani 49 
10 7322de1C 
11 Nonsense substitution Albanian 23 
Y1090X 
12 Frameshift British Pakistani 49 
7322de1C 
13 Splice site Irish/Polish mother, After exon 
c. 5381+3delAA Italian/German father 34 
Table 6.3 - New Harlequin Ichthyosis mutations. 12 new HI families were 
analysed for HI mutations within ABCA12. Mutation type, exon location and 
ethnicity (where known) are all listed. Adapted from (Thomas et al., 2007). 
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Ethnicity Mutation % N 
Pakistani 7322de1C 80 10 
exon 49 
Pakistani W 1294X 20 10 
exon 27 
White skinned UK 2025de1G 100 2 
exon 16 
Navajo American W 1744X 100 2 
exon 34 
Balkan y 1090X 100 2 
exon 23 
Table 6.4 - Ethnic specific mutations. Ethnicity and mutations are indicated. 
% 
is from the total number of ethnic specific patients and N is the total number of 
patients within the specific ethnicity. 
Individual 
Marker 
13132 BC BB 
D2S128 152 152 152 152 154 154 
D2S1345 171 171 171 171 177 177 
D2S2382 308 308 308 308 308 ß(1K 
Table 6.5 - ABCA12 microsatellites in HI affected individuals of Pakistani 
ethnicity homozygous for the 7322de1C mutation. Unrelated individuals BB2 
and BC are homozygous and identical for all three ABCA12 markers and BB 
shares the third marker alleles, these are all marked red. The positioning of these 
markers in relation to ABCA12 can be seen in figure 6.2. 
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6.3 Discussion 
ABCA12 has a significant role in the epidermal skin barrier. It is associated with 
three recessive ichthyotic diseases, HI, L12, and NBCIE. The hypothesis was that 
much milder amino acid substitutions could slightly impair the skin barrier and 
therefore ABCA12 could be contributing to the etiology of Atopic Eczema. 
The microsatellite analysis of ABCA12 showed that there is some degree of 
linkage with AE. A p-value for the microsatellite marker D2S2382 of 0.034, 
using a dominant model, indicates a possible linkage. This microsatellite lies 
closest to ABCA12, approximately 1 Mb away, at the 3' end. This potential 
linkage led to the placement of ABCA12 as a candidate gene on the Illumina 
goldengate assay and allowed further analysis into ABCA12 and its role in AE. 
The initial results of the Illumina goldengate assay for ABCA12 supported 
association with AE. The SNP rs4571054 had an extremely low p-value and 
made it look like ABCA12 was indeed a very significant gene in AE. However, 
further investigation into this SNP showed that this p-value was not real and there 
was some variation in the clustering of the genotypes. This clustering was 
initially thought to be an artefact of the assay with potentially another SNP lying 
underneath the primer. This was true however the SNP lying underneath the 
primer was in complete linkage disequilibrium (LD) with rs4571054 and therefore 
would not have caused the initial clustering. It was then thought that there could 
be some plate specific variation, due to the Illumina platform only having the 
capability to do 96 samples at once and 4 plates were needed to be able to 
complete our population. This however was not the case as the plate samples 
were mixed into each cluster. It does as yet remain unconfirmed as to why the 
clustering of this sample was so wrong. It indicates that other SNPs with very low 
p-values could be false positives and caution is required. Further investigation 
into SNPs with very low p-values should be undertaken when there is any 
variation in the clustering of groups. The strategy adopted in this study allowed 
the variation to be excluded and the real p-value ascertained. 
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There is still one SNP in ABCA12 which is significant, rs6737076 with a p-value 
of 0.017112 at the initial p: 5 0.05, however this does not remain significant when 
corrected for multiple testing. This SNP is located at the 5' end of the ABCA12 
gene. Further investigation into the role of ABCA12 in AE or causal variants in 
ABCA12 could be carried out by resequencing, using a larger cohort of 
Bangladeshi AE patients and also using a different ethnic population of AE 
samples. 
ABCA12 was a very plausible candidate gene due to its involvement in the skin 
barrier and also in its association to three diseases which all have very different 
types of mutations all leading to skin barrier disruption. There are other genes 
that have been associated to multiple diseases as well as AE, such as FLG and its 
association to AE and IV. FLG is also a barrier function gene and aggregates the 
keratin cytoskeleton causing collapse of the granular cells. Therefore the 
association of other barrier function genes in AE indicates that barrier function 
genes also need to be investigated for their contribution to AE. 
Several other candidate genes for this region have been investigated, the results of 
which can be found in chapter 4. ACVR1, FAP and WASIP all lie within the 
linkage peak. KYNU and NRAMPJ also lie just outside the linkage peak. From 
these five genes, two show association to AE, ACVRI and KYNU. KYNU contains 
one linkage signal which remains significant when corrected for multiple testing 
at the all gene level, and would indicate that it has a significant effect in the 
pathogenesis of AE. However no causative mutations have been identified. 
In parallel, further investigation into ABCA12 mutations in HI patients was carried 
out and mutations were identified in all 12 cases. This further strengthens the case 
that ABCA12 is indeed the major Harlequin Ichthyosis gene (Thomas et al., 2007). 
These extra patients have also helped to construct putative founder mutations in 
several populations. The 7322delC mutation is found in 80% of HI individuals 
with Pakistani heritage while the W 1294X is found in the other 20%. In the 
Balkan populations, Y1090X has been found in 100% of cases. W1744X has 
been found in 100% of Navajo American patients and 2025de1G has been found in 
100% of Caucasian UK patients. This analysis into ethnic specific mutations will 
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allow clinicians to target the area of the gene where this lies and allow faster 
diagnosis for the patients. This could also mean a way for fast prenatal diagnosis. 
A so-called two tier screening strategy could be adopted. Stage 1- Screen for 
known ethnic mutations and Stage 2- screen whole gene if no mutations found in 
stage 1. 
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6.4 Summary and conclusions 
This investigation into ABCA12 has provided an insight into a possible candidate 
gene for AE, whilst also increasing the breadth of knowledge of ABCA12 
mutations in Harlequin Ichthyosis. Although ABCA12 does not seem to have a 
strong association to AE, there is still an association there which should be 
investigated. An artefact within the Illumina genotyping removed the most 
significantly associated SNP. Due to the involvement of ABCA12 with several 
other barrier function diseases it is worthwhile to follow up this association. 
A novel method of identifying probable exons containing mutations for targeted 
sequencing within Harlequin Ichthyosis patients was developed alongside Anna 
Thomas, using the current known patients ethnicites. This also allowed the 
development of putative founder mutations within several different ethnicites. 
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Chapter 7 
Discussion and future work 
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7.1 P-value correction 
It is very important when conducting large scale genetic experiments to correct for 
multiple testing (Rice et al., 2008). The Illumina candidate gene association 
study, chapters 3 and 4, is one such experiment where correction is required. As 
this is a targeted candidate gene association study and not a general genome wide 
association study (GWAS) there are three options to correct p-values with. 
Option one is where p-values are corrected by the total number of SNPs in the full 
study. This is a very conservative method and it is possible that some true 
associations with weak p-values could be masked. Under this method there are 
really only two SNPs within the full study which remain significant. These are 
within the novel genes KYNU and JAK3/INSL3. 
Option two is to correct p-values by the total number of SNPs tested in the 
previously associated genes or the total number of SNPs tested in the novel genes. 
This is an interesting technique as the probability, according to Bayes theorem, 
that previously associated SNPs are associated is greater than the probability that 
the novel SNPs are associated. Using this method only the genes previously 
identified (KYNU and JAK3/INSL3) using option one remain significant. 
Option three allows correction for multiple testing on a gene by gene level. This 
means that the total number of SNPs tested in each gene is used to calculate the p- 
value cut-off specific to that gene. This is quite likely to be too little correction. 
However, because the genes were identified separately and the tagSNPs chosen 
specifically for each gene separately is it possible to say that these are indeed 
multiple tests? Using this technique, not including the two genes already 
identified using the other two correction methods, three more genes are found to 
have significant results after correction, IL4RA, ST2 and TIM3. 
It is becoming clear that the most stringent methods for multiple testing p-value 
correction are the most appropriate. It is possible that weak p-values are being 
masked, however this is far outweighed by the false positive results that the 
correction is seeking to remove. 
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7.2 Genetic technology 
With the start of the Human Genome Project (HGP) in 1990 a new era in genetic 
information and technology began (Palca, 1986; Sinsheimer, 1989). The aim of 
this mammoth project was to sequence and map the full human genome, which is 
more than 3 billion base pairs in length, and identify all the genes within the 
genome. A working draft of the genome was published in 2000 and a complete 
version was published in 2003 which was two years earlier than planned (Collins 
et al., 2003a; Collins et al., 2003b; Consortium, 2001a; Consortium, 2001b; 
Venter et al., 2001). However approximately 8% remains unsequenced due to its 
heterochromeric nature (such as in centromeres and telomeres) and further work is 
continuing to unravel these areas. The benefits of such a project are wide ranging. 
The advances in medicine and biotechnology are already beginning to be known 
and this can only continue as time and knowledge are gained from other projects 
as well as the HGP. The sequence of one individual has now also been published 
(Levy et al., 2007) and many more are on the way with the advent of the 1000 
genome project in January 2008 which aims to sequence 100 different genomes in 
full. This publication is an indication of the influence that the HGP will have. In 
the future, with the advent of more efficient and cheaper technology, it is possible 
that every person will have their genome sequenced, the $1000 genome. 
After the HGP, another project was also started, the International HapMap project 
(Consortium, 2003). This project aimed to develop a haplotype map of the human 
genome which will describe the common patterns of human genetic variation. A 
haplotype is a series of consecutive alleles on a particular chromosome. 
Haplotypes are broken down every generation by recombination. Recombination 
occurs at specific regions creating recombination hotspots and coldspots, which 
are also known as haplotype blocks. Knowing a haplotype block allows 
researchers to be able to infer unknown alleles without genotyping of all the 
SNPs, this keeps costs down. Experimental array technology has taken advantage 
of this knowledge. SNP chips are now commercially available where over 1 
million known SNPs across the genome can be typed in one pass. This project 
started in October 2002 and was to be done in 2 phases. Phase I involved one 
common SNP every 5,000 bases being typed and this resulted in over one million 
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polymorphic SNPs being typed. Phase II involves two million SNPs being typed 
by Perlegen and 500,000 SNPs being typed by Affymetrix. Phase II has been 
completed (Consortium, 2007) and phase III is underway. The three phases aim 
to increase the density of the HapMap at specific stages. The HapMap consortium 
initially had to complete a large resequencing project in order to find enough 
variants to type. At the beginning of the HapMap only three million mutations 
were known and within databases and only 10% of these were known to be 
polymorphic where the minor allele frequency is over 1%. By the end of 2006 
more than ten million mutations were in public databases and over 40% of these 
were known to be polymorphic. After phase II of the project was completed it 
was estimated that 25-30% of the known common polymorphic SNPs in the 
human genome had been typed. This demonstrates that there is still plenty of 
scope for expansion of the HapMap in phase III. 
The HapMap has also increased the knowledge available about linkage 
disequilibrium (LD). LD is a useful measurement in human genetics because it 
provides information about the evolutionary background of populations and non- 
random association of alleles. LD in a genomic region gives information on 
natural selection, gene conversion, mutations and other forces that can affect 
gene-frequency evolution (Reich et al., 2001; Slatkin, 2008). LD blocks are 
known to vary between populations often with African and Asian populations 
having significantly shorter LD blocks than European populations. Generally LD 
blocks are created by recombination (Coop and Przeworski, 2007), but LD can 
also be influenced by population changes in size (Chapman and Thompson, 
2001). 
DNA sequencing was first described by chemical cleavage (Maxam and Gilbert, 
1977) or dideoxynucleotides (Sanger et al., 1977) with the Sanger method bing 
the method of choice. Since then it has become absolutely essential in the 
progress of genetic understanding, it has become faster, cheaper and more robust 
and therefore in order to get to the next level of knowledge within genetics the 
development of new technology is necessary. This has happened very recently in 
the form of `next generation sequencing' (Methods, 2008). These sequencers are 
capable of millions of reads in one run and can produce up to one billion base 
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pairs in a ten hour run. There are three main companies leading the way in this, 
Roche's 454 sequencing system (Margulies et al., 2005), Illumina's genome 
analyser (Bentley, 2006) and Applied Biosystems SOLID sequencer (Mardis, 
2008; Morozova and Marra, 2008). All three use slightly different methods, have 
wide varying costs and massively different run times. Roches 454 sequencer 
works via a pyrosequencing technique, where the pyrophosphate molecule 
released on nucleotide incorporation by DNA polymerase fuels a set of 
downstream reactions (Margulies et al., 2005). The Roche system can produce 
around 100 Mb of sequence per run in seven hours. However the cost per Mb of 
sequence is around $85. Illumina's genome analyser works using sequence by 
synthesis, in that sequences of 32-40 bp are produced from millions of surface 
amplified DNA fragments. Illumina's sequencer can produce around 1300 Mb of 
sequence per run' which takes -4 days (Mardis, 2008). The cost per Mb of 
sequence is -$5.50 which is much cheaper than the Roche system. Applied 
Biosystems SOLID (Sequencing by Oligo Ligation and Detection) sequencing 
system uses oligo adapter linked DNA fragments with magnetic beads that have 
complimentary oligos attached and amplifies each bead-DNA complex (Mardis, 
2008). Applied Biosystems SOLID sequencer can produce -3000 Mb of 
sequence per run which takes -5 days. The cost per Mb of sequence is similar to 
Illumina's genome analyser. Next generation sequencing has many applications 
including mutation discovery, non-coding RNA discovery (Mardis, 2008), 
transcriptome sequencing and epigenetic profiling (Morozova and Marra, 2008). 
The applications are almost limitless and will provide the next great discoveries 
within the genetics field. 
7.3 Genome wide association 
Both the HGP and the HapMap project have allowed the acceleration of genetic 
technology. It is now possible to conduct a Genome Wide Association Study 
(GWAS) instead of focussing on candidate genes or linkage studies. GWAS 
involves genotyping markers across the complete genomes of many people to 
detect genetic variation associated with specific diseases. To carry out GWAS 
each individuals DNA is scanned on automated laboratory array based systems 
(such as Illumina or Affymetrix machines) and these machines identify the 
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selected SNPs. If SNPs are found to be more frequent in people with the disease 
than without the disease the variations are said to be associated with the disease. 
These associated SNPs are then useful to direct to the specific area of the genome 
that is associated with the disease. However the SNP that is associated is not 
always the disease causing variant (Morton and Gu, 2008). The HapMap allows 
picking of SNPs that tag many other SNPs in the particular haplotype block and 
therefore additional analysis is often needed to identify the exact disease causing 
variant (Consortium, 2003). 
As of the 14`x' of May 2009, there have been 317 GWAS publications. These 
publications have identified more than 1400 SNPs as being associated with 
specific diseases or groups of diseases. The first small scale GWAS was 
published in 2005 and was investigating the disease age related macular 
degeneration (Klein et al., 2005) and identified a SNP in the complement factor H 
gene. This association has since been replicated and found to be true (Hageman et 
al., 2005). The first major GWAS study which initially included 1,380 cases and 
1,323 controls and was replicated in 2,617 cases and 2,894 controls was published 
in 2007. This study investigated type 2 diabetes (Sladek et al., 2007). Three 
SNPs in three different genes were identified as being associated. These included 
two transcription factors and a zinc transporter related to insulin. Seventeen 
GWAS type 2 diabetes have now been conducted and from this the original three 
findings have been well replicated in at least five studies each. However another 
eight genes have also been well replicated and another thirteen have been 
identified in single studies. When common diseases such as type 2 diabetes are 
studied in this manner it emphasizes just how complex the disease is and weeding 
out the true results is very difficult. The massive numbers of SNPs investigated in 
GWAS studies (usually over 300,000) poses a massive problem for stringent 
statistics. The number of false positives from a massive number of tests is very 
high so therefore trying to find the real results within a sea of false positives is 
very difficult. 
The Illumina goldengate assay performed as part of this study was not a GWAS, it 
was a targeted candidate gene association study. The main reason for not doing a 
GWAS was due to funding and as GWAS is a new technology it was expensive to 
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run. However the targeted candidate gene study has its benefits. Utilisation of the 
same information from the HGP and HapMap project and technology for GWAS, 
but on a lesser scale, allowed validation of the Bangladeshi population that has 
been used in this study through the use of previously associated genes. 
7.4 Final discussion 
This thesis began with a comprehensive study into eleven previously associated 
genes and fifteen novel genes. This involved a custom 384 tagSNP array being 
used to target specific genes utilising information from the HapMap project. Of 
the previously associated genes, six were found to be associated (uncorrected p- 
values) with AE in the Bangladeshi population. All genes analysed had been 
previously associated strongly in at least one study. The result of the study into 
the previously associated genes validates the ability of this population to replicate 
results and therefore as a valid population for investigating AE, it has also allowed 
the ability to see if the population shares similarity with other AE populations that 
have previously been studied. Eight out of the fifteen novel genes showed 
association (uncorrected p-values) with AE. Of these, six are involved in the 
immunological aspect of AE and two are skin specific. When these gene 
associations are corrected for multiple testing there are two novel genes (KYNU 
and JAK3/INSL3) which remain significant at the most stringent threshold and 
three previously associated genes (IL4RA, ST2 and TIM3) at a less stringent 
threshold. It is also important to remember that the power in this study is low due 
to a small sample size. This means that realistically sized effects are perhaps not 
being detected not because they are not there but because the power in the 
population is too small. This gene study into both previously associated and novel 
genes has greatly increased the knowledge in AE within the Bangladeshi 
population but also emphasises the variation of genetic association between 
different ethnicities. It also lays the foundation for a whole genome association 
study within this population and also for replication studies to confirm association 
found within this study. 
Alongside this comprehensive analysis of 26 genes, investigation into the 
emerging FLG association to AE was also conducted. Given that there was a 
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LOD score of 0 in this Bangladeshi population at the microsatellite specific to 
FLG it was thought unlikely that FLG had a major contribution to AE in the 
Bangladeshi population. This was confirmed through genotyping of the two 
known common FLG variants and also a tagSNP study using five tagSNPs in a 
similar manner to the Illumina candidate gene study. No association as found 
with any of these markers. The common FLG mutations were identified in six out 
of the eighty families and these were then clinically re-examined and found to also 
have IV. When alleles were superimposed onto pedigrees it became obvious that 
the FLG mutant alleles were segregating with individuals with IV and not AE. 
Two novel mutations were also identified in the probands from two of the AE and 
IV families. This work has allowed greater insight into the effect of FLG in AE 
within a different ethnicity population to the ones in current use which are of 
Northern European descent. There is currently no indication that FLG contributes 
to AE in this population however it is involved in IV with variable penetrance. 
This further advances the knowledge of variation within ethnic gene association 
variation with AE. 
ABCA12 was also assessed for association with AE. Previous to the Illumina 
study a microsatellite investigation had been carried out around ABCA12 and one 
marker in particular had shown a significant result. On this basis ABCA12 was 
included in the Illumina candidate gene panel. After these results were analysed 
one SNP in particular had a very strong p-value. However, on further 
investigation this was found to be a spurious false positive result. ABCA12 still 
has one SNP which remains significant, however it does not remain significant 
after multiple testing correction. ABCA12 is the known cause of Harlequin 
Ichthyosis (HI) and patient analysis was also conducted. Mutations were 
identified in twelve additional HI samples. This allowed construction of putative 
founder mutations in several populations which will allow for targeted sequencing 
strategies for faster diagnosis and also faster pre-natal diagnosis. 
7.5 Future work 
This thesis has focussed on the replication and discovery of genes involved in AE 
in the Bangladeshi population of East London. In order to confirm that the 
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findings are indeed true, replication is needed.. Another population is required to 
screen for associated variants, particular in the novel genes KYNU and 
JAK3/INSL3. However, as has been seen with FLG in chapter five, there is 
massive variation in associated genes between different ethnic populations, 
therefore even if these results were not replicated in a different ethnic population 
it is difficult to dismiss that these genes are not involved in AE in the Bangladeshi 
population. Therefore a resequencing project would be ideal using the next 
generation sequencing machines. This would allow screening of large regions of 
sequence around and encompassing the gene in question and would help identify 
any potential causative variants. Another method would be conduct exome 
sequencing in a large number of individuals. These methods would hopefully 
identify any causative variants and help to confirm the associations seen in this 
study. This would then allow continuation of study into functional studies, such 
as the effect of any identified mutations in cells which could be done using cell 
monolayer or using an organotypic skin model. 
It would also be very interesting to conduct investigation into the functional 
mechanisms of KYNU, JAK3/INSL3. This could be done using knockdown 
experiments using siRNA and also overexpression studies using both wildtype 
and mutant proteins. This would allow the functional mechanisms within the skin 
to be elucidated by using proliferation assays or staining for differentiation 
markers. Staining could also be conducted to detect where it is expressed and 
again this could be conducted in cell monolayers or using an organotypic skin 
model. Biopsies from patients could be used to look at components of the 
tryptophan pathway (KYNU) or the JAK/STAT pathway. If a particular risk 
allele was identified it would be useful to get a biopsy from a patient with this risk 
allele and compare it with a patient without the risk allele and again look at the 
two pathways. 
To summarise, the experiments described here will help to confirm the results of 
the large candidate gene study and hopefully start to identify causative variants. 
They will also provide further insight into just how complex AE is and the 
proportion of AE cases that can be attributed to barrier dysfunction or immune 
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dysfunction. This would therefore aid the development of therapies in order to be 
able to manage the barrier dysfunction or immune dysfunction. 
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Appendix A 
Questionnaire 
Factors 
of Genetic and Environmental 
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Questionnaire of genetic & environmental factors 
Personal Details: 
Name of the child 
DOB // Sex 
Address (including post code) 
Telephone No 
GP name 
GP address 
GP telephone No. 
Father's name 
DOB / 
Mother's name 
DOB // 
238 
Siblin2s 
Name DOB Sex Place of Birth 
2/ / / 
3/ / / 
4/ / / 
5/ / / 
6/ / / 
7/ / / 
8/ / / 
9/ / / 
10/ / / 
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GENETICS OF ATOPIC ECZEMA Questionnaire Affix bar 
code here 
Centre 
Number 
Family Number 
or Individual 
Number 
Family 
Tree 
Number 
Parents Number 
Mother Father 
Date of Visit: // 
Nrcinancti' and Birth Details: 
Date of Birth: Sex: Male Female 
Place of Birth: 
Gestation at delivery: 1_1_1 Weeks 
Mode ol'delivery: Normal Assisted (eg. ventouse, forceps) Caesarian 
Birth Weight: 1_1_I. I Ikg 
Birth order (i. e. ist child. 2nd child. etc): ..................................... 
Did mother smoke during pregnancy? Yes ; No 
Avoid any föod /drink during pregnancy? Yes 'i No 
If'yes, which töod/drinks were avoided'? 
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Child's Medical History 
Age at the time of diagnosis of atopic dermatitis: J_'I Years 
Does the child have any other medical illnesses apart from Atopic 
dermatitis? 
Yes rl No Q 
If yes, please specify 
Has your child ever had measles infection'? Yes 11 No Q 
If yes, at what age?: 111 Months/Years* 
*delete as appropriate 
Family History 
Mother: Age 1_1_1 Years 
Ethnic origin: Bangladeshi LI Other Q 
Date of moving to UK: 
_/_/, 
Level of education: Illiterate Q Primary school Q Secondary school fi 
University Q Postgraduate Q 
Occupation: 
Mother's medical history: I layfever Q Asthma I1 Atopic dermatitis Q 
Food allergy LI Other Ll 
Father: Age I-I-I Years 
Ethnic origin: Bangladeshi L 11 Other 11 
Date of moving to UK: // 
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Level of education: Illiterate 0 Primary school 0 Secondary school Q 
University Q Postgraduate Q 
Occupation: 
Father's medical history: Hayfever Q Asthma Q Atopic dermatitis Q 
Food allergy Q Other Q 
Parents history of consanguinity: Yes 0 No Q 
Sibling/s born in UK: 
DOB Hay fever Asthma Food allergy AD 
(tick if affected) 
// Q Q Q Q 
Q Q Q Q 
Q 0 Q Q 
Q Q Q Q 
Q Q Q Q 
// Q Q Q Q 
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Sibling/s born outside UK: 
DOB Hay fever Asthma Food allergy AD 
Age of onset of AD 
//Q Q Q Q 
Years 
//Q Q 0 Q 
-I-I 
Years 
//Q Q Q 0 
Years 
//Q Q Q Q 
(_I_I Years 
//Q Q Q Q 
I-I_I Years 
//Q Q Q Q 
I_I_I Years 
AD=Atopic Dermatitis 
Nutrition & Diet 
Was the child breastfed? Yes Q No Q 
If Yes, for how long? I_I_ 
_I 
Months 
At what age were solids introduced? I_I_I months 
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Is your child allergic to the following: 
If yes what allergy symptoms occur? 
Milk Yes 0 No 0 
Dairy products Yes 0 No O 
Eggs Yes 0 No Q 
Peanuts Yes Q No Q 
Fruits Yes Q No Q 
Cereals Yes Q No Q 
Fish & seafood Yes Q No Q 
Other Yes Q No Q Please specify: 
Results of any food allergy test: 
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Social History 
Type of accommodation: 
Flat Q Detached House 0 Semi-detached house Q Terrace house 0 
Bungalow Q 
Other Q please specify 
Does the family have access to a car? Yes Q No Q 
If yes, how many? I-I-I 
How many people live at this address? L_1-j 
How many rooms do you have? 1_1_1 
(Not including toilet, bathroom or rooms used for storage) 
Of these rooms how many are carpeted? I_I_I 
Is the affected child's room; Fully carpeted 0 Partly carpeted Q Not carpeted 
Q 
Type of heating: 
Central Q Electric fire Q 
Gas fire Q Coal fire Q 
Wood burner Q 
No heating Q 
Other (Please specify) 
Have you moved houses over the last 3 years? 
If yes, please give dates 
Yes Q No Q 
How did the severity of eczema change after moving? 
Got better Q Got worse Q No change Q 
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Pets 
Do you have any pets at home? Yes Q No Q 
If yes, please specify: Cats Q Dogs Q Hamster/Rabbit/Mouse Q Birds Q 
Other Q 
School 
Name of school/ Nursery: 
If in school, what year (e. g. year 4): 1 1_I 
During the last 3 months, how many days has your child missed school/ Nursery 
because of atopic dermatitis? 
None Q 1-3 days Q 4-7 days Q 8-14 days Q 
15-30 days Q more than 30 days Q 
Immunisation history 
Has the child had the following immunisations?: 
Age Immunisation If no, reason why: 
Birth BCG Yes Q No Q flares eczema: Q 
other: Q 
2 months D/T/P +* Yes 0 No 0 flares eczema: Q 
other: Q 
3 months D/T/P +* Yes Q No Q flares eczema: 0 
other: Q 
4 months D/T/P +* Yes Q No Q flares eczema: Q 
other: 0 
12 months MMR Yes 0 No Q flares eczema: Q 
other: Q 
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3 years D/T/P + MMR Yes Q No Q flares eczema: Q 
other: Q 
10-14 years Heath/BCG/Rubella Yes Q No Q flares eczema: Q 
other: Q 
15-18 years D/T + polio Yes Q No Q flares eczema: Q 
other: Q 
DTP= Diptheria, Tetanus, Whooping Cough 
*= Polio, Hib, Meningitis C 
If child has been vaccinated against BCG: 
At what age?: Birth 0 or uI months or (-J_I years 
Does the child have a BCG scar? Yes Q No 0 
If child has been vaccinated against MMR: 
At what age?: IJ_j years 
What happens to your child's atonic dermatitis? 
Gets better Gets worse No change 
During school exams QQQ 
During school holiday 0QQ 
During his/her illnesses 0QQ 
During family crises QQQ 
On going back to Bangladesh QQQ 
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Smoking 
Does anyone in the family smoke? 
If yes, who? 
Father Q Mother Q 
Grandmother Q 
Summer Q 
Relative who lives with you 0 Relative who does not live with you Q 
Seasonal variation 
Does your child's atopic dermatitis change with seasons? Yes 0 No Q 
If yes, in which season(s) is it worse? 
Spring Q Summer Q 
In which season(s) is it better? 
Spring p 
Date completed 
Interviewer: 
Yes 0 No Q 
Sibling Q Grandfather Q 
Autumn Q Winter Q 
Autumn 0 Winter Q 
// 
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Appendix B 
Family details with affection status and IgE levels 
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Family 
Number 
Individual 
Number 
Eczema Asthma Hayfever IgE 
 
1 1685 
2 N/A 
3 Y 26720 
4 Y 54 
5 1540 
6 Y 1582 
7 496 
2 1 82 
2 34 
3 Y Y 474 
4 y y 1023 
5 y 91 
6 13 
3 1 33 
2 41 
3 y Y Y 14616 
4 Y Y N/A 
5 Y Y Y N/A 
4 1 N/A 
2 108 
3 Y Y 2273 
4 Y N/A 
5 54 
6 167 
5 1 21 
2 284 
3 Y 437 
4 Y Y 6693 
5 Y 912 
6 Y N/A 
6 1 N/A 
2 340 
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3 Y Y Y 2762 
4 Y Y 112 
5 Y Y 1815 
7 1 192 
2 57 
3 Y 922 
4 Y Y 1214 
5 Y 508 
6 Y 19 
7 Y Y Y 247 
8 Y N/A 
8 1 N/A 
2 237 
3 Y Y 271 
4 Y Y 3166 
5 130 
6 Y Y N/A 
9 1 115 
2 23 
3 Y Y 4442 
4 Y 1490 
5 Y 62 
6 16 
7 Y 304 
8 177 
10 2 463 
3 Y 67 
4 Y N/A 
11 1 123 
2 257 
3 Y Y 2936 
4 Y Y 1845 
5 Y 1528 
6 Y 1156 
12 1 404 
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2 Y 129 
3 Y Y 6 
4 Y Y N/A 
5 Y Y Y 668 
6 223 
13 1 582 
2 52 
3 Y Y 99 
5 Y 21 
6 30 
7 Y Y N/A 
8 y 38 
9 Y 3968 
10 Y 2499 
11 Y 2765 
12 N/A 
14 1 y 1155 
2 57 
3 Y Y 2706 
4 Y N/A 
6 1686 
8 Y 1332 
9 1795 
11 N/A 
15 1 93 
2 128 
3 Y 46342 
4 153 
5 Y 1177 
6 Y Y 29564 
16 1 164 
2 Y 38 
3 Y 10216 
4 Y 68 
5 Y 36 
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6 N/A 
17 1 655 
2 193 
3 Y Y 4990 
4 Y Y 1612 
5 Y 85 
18 1 47 
2 y 52 
3 Y Y 7530 
4 Y Y 144 
5 Y 64 
6 y y y 132 
7 10 
19 1 y 53 
2 Y 74 
3 Y Y 1695 
4 Y Y 2794 
5 Y Y Y 51 
6 Y Y Y 507 
20 1 155 
2 367 
3 Y 6347 
4 Y N/A 
5 904 
6 N/A 
7 1610 
8 70 
22 1 1354 
2 Y 93 
3 Y 3311- 
4 Y 61 
5 Y 568 
23 1 727 
2 337 
3 Y N/A 
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4 Y N/A 
5 N/A 
25 1 1024 
2 25 
3 Y 2617 
4 Y 16 
5 12 
6 21 
26 1 N/A 
2 Y 280 
3 Y Y 101 
4 N/A 
5 N/A 
6 Y Y 567 
7 N/A 
27 1 406 
2 25 
3 Y 17 
4 Y N/A 
5 Y Y 714 
6 N/A 
7 Y Y 975 
29 1 2126 
2 815 
3 Y 141 
4 9 
5 628 
6 430 
7 Y Y Y 1976 
8 Y 714 
30 1 61 
2 Y 31 
3 Y 146 
4 Y 102 
5 Y Y 171 
254 
6 83 
7 N/A 
8 N/A 
31 1 386 
2 130 
3 Y Y 1589 
4 Y Y 57 
5 Y N/A 
32 1 991 
2 35 
3 y 67006 
4 73 
5 429 
6 N/A 
7 y y 1837 
33 1 67 
2 135 
3 Y Y 64 
4 Y Y Y 142 
5 Y Y 40 
34 1 74 
2 137 
3 Y 23821 
4 Y 88 
5 88 
6 72 
35 1 664 
2 521 
3 Y Y 7394 
4 Y Y 1634 
5 Y Y 1724 
6 N/A 
7 Y N/A 
8 Y Y N/A 
36 1 27 
255 
2 86 
3 Y N/A 
4 Y Y Y 514 
5 Y Y Y 18911 
6 Y Y Y 4024 
7 Y N/A 
8 Y N/A 
37 1 86 
2 67 
3 Y 39 
4 Y 806 
5 Y 137 
6 93 
7 N/A 
38 1 Y 234 
2 96 
3 Y Y 4278 
4 Y 149 
5 Y Y 3288 
6 Y Y 1119 
40 1 268 
2 59 
3 Y 380 
4 Y Y 3011 
5 1273 
6 58 
41 1 21 
2 170 
3 Y Y 1865 
4 Y Y 291 
5 N/A 
6 52 
7 N/A 
42 1 178 
2 35 
256 
3 Y Y 351 
4 19 
5 Y 2226 
6 Y 349 
43 1 65 
2 82 
3 Y 116 
4 Y 24 
45 1 y 62 
2 10 
3 Y y 8 
4 Y Y Y 51 
47 1 284 
2 228 
3 Y 2596 
4 Y 1232 
5 280 
6 N/A 
7 Y 312 
48 1 1338 
2 25 
3 Y Y Y 2982 
4 Y 39 
5 Y 443 
6 Y Y Y 659 
7 Y 887 
49 1 33 
2 223 
3 Y Y 1327 
4 Y 64 
5 Y 113 
6 Y 1912 
51 1 12419 
2 925 
3 Y 14916 
257 
4 Y 849 
5 1939 
6 2867 
52 1 Y 254 
2 24 
3 Y 202 
4 Y 29 
5 17 
6 283 
7 53 
54 1 48 
2 24 
3 Y 630 
4 N/A 
5 Y 67 
6 Y 16 
7 N/A 
55 1 85 
2 119 
3 Y 1334 
4 Y 16 
5 Y 269 
6 673 
7 Y N/A 
56 1 y 583 
2 Y 30 
3 Y 1761 
4 Y 49 
5 34 
6 78 
57 1 617 
2 2651 
3 Y N/A 
4 Y 551 
258 
5 Y Y N/A 
58 1 171 
2 192 
3 Y 1848 
4 Y 59 
5 Y 811 
60 1 131 
2 1386 
3 Y Y Y 2785 
4 2000 
5 Y Y 877 
6 N/A 
7 Y 609 
61 1 253 
2 164 
3 Y 439 
4 Y 11 
62 1 4 
2 64 
3 Y Y 6448 
4 Y Y 276 
5 Y Y Y 525 
6 Y Y Y 34 
7 Y Y Y 420 
8 7 
9 Y Y Y 1036 
10 Y Y Y 60 
11 N/A 
63 2 98 
3 Y 54 
4 N/A 
5 Y 151 
6 y 109 
7 Y N/A 
8 N/A 
259 
64 1 229 
2 201 
3 Y YY 3347 
4 Y 46 
5 515 
6 177 
65 1 61 
2 506 
3 Y 4860 
4 Y 27 
5 Y 42 
6 39 
66 1 123 
2 53 
3 y N/A 
67 
4 
3 
y 
y 
y 
yY 
780 
N/A 
4 y y N/A 
5 N/A 
6 N/A 
7 N/A 
8 N/A 
69 1 161 
2 188 
3 Y 95 
4 N/A 
5 N/A 
6 Y 2824 
7 50 
8 Y 5948 
70 1 39 
2 43 
3 Y 147 
4 N/A 
5 8 
260 
6 40 
7 Y Y 300 
8 Y 63 
71 1 53 
2 82 
3 Y 15 
4 Y 473 
5 Y 1820 
72 1 513 
2 19 
3 Y 15 
4 Y 71 
73 1 48 
2 42 
3 Y Y 371 
4 Y 199 
5 Y 473 
6 69 
75 1 314 
2 Y 152 
3 Y 635 
4 Y N/A 
5 Y 1454 
76 1 279 
2 8 
3 Y 794 
4 Y 27 
78 1 308 
2 130 
3 Y 84 
4 Y 672 
5 Y 262 
6 14 
79 1 N/A 
2 1940 
261 
3 Y 4709 
4 Y Y 1873 
5 Y Y N/A 
6 N/A 
7 Y Y N/A 
80 1 y 11 
2 332 
3 Y Y 884 
4 Y 58 
5 Y 10 
6 y 10 
7 Y 99 
8 12 
9 Y N/A 
10 N/A 
81 1 196 
2 76 
3 Y 35 
4 Y 1509 
5 Y 204 
6 Y 257 
82 1 316 
2 591 
3 Y Y Y 31830 
4 Y 521 
262 
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Gene Corner 
Filaggrin mutations are associated with ichthyosis vulgaris in the Bangladeshi population 
DOI: 10.1111/j. 1365-2133.2009.090S0. x 
Ichthyosis vulgaris (N) is an inherited skin disorder causing 
dry, scaly skin and affects approximately one in 250 people. 
Phenotypically, patients have palmar hyperlinearity, keratosis 
pilaris and fine scaling on the lower abdomen, legs and arms 
and symptoms usually manifest within the first year of life. 
Filaggrin (filament aggregating protein, FLG) is involved in 
the formation of the stratum corneum'. 2 and has been impli- 
cated in N. Immunoblotting studies showed loss of profilag- 
grin expression in N-affected keratinocyte extracts compared 
with controls. 3 3,4 Keratohyaline granules, which contain profi- 
laggrin, were found by electron microscopy to be absent in 
several patients with IV and markedly reduced in several oth- 
ers. s In addition, mRNA of profilaggrin in patients with IV 
was found to be unstable and had a much shorter half-life 
than controls. " These early studies suggested that defective 
FLG was involved in the development of IV. 
Conclusive evidence for the role of FLG in IV was demon- 
strated when two mutations (R501X and 2282del4) in FLG 
were found to be associated with N. 7 These and other FLG 
mutations have also been shown to be associated with atopic 
eczema (AE) .8 
12 The pattern of inheritance of IV seems to be 
semidominant with homozygous and heterozygous FLG muta- 
tions underlying the severe and milder forms of IV, respec- 
tively. The association of FLG mutations with N in Northern 
European and Japanese populations has been confirmed in 
subsequent studies. 7 9-13 The present report is the first to 
describe FLG mutation analysis in IV in an Indian subcontinent 
population, the Bangladeshi population residing in the East 
London area of the U. K. 
Cases and methods 
We have collected a cohort of 80 Bangladeshi families with 
two or more siblings with AE frone East London, U. K. We 
have defined AE as eczema symptoms along with IgE sensitiv- 
ity. Probands were identified at the Paediatric Dermatology 
clinic at the Royal London Hospital and were phenotyped 
using the U. K. Working Party's diagnostic criteria for AE. A 
Sylheti-speaking research assistant, trained and validated in 
using the diagnostic criteria for AE, visited family members at 
home to perform phenotyping of other family members and 
to obtain blood samples from consenting individuals. Ethical 
approval was obtained from the North East London and City 
Health Authority Research Ethic Committee. All affected indi- 
viduals had elevated IgE. In addition to the two most common 
FLG mutations (R501X and 2282del4), five tagSNPs were also 
screened across all 80 families (370 individuals). Six families 
were found to have one or both of these mutations. These 
families were assessed for IV and clinical phenotype was cor- 
related with the presence/absence of these two FLG mutations. 
R50IX leads to a complete loss of the FLG product as it is 
located very close to the beginning of repeat I in exon 3 of 
FLG. The other mutation, 2282de14, a 4-bp deletion, also leads 
to complete loss of the FLG product and is located 107 bp 
downstream of R50IX in exon 3. Primers for these assays are 
as described. 7 R5OIX was genotyped using an annealing tem- 
perature of 56 °C and 1.5 mmol L-' of MgCI2. This polymer- 
ase chain reaction (PCR) fragment was then digested with one 
unit of NIaIII for 16 h at 37 T. Fragments were then resolved 
on a 3% agarose gel. 2282de14 was genotyped using an 
annealing temperature of 55 °C and 1.5 mmol L-' of MgCI2. 
This fragment was then digested with one unit of DraIII for 
16 h at 37 °C. Restricted PCR fragments were then resolved 
on a 2% agarose gel. Two other novel FLG mtations, R826X 
and 2767insT, were identified after sequencing two unrelated 
individuals who were heterozygous for the 2282de14 muta- 
tions and also had IV, using the previously described sequenc- 
ing strategy. ' 2 These mutations were genotyped in the two 
families where the mutations were found and in the parental 
population of the 80 families (168 individuals). These two 
mutations were analysed using PCR and sequencing. The 
primers used were FILr I .FI 
5'-3' CAGGCCATGGACAGGCT- 
GGTCA and FILr2. RI 5'-3' GAAGTCTCTGCGTGAGGAGTT. 
These were amplified using the AbGene (Epsom, U. K. ) long- 
range high-fidelity PCR system and an annealing temperature 
of 62 T. These products were then sequenced on an Applied 
Biosystems (Foster City, CA, U. S. A. ) 3700 machine. 
Results and discussion 
Initially a haplotype SNP tagging approach was used along 
with screening of the two prevalent Northern European 
mutations in a study examining FLG in AE in the Bangladeshi 
population of East London. Although no strong association 
with FLG and AE was observed (data not shown), six 
Bangladeshi families of the 80 AE families harboured the two 
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FLG mutations, R5OIX and 2282de14. We clinically re-assessed 
all six families carrying these two FLG mutations, specifically 
looking for signs of IV. All four RSOIX heterozygotes 
from family 13 had no evidence of W. However, four 
2282de14 homozygotes and four of the 11 2282de14 hetero- 
zygotes had clinical evidence of IV presenting as fine scaling 
on the arms and lower legs and hyperlinear palms. There may 
be more patients with i in this cohort but they were not 
investigated. 
Heterozygous FLG mutations were found in affected individ- 
uals in two families (4 and 3S). The DNA from these individ- 
uals was used for sequencing in order to try and find any 
other FLG mutations. Two further novel FLG mutations were 
identified, R826X and 2767insT (Fig. la, b). The mutation 
2767insT has been previously found in an individual of 
Bangladeshi American descent (W. H. I. McLean, unpublished 
data). These two mutations were then screened in the parental 
population of the 80 families and were found to be only 
within the two families 4 and 35, in which they were initially 
identified (Fig. Ib). The two compound heterozygotes for the 
2282de14/R50IX mutations both had clinical signs of IV. One 
2282de14/R826X compound heterozygote showed signs of IV; 
however, the other individual with the same genotype within 
the same family did not. This indicates that there is variable 
disease expression but it is not clear why there is a difference 
in clinical presentation. 
Loss-of-function mutations in the gene encoding FLG are 
linked with IV in Northern European and Japanese popula- 
tions. Here we extend these studies and demonstrate that 
FLG mutations are also associated with IV in a Bangladeshi 
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(b) 
Family 35 ý Family 4 
HAP 
i12730241 GA GA n12730241 -- GG 
r$3814300 CC CC n3814300 -- CC 
n2065958 AC AC n2065958 -- AA 
2767iniT wl wt wt 27671nsT 2767insT -- WI W1 
r. 2184953 AA AG rs2184953 -- AA 
R826X wt wt wl vn RB26X -- wt W'I 
2282de14 2282de14 wt wl wt 2282d& 4-- wt 2282de14 
R501 x wl wl wt wt R501 X-- 'M'M M 
Rs11582620 GA AA Rs11582620 -- AA 
AE 
Hip AE AE wo AE AE 
GA GA GGAG GA GG GA GG 
CC CC CCCC CC CC CC CC 
AC AC AACA AC AA AC AA 
wt 2767insT wl wt wt WI 27671nsT wt -- Wi WI wl wt wl wt 'A wt 
AG AA AAGA AG AA AG AA 
wt wt VA WI VA wl wt VA wl R826X n wt wl R826X wI wl 
2282de14 wt VA VA wt 2282de4 wt 2262de14 - 2282de14 wt 2282de14 2282d&4 2282dei4 wl wt 2282de14 
VA wt VA 'A wt VA VA wl wt wt wt wt wt wt wt wl 
GA AA AGAG AA AG AA AG 
Fig 1. FLG mutations found in specific families. (a) The upper left hand panel contains a sequencing chromatogram showing the 2767insT and 
the lower panel shows a sequencing chromatogram with no insT. The upper right hand panel shows an R826X heterozygote and the lower panel 
shows an individual with no mutation at this position. (b) Family 4 and family 35 are the two families where additional FLG mutations have 
been found. Family 35 contains two ichthyosis vulgaris (IV)-affected individuals with the genotype 2282del4/2767insT. Family 4 contains two 
IV-affected individuals with the genotypes 2282de14/R826X, 2282del4/2282del4. Coloured symbols indicate individuals affected with IV. 
HLP, hyperlinear palms; AE, atopic eczema. 
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population, although the disease expression varies between 
individuals harbouring the same FLG genotype. 
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